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Abstract  
 
 Hematopoietic stem cells (HSC) are maintained throughout life in 
specialized niches in bone marrow (BM). The hematopoietic niches are 
suggested to support the maintenance and differentiation of hematopoietic 
progenitor cells. It is still unknown whether and how the niche contributes to 
lymphocyte differentiation. The CXCR4/CXCL12 pathway is fundamental for 
positioning of HSC within the hematopoietic niches, and therefore is a 
potential candidate to mediate chemoattraction to regulatory cues of lineage 
differentiation. Deficiencies in CXCR4 affect hematopoiesis, and specifically 
compromise B lymphopoiesis.  Whether CXCR4 is required at early progenitor 
stages for differentiation or only required for HSC quiescence has not been 
addressed. Here, we conditionally deleted CXCR4 at different hematopoietic 
checkpoints, and found that CXCR4 was critically required at the MPP and 
CLP stage for cell positioning in proximity to rare IL-7-expressing cells. 
Moreover, this close positioning is critical for achieving sufficient IL-7R 
signaling. Deficiency in CXCR4 compromises the close positioning of CLP 
relative to IL-7-expressing cells, indicating that CXCR4 chemoattraction is 
fundamental for IL-7 consumption at this stage and that IL-7 producers in 
bone marrow are components of the B cell differentiation niche.  We further 
showed that IL-7 is expressed by a heterogeneous population of 
mesenchymal progenitor cells, which express Leptin receptor, and 
differentiated into adipocytes and osteoblasts in vivo.  
 After the commitment to B lymphocyte lineage, CXCR4 is required for 
the retention of immature B cells in bone marrow parenchyma. We found that 
a twofold down-regulation of CXCR4 together with a GPCR-independent 
mechanism is critical for B cell egress into the periphery, where they 
complete their differentiation pathway. The passive mode of BM cell egress 
also contributes significantly to the export of NK cells. 
 Collectively, our findings provide a groundbreaking evidence of the 
overlapping between HSC maintenance and lymphoid differentiation niches, 
and are a valuable contribution to the understanding of B lymphopoeisis in 
vivo. 
"  
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Resumo 
 
 Na medula óssea, nichos especializados são responsáveis pela 
manutenção e diferenciação das células estaminais hematopoiéticas. Pouco  
ainda se sabe sobre a intervenção do nicho na diferenciação das células 
estaminais. O receptor CXCR4 e o seu ligando CXCL12 são cruciais para o 
posicionamento das células estaminais hematopoieticas nos referidos nichos 
e daí serem potenciais candidatos na mediação da quimoatracção dos 
progenitores durante a diferenciação hematopoietica. A deficiência em 
CXCR4 compromete a hematopoiese, sobretudo o desenvolvimento de 
linfócitos B. Desconhece-se se o CXCR4 atua nas células estaminais 
hematopoiéticas ou se é fundamental a nível dos progenitores. A deleção de 
CXCR4 em diferentes etapas da hematopoiese foi a estratégia escolhida para 
responder a esta questão. Progenitores multipotentes e progenitores de 
linfócitos dependem de CXCR4 para se posicionarem perto de células 
produtoras de IL-7. A deficiência em CXCR4 compromete o posicionamento e 
o consumo de IL-7, indicando que as células produtoras de IL-7 são 
importantes constituintes do nicho de diferenciação de linfócitos B. Este 
estudo também revela que uma população heterogénea de progenitores do 
mesênquima produz IL-7, bem como CXCL12, expressa o receptor de Leptina 
e tem capacidade de diferenciação em adipócitos e osteoblastos.   
 Após entrada  na via de desenvolvimento de linfócitos B, o CXCR4 
retêm células B imaturas no parênquima da medula óssea. Para saírem da 
medula óssea para a circulação, as células B reduzem para metade a 
quantidade de CXCR4 que é expressa na superfície celular e são auxiliadas 
por um mecanismo independente de GPCR que as empurra para a circulação. 
Este mecanismo também contribui para a exportação de células NK. 
 Os resultados obtidos no âmbito desta tese alicerçam o modelo no 
qual o nicho de manutenção das células estaminais hematopoiéticas controla 
a diferenciação hematopoiética.  Ademais, contribuem para a compreensão 
do desenvolvimento de linfócitos B in vivo. 
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Chapter 1 
 
Introduction  
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Chapter 1 | Introduction 
 
 Hematopoiesis generates erythrocytes and the various types of 
leukocytes (Figure 1.1). Hematopoietic Stem Cells (HSC) are the only cells 
capable of generating all hematopoietic lineages throughout life, and have 
been characterized by two main characteristics, at single cell level(Cumano 
and Godin, 2007):  
- multipotency, which is the capacity of a single cell to originate a 
differentiated progeny comprising different cell types; 
- self-renewal, which allows maintenance of HSC pool. 
  HCS have been detected in several tissues throughout development. 
The first HSC arise in the aorta-gonad-mesonephros (AGM) region, and the 
yolk sac, followed by the placenta, fetal liver, spleen, and finally migrate to 
bone marrow (BM) right after birth(Cumano and Godin, 2007). Seminal work 
by Metcalf and Moore(Metcalf, 1970, Moore and Metcalf, 1970) and by Till 
and McCullough(Till, 1961) introduced the notion that multipotent 
progenitors found in adult BM are responsible for the active regeneration of 
the hematopoietic compartment.  
 
Figure 1.1| Scheme of murine 
adult hematopoiesis. Distinct 
hematopoietic stem and 
progenitor cell stages have been 
described by correlating surface 
markers expression (in green) and 
functional properties. HSC, 
hematopoietic stem cell; MPP, 
multipotent progenitor; CLP, 
common lymphoid progenitor; 
CMP, common myeloid progenitor; 
GMP, granulocyte-macrophage 
progenitor; MEP, megakaryocyte-
erythrocyte progenitor; NK, natural 
killer cell.  
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1. Anatomy of the Bone Marrow 
 The BM is a versatile organ, harboring not only most of the adult 
hematopoiesis but also osteogenesis. In addition to hematopoietic cells, BM 
also contains different types of cells. Mesenchymal stem cells (MSC) originate 
osteoblasts, adipocytes, and chondrocytes. Osteoprogenitors, osteoblasts, 
osteocytes support the bone formation. Other BM stromal cell populations, 
such as neuronal cells, glial cells, and adipocytes, may regulate 
hematopoiesis (Anthony and Link, 2014). 
 Within the BM parenchyma, there is a rich network of stromal cells, 
MSC and adipocytes interspersed between islands of hematopoietic cells 
(Anthony and Link, 2014). Osteoblasts and bone lining cells form a layer 
between mineralized bone and the bone marrow known as endosteum. Near 
the endosteum there is a rich supply of arterioles, as well as sinusoids 
(Morrison and Scadden, 2014). The BM of long (e.g., femur and tibia) and flat 
(e.g., calvaria) bones is highly vascular (Nombela-Arrieta et al., 2013, Sipkins 
et al., 2005). In long bones, central longitudinal arteries transform into radial 
arteries that in turn divide into arterioles near the endosteum (Nombela-
Arrieta et al., 2013). Arteries feed into sinusoids, which in turn extend back 
towards the central cavity where they coalesce into a large central sinus to 
form the venous circulation (Anthony and Link, 2014, Morrison and Scadden, 
2014). The venous sinusoids, which form a reticular network of fenestrated 
vessels, are thought to be the major sites of leukocyte egress from the bone 
marrow into the circulation (Campbell, 1972). Surrounding BM sinuses, 
adventitial reticular cells branch into the surrounding hematopoietic space 
(Lichtman, 1981, Weiss, 1976). B cells have been described to associate with 
this abundant type of BM stromal cell (Jacobsen and Osmond, 1990).  
 The positioning of hematopoietic stem and progenitor cells within BM 
is critical to understand the homeostasis, repair of the hematopoietic system, 
and as well to further clarify the architectural organization of the BM.  
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2. The Hematopoietic Stem Cell Niche Concept 
 Like all metazoan cells, HSC and hematopoietic progenitors require a 
supporting milieu. Dexter and colleagues demonstrated the dependence of 
HSC on supporting non-hematopoietic cells in BM (Dexter et al., 1977). Lord 
demonstrated the importance of the architectural organization of bone 
marrow to support hematopoiesis (Lord et al., 1975). Then, Raymond 
Schofield formally proposed the stem cell niche (Schofield, 1978).  
 The theory of Schofield postulated that hematopoietic stem cells were 
located in physical sites denominated niches (Table 1.1 and Figure 1.2). The 
niche is an anatomical location that affects stem cell number and behavior by 
inducing self-renewal in proximity of this location or inducing differentiation 
at a distance (Schofield, 1978). In addition, the niche was capable of 
preventing the accumulation of genetic mutations during self-renewal 
(Schofield, 1978). 
 
Table 1.1| Schofield’s proposed features of a stem cell niche. Adapted from (Scadden, 
2014). 
- Restriction on stem cell entry into cell cycle and differentiation programs 
- Integration of signals reflecting tissue and organismal state 
- Imposition of stem cell features on daughter cells 
- Mechanism for limiting “mutational errors” 
 
 
 
Figure 1.2| Functions of the hematopoietic 
niche.  Through the production of several 
factors like cytokines and membrane-
molecules, the niche instructs the cell-fate 
decision of HSC. Adapted from (Rieger and 
Schroeder, 2012). 
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 Even though the niche theory has been around for several decades 
now, only about 10 years ago in vitro and in vivo studies have experimentally 
demonstrated that non-hematopoietic cells in BM are capable of regulating 
HSC (Taichman and Emerson, 1994, Calvi et al., 2003, Zhang et al., 2003). In 
the following sections I will cover the progress made in unveiling the 
localization and the cellular components of the HSC niche. 
 
 
3. Mapping of HSC and their niches within BM  
 Analyses of different transgenic mice have implicated osteoblasts in 
the regulation of HSC in BM (Calvi et al., 2003, Zhang et al., 2003, Visnjic et 
al., 2004). HSC have also been suggested to interact with osteoblasts in the 
endosteum (Zhang et al., 2003, Arai et al., 2004, Wilson et al., 2004). 
However, several evidences indicate that the endosteum is unlikely to be the 
only niche for HSC. First, sites of extramedullary hematopoiesis, such as the 
liver, lack osteoblasts (Taniguchi et al., 1996).  Second, cytokines readily 
mobilize HSC into circulation (Laterveer et al., 1995). Finally, HSC are motile 
and recirculate (Wright et al., 2001). Therefore, it became fundamental to 
identify unequivocally HSC in situ.   
 The positive staining for CD150 combined with negative staining for 
lineage markers, CD48 and CD41 is a hallmark in HSC biology because it 
allowed the identification of HSC in situ using a simple two color staining 
(Kiel et al., 2005). The majority of HSC in bone marrow and spleen were 
observed adjacent to sinusoidal vessels (Kiel et al., 2007, Kiel et al., 2005). 
Indeed, HSC are five times more likely than other hematopoietic cells to be 
localized close to a sinusoidal vessel (Kiel et al., 2007). Moreover, less than 
20% of HSC are localized within 10 µm of the endosteum (Kiel et al., 2007, 
Kiel et al., 2005, Lo Celso et al., 2009). These observations suggested that 
HSC might be maintained in a perivascular niche. Still, it is possible that HSC 
near vessels were in transit. Therefore, the niche cellular components have 
to be further characterized.  
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4. Dissecting the elements of the HSC niche   
 The complexity of the anatomy and cellular composition of the HSC 
maintenance niche has increased over the last decade, in part due to the 
heterogeneity of HSC and the fact that several stromal cells in BM seem to 
exhibit HSC maintenance properties (table 1.2, on next page). Despite early 
reports implying osteoblasts in the regulation of HSC maintenance niche 
(Calvi et al., 2003, Zhang et al., 2003, Visnjic et al., 2004, Arai et al., 2004, 
Wilson et al., 2004), it is currently accepted that osteoblasts do not directly 
regulate HSC, but support B lymphopoiesis (Taichman et al., 1996, Taichman, 
2005, Visnjic et al., 2004, Zhu et al., 2007, Ding and Morrison, 2013b). 
Mesenchymal stem and progenitors cells (MSPC), which are multipotent cells 
capable of differentiating into osteoblasts, chondrocytes, adipocytes and 
stromal cells (Frenette et al., 2013), have been described as critical niche 
cells (see below)(Mendez-Ferrer et al., 2010b, Kunisaki et al., 2013, Pinho et 
al., 2013, Morrison et al., 1995, Ding et al., 2012, Ding and Morrison, 2013b, 
Zhou et al., 2014, Nagasawa et al., 1991, Sugiyama et al., 2006, Omatsu et 
al., 2010, Greenbaum et al., 2013, Omatsu et al., 2014). Mature 
hematopoietic cells also play a role in forming the hematopoietic niche. 
Megakaryocytes secrete the chemokine CXCL4, which controls HSC cell cycle 
activity (Bruns et al., 2014). CD169+ macrophages, besides being a key 
components for medullary erythropoiesis (Chow et al., 2013), also regulate 
the hematopoietic niche by cross-talking with MSPC, inducing the expression 
of CXCL12 and thus promoting the retention of HSC and progenitors in the 
hematopoietic niche (Chow et al., 2011). Sympathetic nerves enwrap MSPC 
and secret noradrenaline in a circadian-manner, which is sensed by MSPC 
and causes them to reduce the expression of CXCL12, thus enhancing the 
BM egress of HSC and progenitors (Mendez-Ferrer et al., 2008, Mendez-
Ferrer et al., 2010a). Besides demonstrating the diversity of cells supporting 
HSC maintenance, these studies also support that MSPC regulate 
hematopoietic differentiation in response to environmental cues. We have 
recently reviewed how hematopoietic progenitors and niche supporting cells 
sense and respond to stress cues, suggesting a potential role for the 
hematopoietic niche in the development pathologies such as rheumatoid 
arthritis and anemia of chronic infections (see appendix).    
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Table 1.2| BM populations of the HSC niche. Adapted from [(Ugarte and Forsberg, 2013)]. 
Cell Type Markers  Mouse Model a Niche function 
Perivascular 
Stromal cell 
 
- Nestin+ cells 
- SCF+ cells 
- CXCL12-
abundant cells 
(CAR) 
CXCL12hi 
SCFhi 
NG2 
Pdgfr-a 
Pdgfr-b 
CD146 
Sca-1 
VCAM1 
CFU-F potencial 
Mesenchymal 
lineage 
differentiation 
 
Nestin-GFP (Mendez-
Ferrer et al., 2010b, Ding 
et al., 2012) 
Prx1-cre (Ding and 
Morrison, 2013b, 
Greenbaum et al., 2013) 
Cxcl12-GFP (Sugiyama et 
al., 2006)/ DsRed (Ding 
and Morrison, 2013b) 
Cxcl12-DTR-GFP (Omatsu 
et al., 2010) 
Lepr-cre (Ding and 
Morrison, 2013b, Ding et 
al., 2012) 
Scf-GFP (Ding et al., 
2012) 
HSC maintenance and retention in 
BM 
 
Direct supply of soluble and non-
soluble factors for HSC 
 
Precursors of other niche cells – 
osteoblasts, adipocytes, 
chondrocytes, etc. 
Sinusoidal 
endothelial cells 
CD31 
Endomucin 
VE-cadherin 
VCAM1 
Laminin 
Sca-1 
MECA-32 
Endoglin 
 
Tie2-cre (Ding and 
Morrison, 2013b, Ding et 
al., 2012, Greenbaum et 
al., 2013) 
Cdh5-CreER (Wang et al., 
2013) 
HSC maintenance 
Osteoprogenitors Osterix 
Runx2 
CD146 
Osx-cre (Greenbaum et 
al., 2013) 
Prx1-cre (Greenbaum et 
al., 2013, Ding and 
Morrison, 2013b) 
 
Lymphoid progenitor cell niche 
Osteoblasts (OB) Osteocalcin 
Osteopontin 
ALPL 
N-cad 
CXCL12low 
Prx1-cre (Greenbaum et 
al., 2013, Ding and 
Morrison, 2013b) 
Col2.3-cre (Ding and 
Morrison, 2013b, Ding et 
al., 2012) 
Osteocalcin-cre 
(Greenbaum et al., 2013) 
Osx-cre (Greenbaum et 
al., 2013, Ding and 
Morrison, 2013b) 
 
Lymphoid progenitor cell niche 
Adipocytes 
 
 
Fabp4 
Adiponectin 
Perilipin 
 
A-ZIP/F1 (Naveiras et al., 
2009) 
Negative regulators of 
hematopoiesis 
Monocytes/ 
Macrophages 
 
 
Gr-1 
CD169 
CD11b 
F4/80 
Cd169-DTR (Chow et al., 
2011) 
Gr1-DTR (Chow et al., 
2011) 
MAFIA (Winkler et al., 
2010, Chow et al., 2011) 
Clodronate liposomes 
(Winkler et al., 2010, 
Chow et al., 2011) 
CD68:G-CSFR 
(Christopher et al., 2011) 
Regulating MSC and OB function. 
Active player in G-CSF 
mobilization. 
Non-myelinating 
Schwann cells 
Active TGF-B 
GFAP 
Nestin 
Tgfbr2fl/- (Yamazaki et al., 
2011) 
Maintenance of HSC quiescence 
Regulatory T cells CD4+CD25+Foxp3+ Foxp3GFP (Fujisaki et al., 
2011) 
Foxp3-GFP-DTR 
(Yamazaki et al., 2011) 
Immune protection to the HSC 
niche 
a Mouse models used to determine the role of the respective cell population on the HSC niche.  
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 The following paragraphs focus on the principal studies and the 
experimental approaches used to identify non-hematopoietic niche cells. The 
niche cells must meet the following criteria: 1) be a rare population in BM; 2) 
harbor HSC and hematopoietic progenitors close by; 3) produce HSC 
maintenance factors, which are important regulators of the HSC niche; and 4) 
capable of sensing and responding accordingly to systemic and local cues in 
order to maintain an optimal hematopoietic output (Frenette et al., 2013). 
For the purpose of elucidating the niche cells and its molecular regulators, 
some studies focused on the extracellular signals that maintain and regulate 
HSC, while others attempt to identify the cells producing such factors. The 
conditional deletion of key factors in restricted cell populations using Cre 
recombinase expressed under the control of (in principle) cell type-specific 
promoters and the improvement in BM imaging techniques have become key 
tools to determine whether a single factor used by a candidate cell type is 
critical for the maintenance of HSC and hematopoietic progenitors. 
 CXC chemokine ligand 12 (CXCL12) and Stem Cell Factor (SCF) are 
critical for the maintenance of HSC within their niche, and their sources in 
BM are potential constituents of the HSC niche. One of the first attempts to 
identify the cellular constituents of the HSC niche was to identify the sources 
of CXCL12 in BM. CXCL12 (also known as stromal cell-derived factor-1, SDF-
1) was first isolated from stromal cell lines used in in vitro B lymphocyte 
development assays (Tashiro et al., 1993, Nagasawa et al., 1994), and was 
first characterized as a growth-stimulating factor for a stromal cell-
dependent B cell precursor clone (Nagasawa et al., 1994). Nonetheless, 
CXCL12 and its receptor CXCR4 (Nagasawa et al., 1994, Nagasawa et al., 
1996, Bleul et al., 1996, Oberlin et al., 1996, Tachibana et al., 1998, Zou et 
al., 1998, Ma et al., 1998) are involved in a variety of important processes, 
like the colonization of BM by hematopoietic cells, namely HSC, during 
ontogeny (Nagasawa et al., 1996, Tachibana et al., 1998, Ma et al., 1998, 
Ara et al., 2003b), the intestinal angiogenesis, and the development of the 
cerebellum (Nagasawa et al., 1996, Tachibana et al., 1998, Zou et al., 1998, 
Ma et al., 1998). CXCR4 signaling also retains hematopoietic cells in primary 
lymphoid organs (Ma et al., 1999).  Within the HSC niche, CXCL12 and CXCR4 
regulate the retention and quiescence of HSC (Greenbaum et al., 2013, Ding 
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and Morrison, 2013b, Schajnovitz et al., 2011, Nie et al., 2008, Sugiyama et 
al., 2006).  
 Using Cxcl12GFP/+ reporter mice, Nagasawa’s group identified a 
population of perivascular reticular cells, which were denominated as 
CXCL12-abundant reticular cells (CAR cells). CAR cells were observed in close 
proximity with HSC in situ, suggesting that the CAR cell population were 
niche cells (Sugiyama et al., 2006). In a follow-up study, depletion of CAR 
cells using a diphtheria toxin inducible system led to HSC loss, indicating 
that the CAR cell population contained cells with niche activity. Moreover, 
CAR cells produce most of the CXCL12 (and SCF, see below) in BM, exhibited 
multipotent progenitor activity, and showed osteoblastic and adipocytic 
lineage differentiation potential in vivo (Omatsu et al., 2010). The 
transcription factor FOXC1 inhibits adipogenic differentiation in CAR cells, 
which is critical for the maintenance of HSC and hematopoietic progenitors. 
This transcription factor is also involved in up-regulating CXCL12 and SCF. 
Therefore, FOXC1 is a specific transcriptional regulator essential for the 
development and maintenance of mesenchymal niche for hematopoietic cells 
and progenitors (Omatsu et al., 2014).  Around the same time, Frenette’s lab 
identified Nestin-expressing mesenchymal stem cells (MSC) as components 
of the HSC niche (Mendez-Ferrer et al., 2010b). Nestin+ MSC have been 
observed in close contact with HSC and express HSC maintenance genes like 
Cxcl12 and Scf (Mendez-Ferrer et al., 2010b). 
 In 2012, Morrison and colleagues focused on the BM sources of SCF. 
SCF, whose receptor is cKIT, is required for HSC maintenance in vivo 
(Czechowicz et al., 2007, Broudy, 1997, Russell, 1979, Ogawa et al., 1991). 
Membrane-bound SCF is critical for HSC maintenance by acting locally to 
form a niche (Wolf, 1978, Barker, 1994, Barker, 1997). Perivascular and 
endothelial cells are the major SCF producers in BM (Ding et al., 2012). 
Profiling of SCF-expressing cells revealed that SCF cells highly express Lepr. 
Conditional deletion of Scf in endothelial cells or leptin receptor (Lepr)-
expressing perivascular stromal cells depleted the HSC pool, indicating that 
perivascular Lepr+ stromal cells are niche cells. Furthermore, this study 
demonstrated that the HSC niche is perivascular (Ding et al., 2012). 
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 Lepr+ cells have been shown to be mesenchymal progenitor cells with 
osteoblastic and adipocytic lineage potential (Zhou et al., 2014). This is in 
agreement with the observation that Nestin-expressing mesenchymal stem 
cells (MSC) are constituents of the HSC niche (Mendez-Ferrer et al., 2010b). 
In addition, perivascular Lepr+ cells and Nestin+ reticular MSC localize largely 
together in the bone marrow (Kunisaki et al., 2013, Pinho et al., 2013). 
Noteworthy, SCF is not expressed in bone-lining osteoblasts, indicating that 
osteoblasts are not an essential source of SCF for HSC maintenance (Ding et 
al., 2012). 
 A year later, another study from the Morrison’s group demonstrated 
that CXCL12-producing cells highly overlap with SCF expressing cells.  
Conditional ablation of Cxcl12 from Lepr+ cells and endothelial cells 
mobilized HSC and hematopoietic progenitors from the bone marrow to the 
periphery (Ding and Morrison, 2013b), suggesting that CXCL12/ CXCR4 axis 
positions and retain HSC and progenitors within the niche. Some overlap may 
occur among CAR cells, Nestin+, and Lepr+ cells, which will require further 
investigation.  
 Conditional deletion of Cxcl12 in osteoblasts did not significantly 
affect the HSC pool but slightly reduced early lymphoid progenitors in BM 
(Ding and Morrison, 2013b). These results argue that osteoblastic cells 
regulate lymphoid progenitors. Lepr-expressing mesenchymal progenitor 
cells have been described as the major sources of bone and adipocytes in the 
marrow (Zhou et al., 2014). Taken together, the data supports a model in 
which CXCR4/CXCL12 pathway is important for lineage differentiation. 
Indeed, CXCR4 deficiency during adult hematopoiesis affected predominantly 
B lymphopoiesis (Ma et al., 1999, Kawabata et al., 1999, Ara et al., 2003a, 
Nie et al., 2008). The mechanism by which CXCL12 and CXCR4 function to 
regulate HSC differentiation, namely into the B cell lineage, remains unclear. 
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5. B Lymphopoiesis 
 In BM, B lymphocyte development occurs in sequential stages defined 
by the recombination status of V(D)J genes, cell surface receptors, and also 
growth factors requirements. Immature B cells egress to the blood to reach 
secondary lymphoid organs, where they complete their differentiation 
program (Figure 1.3).  Antigen-activated mature B cells proliferate and 
differentiate into plasmablasts, which are fundamental for humoral immune 
responses, home back and colonize the BM (Manz et al., 1997).  
 The following sections will focus on the stages of B cell development 
until their bone marrow egress, and the crucial factors and 
microenvironments that maintain B cells and their precursors during 
development in the bone marrow. 
  
 
 5.1 Ontogeny of B cells 
 In mammals, B cells arise from HSC in the fetal liver (FL) (Gathings et 
al., 1977, Velardi and Cooper, 1984). Progenitor cells from FL seed the fetal 
BM, and after birth, BM is the chief site of B lymphopoiesis. In the BM, the 
interplay between different transcription factors (TF) and specific factors, 
namely, the cytokines FLT3L and IL-7 instructs a progressive development of 
B lymphocyte traits while repressing traits of other hematopoietic lineages.  
 During hematopoietic differentiation, HSC lose their self-renewal 
potential and transit to a progenitor stage expressing FLT3 denominated 
MPP (multipotent progenitor), which still maintains the potential to 
differentiate into all blood cells (Boyer et al., 2011). Gradual expression of 
recombination of activation genes (Rag), terminal 
deoxynucleotidyltransferase (TdT), and expression of the interleukin-7 
receptor (IL-7R) hallmarks the transition to common lymphoid progenitors 
(CLP). CLP are the first lymphoid-restricted progenitor, and has B, T, natural 
killer (NK), and dendritic (DC) cell potential (Kondo et al., 1997). Interestingly, 
CLP can be redirected to the myeloid lineage by stimulation through 
exogenously expressed IL-2 and GM-CSF (granulocyte/macrophage colony-
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stimulating factor) receptors. Moreover, GM-CSF and macrophage colony-
stimulating factor (M-CSF) receptors are expressed at low to moderate 
amounts on HSC, are absent on CLP, and are up-regulated after myeloid 
induction by IL-2. The data indicates that cytokine signaling instruct lineage 
differentiation. Plus, the data also supports that a critical step in lymphoid 
commitment is the down-regulation of cytokine receptors that drive myeloid 
cell development (Kondo et al., 2000). CLP are a heterogeneous population, 
which can be further sub-divided by the surface expression of the markers 
Ly6D and AA4.1 (CD93). Acquisition of Ly6D expression is linked to a higher 
B lymphocyte lineage potential, suggesting that Ly6D+ CLP is the first B-cell 
progenitor (Inlay et al., 2009). The development of AA4.1+ CLP is dependent 
on CXCR4 and CXCL12 (Egawa et al., 2001), but the role of CXCR4 and 
CXCL12 at the CLP stage is not understood. 
 The different stages of B cell development have been described by 
various conventions, which differ in nomenclature (Hardy and Hayakawa, 
2001). In the Basel nomenclature, RAG proteins initiate immunoglobulin (Ig) 
recombination at cKit+ Pro-B cell stage, initiating the transition into Pre-BI 
cells. At the Pre-BI stage, heavy chain genes are rearranged and surrogate 
light chain is expressed. The large cycling Pre-BII cells express the pre-BCR, 
down-regulate cKit, and start expressing IL-2Rα (CD25). At this stage Rag 
proteins are re-expressed to allow Ig rearrangements. The mature BCR is first 
expressed on the surface of CD25- immature B cells (Ernst, 2009). 
 Hardy’s classification distinguishes developmental B cell stages into 
fractions based on their expression of the surface markers CD43, B220, B.P.1, 
HSA (CD24), and IgM (Figure 1.3). Fractions A (pre-Pro-B cells) to C’ (large 
Pre-B) contain early B cell stages identified as B220+CD43+ cells and are 
subdivided by increased expression of HSA and BP.1. Fraction A can be 
further distinguished by the expression of AA4.1 (CD93); AA4.1+ cells 
express RAG proteins, are IL-7 responsive, and are thought to represent true 
B cell precursors (Miller et al., 2002). Mostly after the pre-Pro-B stage, Ig 
gene rearrangements occur. First, heavy-chain DJ (diversity and junction) 
occurs, followed by heavy-chain V(variable)DJ rearrangements. Fractions B 
and C consist of large mitotically active cells, which have heavy-chain DJ 
rearrangements or VDJ rearrangements, and are named Pro-B cells. Loss of 
CD43 marks the maturation to small Pre-B (fraction D). Expression of surface 
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IgM characterizes Immature B cells (fraction E).  Mature re-circulating B cells 
(fraction F) in BM co-express IgD and IgM (Hardy et al., 1991, Nagasawa, 
2006).  
 Immature B cells progress through transitional stages. T1 cells  
(IgMhiIgDloCD93+CD23-) originate T2 cells, which increase IgD expression and 
express CD23. T2 cells develop directly into Follicular B cells (FOB) and 
Marginal Zone B cells (MZ) or become T3 (IgMloIgDhiCD23+) cells. Mature B 
cells do not express AA4.1, are FOB cells (IgMloIgDhiCD21intCD23hi). In the 
spleen, non-circulating mature B cells differentiate into MZ cells 
(IgMhiIgDloCD21hiCD23lo/-) (Allman and Pillai, 2008).  
 
Figure 1.3| Scheme of developmental progression of B lymphoid lineage from 
CLP to mature B cells in mice. Hatched bars denote growth factor and stroma-
dependent stages. Adapted from (Ernst, 2009). 
  
 
 5.2 Essential Factors for B cell development 
 The functional mechanisms of B cell development have been mostly 
characterized using in vitro studies. Knockout and transgenic mice have been 
widely used to understand the mechanisms regulating specific stages of 
maturation, namely to identify the transcription factors responsible for B cell 
identity. Transcriptions factors can induce or repress target genes, therefore 
controlling many events leading to lineage specification, commitment and 
development. Transcription factors are in turn regulated by growth factors, 
cytokines, and chemokines, some of which are produced by niche cells. The 
coordinated crosstalk between the niche environment and cell intrinsic 
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molecular pathways, such as the transcription factors Ikaros, E2A, and early 
B-cell factor (EBF) and PAX5, is fundamental for B cell development. Here, I 
will focus on how chemokines and cytokines instruct and shape B 
lymphopoiesis.  
 It has been well established that B cell development in vitro requires a 
supporting feeding layer of bone marrow-derived stromal cells (Whitlock and 
Witte, 1982, Whitlock et al., 1987, Collins and Dorshkind, 1987, Hunt et al., 
1987), suggesting that in vivo B lymphopoiesis is highly dependent on the 
interaction between developing B lymphocytes and BM stroma. Therefore, 
stromal cells most likely attract B cell precursors by means of adhesion 
molecules and chemokines, such as CXCL12.   
 CXCR4, the receptor for CXCL12, is expressed on subsets of 
developing B cells and both CXCR4 and CXCL12 are critical for B 
lymphopoiesis at the earliest stages of development. CXCL12-deficient 
mouse embryos show severely reduced numbers of the very early B cell 
precursors (Lin-CD19-cKit+IL-7R+AA4.1+ population) in fetal liver. Moreover, B 
cell precursors are decreased in adult BM in chimeric wild-type mice 
reconstituted with CXCR4-deficent fetal cells, compared with control mice 
(Egawa et al., 2001). As mentioned before, CXCR4 has been implied in the 
retention of early developing B cells in BM (Ma et al., 1999, Nie et al., 2004). 
However, the number of Pre-B cells in BM of B cell lineage specific conditional 
CXCR4 knockout is not affected (Nie et al., 2004), suggesting that CXCR4 
and CXCL12 act on B cell development at stages before B cell lineage 
commitment. How CXCR4/CXCL12 regulates B lymphopoeisis at early 
hematopoietic stages needs to be further investigated.  
 
 FLT3L is the ligand for the tyrosine kinase receptor FLT3. FLT3 
expression labels all hematopoietic progenitors (Boyer et al., 2011). 
Deficiency in FLT3 reduces pre-Pro-B, and Pro-B cells numbers by twofold, but 
Pre-, immature and mature B cells numbers are not significantly affected 
(Mackarehtschian et al., 1995). By contrast, FLT3L deficiency results in a 
dramatic reduction in pre-Pro-B cell numbers, slightly reduced Pro- and Pre-B 
cells numbers, but did not affect more differentiated B lymphocytes (Sitnicka 
et al., 2002, Sitnicka et al., 2003). The existence of uncharacterized 
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receptors for FLT3L may explain the phenotypic differences between FLT3 
and FLT3L knockout mice (Nagasawa, 2006). Before commitment to B cell 
lineage, FLT3-deficiency impairs dramatically the CLP population, which also 
leads to a severe reduction in ETP (emigrant thymocyte progenitors) but only 
mildly reduces more differentiated thymocytes (Sambandam et al., 2005, 
Sitnicka et al., 2002). Taken together, these data suggest that FLT3 signaling 
acts on MPP, CLP, pre-Pro-B cells and ETP. Furthermore, FLT3L is also 
important for the development of some types of DC (McKenna et al., 2000, 
Brawand et al., 2002), and NK cells (McKenna et al., 2000), which arise from 
CLP or pre-Pro-B cells (Rolink et al., 1996, Pelayo et al., 2005, Diao et al., 
2004). FLT3L acting synergistically with IL-7 also stimulates pre-pro-B cell 
growth (Hunte et al., 1996). 
 
 The SCF and cKit pathway is not required for B lymphopoiesis per se 
(Takeda et al., 1997). Instead, SCF is required at the MPP and CLP stages. The 
cKit-deficiency at CLP stage leads to a block in B lymphopoiesis at the Pro-B 
stage, in the adult mice (Waskow et al., 2002), when B lymphopoiesis occurs 
in BM and is highly dependent on IL-7.  
 
 RANKL (also known as OPGL and ODF) is a transmembrane protein 
essential for osteoclast development and for bone remodeling (Kong et al., 
1999, Yasuda et al., 1998, Lacey et al., 1998). RANK is the receptor for 
RANKL, and is expressed by DC, T cells and osteoclast precursors (Anderson 
et al., 1997, Dougall et al., 1999). RANKL is highly expressed by BM-derived 
primary stromal cells, osteoblasts and osteocytes (Yasuda et al., 1998, 
Nakashima et al., 2011). However, RANKL expressed by lymphoid cells is 
important for B lymphopoiesis (Kong et al., 1999). It is still unknown which 
RANKL-expressing cells acts on B cell development (Nagasawa, 2006).      
  
 IL-7 is essential for adult B lymphopoiesis (von Freeden-Jeffry et al., 
1995, Carvalho et al., 2001, Peschon et al., 1994). The stromal compartment 
in FL, BM, thymus, spleen and lymph nodes produces IL-7. IL-7 binds to IL-7R, 
which is a heterodimer composed of the IL-7Rα chain and the common γ (γc) 
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chain. The IL-7Rα chain confers receptor specificity for IL-7 binding (Jiang et 
al., 2005, Corfe and Paige, 2012). IL-7 binding triggers the 
heterodimerization of the α and γc chains, resulting in the trans-
phosphorylation of the constitutively associated JAK1 and JAK3. Activated 
JAK kinases phosphorylate tyrosine residues in the α chain. Receptor 
phosphorylation leads to activation of Src kinases (LYN/ FYN/ Btk) and also 
creates docking sites for SH2 domain containing proteins PI3K and STAT 
(Jiang et al., 2005).  Phosphorylation of the IL-7Rα chain allows the 
recruitment of mostly STAT5 and STAT3, which hetero- and homodimerize 
and then translocate to the nucleus, where they act as transcription factors. 
STAT3 mediates the survival e differentiation of Pro-, Pre-, and Immature B 
cells (Chou et al., 2006). STAT5 carries out the majority of STAT-mediated 
responses in B lymphopoiesis. STAT5 is critical for the expression of EBF 
and PAX5 (Dai et al., 2007). Src kinases potentially help to activate STAT 
proteins (Ingley and Klinken, 2006).    
 IL-7/IL-7R signaling is required for the maintenance of the B cell 
potential at the CLP stage and for survival and proliferation of developing B 
cells.  Deficiency in IL-7 or IL-7R arrests the development of B and T cells but 
not NK cells or DC (Peschon et al., 1994, von Freeden-Jeffry et al., 1995, 
Moore et al., 1996, Rodewald et al., 1999). IL-7 deficiency arrest B 
lymphopoiesis before the Pro-B cell stage (Peschon et al., 1994, von Freeden-
Jeffry et al., 1995, Carvalho et al., 2001, Dias et al., 2005). In the periphery, 
some B lymphocytes are detected when IL-7 is absent.  Most likely, these 
lymphocytes were generated during fetal life, when B cell development is not 
strictly dependent on IL-7. Fetal derived Pro- and Pre-B cells respond to 
thymic stromal lymphopoietin (TSLP), whose receptor is formed by IL-7Rα 
chain and a TSLP-dedicated chain, while in adult BM, only Pre-B cells are TSLP 
responsive (Vosshenrich et al., 2003, Vosshenrich et al., 2004). Transgenic 
expression of TSLP in IL-7 knockout mice restored both fetal and adult B cell 
development, suggesting that TSLP could substitute for IL-7 in fetal B 
lymphopoiesis (Chappaz et al., 2007). However, deficiency for IL-7 and TSLP 
did not translate into more severe fetal B lymphopenia. Instead, FLT3L and IL-
7 deficiency completely abolished fetal and adult B cell development 
(Adolfsson et al., 2005, Jensen et al., 2007, Jensen et al., 2008), suggesting 
that during fetal development FLT3 and IL-7R signaling is critical for B cell 
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development. Furthermore, FLT3 signaling is fundamental for the residual B 
cell development in IL-7Rα-deficient mice (Vosshenrich et al., 2003). IL-7 is 
also fundamental for non-committed hematopoietic progenitors as IL-7 
signaling deficiency strongly depletes CLP, specially the Ly6D+ population 
(Dias et al., 2005, Tsapogas et al., 2011), which leads to a strong arrest in 
adult BM-dependent B cell development. In addition, CLP isolated from IL-7 
deficient mice show reduced ability to generate B cells both in vitro and in 
vitro (Dias et al., 2005, Tsapogas et al., 2011), and Ly6D+ CLP have lower 
levels of EBF (Tsapogas et al., 2011). Overexpression of EBF restores the B 
cell differentiation potential of IL-7 deficient CLP (Dias et al., 2005, Kikuchi et 
al., 2005). IL-7 signaling also regulates E2A and PAX5 expression (Hirokawa 
et al., 2003), and promotes V(D)J recombination. IL-7 mediated survival of B 
cell precursors by inducing the expression of myeloid-cell leukemia sequence 
1 (MCL1) protein (Opferman et al., 2003).  
 After commitment to the B cell lineage, the main function of the IL-7R 
is to maintain and expand early B cell stages by activating STAT5, inducing in 
turn the expression of anti-apoptotic factors and cyclin D3, which mediates 
transit through the cell cycle. Via STAT5, IL-7R signaling leads to 
hyperacetylation at the distal V-heavy chain segments and thus allows for 
heavy chain loci accessibility in B cells (Bertolino et al., 2005) and also 
signals to specifically induce the recombination of D-heavy chain to distal V-
heavy chain segments in pro-B cells, by altering the accessibility of DNA 
substrates to RAG proteins (Corcoran et al., 1998). Complementary signaling 
through PI3K-AKT pathway represses apoptotic factors and provides the 
growth and energetic states that are required for proliferation and survival 
(Clark et al., 2014). In addition, IL-7R signaling also prevents Igλ gene 
recombination by repressing its locus and by preventing FOXO-induced Rag 
expression (Clark et al., 2014).  
 Even though IL-7 is fundamental for adult murine B lymphopoiesis, for 
a long time IL-7 was considered dispensable for human B lymphocyte 
development. In humans, the disruption of the IL-7R due to genetic 
mutations causes severe combined immunodeficiency disease (X-SCID), 
resulting in absence of T lymphocytes and NK cells but no effects on B cell 
numbers are detected (Puel et al., 1998). Yet, similar to mice, B cells in X-
SCID patients may arise during fetal or neonatal development. Co-cultures of 
37"
human BM stroma with either cord blood or adult BM HSC were dependent 
on IL-7 for B lymphopoiesis, while neonatal cord blood generated B 
lymphocytes independent of IL-7 (Parrish et al., 2009). Similarly to observed 
in murine models, TSLP does not substitute IL-7 in human B lymphopoiesis, 
but FLT3L supports IL-7-independent B cell development in neonatal cord 
blood (Parrish et al., 2009). Human B lymphocyte progenitors express IL-7R 
and are responsive to IL-7 in a STAT5 mediated manner (Johnson et al., 
2005). A recent study using mass cytometry detected phosphorylation of 
STAT5 in response to IL-7 in a rare population of human B cell progenitors, 
suggesting that IL-7 plays an instructive role in early B lymphopoiesis in 
humans (Bendall et al., 2014).  
  
 Bone marrow stromal compartment most likely produces and delivers 
the key factors described above to B cell progenitors. However, the precise 
identity of the stromal cells supporting B cell development from commitment 
to differentiation is still not clear. 
 
 
 5.3 B lymphopoiesis supporting cells 
 Different stromal-cell lines have shown to produce different 
environmental factors in vitro (Sudo et al., 1989, Zipori et al., 1985b, Zipori 
et al., 1985c, Zipori et al., 1985a), but whether a single stromal cell type or 
different types of stromal cells in vivo support B lymphopoiesis is unknown. 
Recent studies have implicated some BM cell types as the specific cellular 
niches for B lymphopoieisis.  
 
 CXCL12-expressing cells are likely candidate cells to support B 
lymphopoiesis because CXCL12 is required for the generation of pre-pro-B 
cells (Egawa et al., 2001). As stated before, different types of BM stromal 
cells have been described to produce CXCL12 (table 1.2). Interestingly, most 
of CXCL12-producers stromal cells are perivascular and show mesenchymal 
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stem and progenitor cell characteristics (Omatsu et al., 2010). Therefore, for 
clarification, these cells will be referred as CAR cells (Sugiyama et al., 2006). 
CAR cells express VCAM-1 (Tokoyoda et al., 2004), SCF (Ding et al., 2012), 
Nestin (Mendez-Ferrer et al., 2010b), LEPR (Ding and Morrison, 2013b), 
platelet-derived growth factor receptor (PDGFRα), CD51 (Pinho et al., 2013), 
myxovirus resistance-1 (MX-1) (Park et al., 2012), the transcription factor pair 
related homeobox-1 (PRX-1) that marks cells of the limb bud mesoderm, and 
the transcription factor Osterix (OSX, also called SP7) (Greenbaum et al., 
2013), which is necessary for osteoblast differentiation. Remarkably, mature 
osteoblast express low amounts of CXCL12 (Greenbaum et al., 2013, Ding 
and Morrison, 2013b).  
 
 Osteoblasts arise from MSC, and are responsible for synthesis, 
deposition and mineralization of bone extracellular matrix (Nagasawa, 2006, 
Frenette et al., 2013). Contrary to initial observations (Calvi et al., 2003, 
Zhang et al., 2003), osteoblasts do not directly regulate HSC maintenance 
but have been implicated in regulating B cell progenitors (Taichman et al., 
1996, Taichman, 2005, Visnjic et al., 2004). Cultures enriched for 
osteoblasts support B lymphopoiesis (Zhu et al., 2007). In addition, 
osteoblast depletion affects some B cell progenitors (Visnjic et al., 2004). 
Conditional deletion of CXCL12 in osteoblasts and their progenitors causes a 
twofold reduction in CLP (Ding and Morrison, 2013b). Nonetheless, only 
~30% of IL-7R+lineage- BM cells localize in proximity to the endosteum (Ding 
and Morrison, 2013b). Furthermore, CXCL12 expression by osteoblast is low 
and conditional deletion of CXCL12 in mature osteoblasts (by expression of 
Cre recombinase under the promoter for Bglap, which codes for Osteocalcin) 
did not affect CLP nor B lymphopoiesis (Greenbaum et al., 2013). 
Consequently, the role of osteoblasts as a niche for B lymphopoiesis needs 
to be further analyzed. The previous studies accessing a role for osteoblasts 
as the B lymphoioiesis niche have the caveat of using Cre recombinase 
systems that are active at the progenitor stage. Since osteoblasts arise from 
MSPC, it is possible that the effects observed are due to the deletion of 
CXCL12 at the MSPC. It is unknown whether fully differentiated osteoblasts 
produce IL-7, which is fundamental to support B lymphopoiesis.  
39"
 IL-7-expressing cells in the BM were first identified by 
immunohistochemical analysis, and characterized by the expression of 
VCAM-1, fibroblast-like shape, and lack of CXCL12 expression (Tokoyoda et 
al., 2004), suggesting that CAR cells and IL-7-expressing cells represent 
distinct stromal subsets. However, the specific immunostaining for IL-7 is 
technically challenging (Mazzucchelli et al., 2009).  Most likely IL-7 
immunostaining only captures a small fraction of the IL-7+ cells, perhaps 
those cells that expressed the highest amount of the cytokine. Therefore, the 
generation of reporter mice for Il7 greatly facilitates the detection of IL-7-
expressing cells.  Using Il7GFP/+ mice, IL-7 production was detected in VCAM-1+ 
mesenchymal stromal cells, in ~10% of endothelial cells (VCAM-1+CD31+) and 
in some PDGFα+ stromal cells (Hara et al., 2012). Interestingly, data from 
gene array (Mendez-Ferrer et al., 2010b) and RNA-seq (Kunisaki et al., 2013) 
studies detected IL-7 and CXCL12 expression in Nestin-expressing MSC. IL-7 
expression by a stromal-cell line is induced by stimuli, such as cytokines, and 
B-cell precursors (Sudo et al., 1989). Consequently, IL-7-expressing cells 
need to be further characterized in terms of factors expressed, nature and 
localization within BM parenchyma.  
   
 
 5.4 In vivo model for B lymphopoiesis  
 Commitment to B cell lineage seems to occur in proximity to the CAR 
cells as HSC and pre-pro-B cells were shown to be in contact with CAR cells 
(Tokoyoda et al., 2004, Ding et al., 2012, Ding and Morrison, 2013b, 
Mendez-Ferrer et al., 2010b, Sugiyama et al., 2006). The observation of B cell 
precursors in direct contact with stromal cells raises the question of whether 
adhesion interactions mediate the positioning of developing lymphocytes 
relative to stromal cells. Cell adhesion is mediated through reversible 
interactions between cell-surface receptors and their counter-receptors. The 
observation that BM stromal cells express VCAM-1 (Tokoyoda et al., 2004) 
suggests that integrins expressed by B cell progenitor cells might have a role 
in refereeing the adhesion of these cells to stromal cells. Integrins are 
transmembrane heterodimers of noncovalently paired α and β subunits (Luo 
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et al., 2007). Integrins α
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belong to the family of 
leukocyte-specific integrins (Hynes, 2002). α
4
 and
 
β
2 
integrins mediate 
leukocyte rolling as well as arrest (Ley et al., 2007). The major ligands for 
leukocyte integrins are transmembrane glycoproteins with multiple domains 
that belong to the immunoglobulin superfamily. α
L
β
2 
binds to ICAM-1, α
4
β
1 
binds to VCAM-1, and α
4
β
7
, to VCAM-1 and to mucosal addressin cell 
adhesion molecule-1 (McEver and Zhu, 2010).  
 The role of α
4
 integrin and its counter parts β
1
 and β
7
 integrins in the 
hematopoietic development has been controversial. α
4
 integrins have been 
implicated in hematopoiesis (Williams et al., 1991), lymphocyte homing 
(Holzmann and Weissman, 1989), and recruitment of leukocytes to the 
inflammatory focci (Yednock et al., 1992). In addition, α
4
β
1
 receptor has been 
suggested to have a role in the attachment and homing of hematopoietic 
progenitors to the bone marrow in primates and mice (Papayannopoulou et 
al., 1995, Papayannopoulou and Nakamoto, 1993, Papayannopoulou et al., 
1998). Even though the adult and fetal hematopoietic development are α
4
 
integrin-independent, the seeding and retention of hematopoietic 
progenitors in the bone marrow depends on α
4
 and β
1
 integrins (Bungartz et 
al., 2006, Potocnik et al., 2000, Brakebusch et al., 2002). Based on these 
results, α
4
 integrin might be mediating the interactions between B cell 
progenitors and IL-7-producing stromal cells but this integrin would not be 
critical because the adult B cell development, which is independent on β
1
 and 
β
7
 integrins, the counterparts of α
4
 integrin (Bungartz et al., 2006). α
4
β
1
 
integrin has a dominant role in bone marrow homing of hematopoietic 
progenitors (Papayannopoulou et al., 2001a), but it can synergize with β
2
 
integrins to retain hematopoietic progenitors in bone marrow parenchyma 
(Papayannopoulou et al., 2001b).  Along these lines, CLPs express α
4
β
1
 and 
α
L
β
2
 integrins and migrate to the thymus (Scimone et al., 2006). These 
findings indicate that α
L
β
2
 integrin is expressed at CLP stage and its 
activation is dependent on a Gα
i
-dependent pathway. 
 The current model of B lymphopoiesis implies that CLP are attracted 
to IL-7 sources in a CXCR4-independent manner, and pre-Pro-B cells relocate 
to close proximity to CAR cells. Nevertheless, the earliest B cell progenitors 
are dependent on IL-7 (Dias et al., 2005, Tsapogas et al., 2011), CXCR4 and 
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CXCL12 (Egawa et al., 2001). It is puzzling how this population is able to 
receive these critical factors when they are produced by different sources in 
BM. Moreover, it is also not known the mechanism controlling the migration 
of the pro-B cells from the CAR cells to the IL-7 expressing cells where they 
were observed in close proximity (Tokoyoda et al., 2004).  
 Pre-B cells have been described to be away from both CAR and IL-7-
expressing cells and in close contact with Galectin-1 (GAL1) expressing 
stromal cells (Tokoyoda et al., 2004, Mourcin et al., 2011). GAL1 may be a 
ligand for pre-BCR (Gauthier et al., 2002) and has been shown to interact 
with integrins, such as α
4
β
1
 on pre-B cells. At the contact area, integrins and 
their ligands, the pre-BCR and GAL1 form a matrix. Moreover, when the 
cross-linking of pre-B cells integrins occurs in the presence of GAL1, the pre-
BCR is recruited into the synapse, triggering the pre-BCR signaling (Rossi et 
al., 2006). Most strikingly, GAL1-deficient mice do not show an apparent B-
cell phenotype (Espeli et al., 2009). In addition, structural biochemical 
analyses of the pre-BCR indicate that the pre-BCR cannot bind antigen 
(Bankovich et al., 2007).  Pre-B cells transit between an IL-7-dependent 
proliferative state to a pre-BCR-dependent stage to subsequently re-express 
RAG proteins and assemble and express a fully functional BCR (Ochiai et al., 
2012, Clark et al., 2014). It is likely that the positioning of pre-B cells relative 
to IL-7-expressing cells reinforces the switch from a fate that is directed by 
the IL-7R to one that is determined by the pre-BCR. Downstream of the pre-
BCR, IRF4 induces expression of CXCR4 (Johnson et al., 2008), which has 
been suggested to facilitate the movement of pre-B cells away from IL-7-
expressing cells and the attenuation of IL-7R signaling.  
 Immature B cells are distributed between BM parenchyma and 
sinusoids, and are particularly dependent on CXCR4 for retention within BM 
parenchyma (Pereira et al., 2009). However, immature B cells were not seen 
in contact with CAR or IL-7-expressing cells (Tokoyoda et al., 2004). CXCL12 
is a long-range soluble cytokine and thus, immature B cells do not require to 
be in close proximity to CAR cells. Immature B cells egress from BM 
parenchyma to the sinusoids. The mechanisms regulating BM B cell egress 
are not fully understood (see below). Within sinusoids, immature B cells rely 
on α
4
β
1
-VCAM-1 interactions and on the Gα
i
-coupled receptor Cannabinoid 
receptor 2 (CB2) for their retention. Furthermore, the presence of large 
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numbers of adherent and migrating immature B cells in the sinusoids 
suggested that rather than serving solely to support blow flow, these vessels 
constitute a specialized cellular niche in BM that may influence B cell 
development. In support of this possibility, CB2 deficiency led to a lower 
frequency of λ+ immature B cells in the periphery (Pereira et al., 2009).   
 
Figure 1.4| Model of B 
lymphopoiesis in BM.  HSC and 
pre-Pro-B cells are located near 
perivascular CAR cells (Tokoyoda 
et al., 2004, Sugiyama et al., 2006), 
whereas Pro-B cells adjoin IL-7+ 
cells. Pre-B cells are near GAL1+ 
cells and away from IL-7+ cells 
(Mourcin et al., 2011, Tokoyoda et 
al., 2004).  Immature B cells are 
partitioned between the BM 
parenchyma and the sinusoids 
(Pereira et al., 2009). 
 
 The regulatory mechanisms of the interactions between developing B 
cells and their cellular niches remain unclear. It is also still unclear the role of 
CXCR4/ CXCL12 axis in B lymphopoiesis. It may mediate cell attraction to the 
niche, enhance developing B cell adherence to the stroma (possibly through 
activation of integrins), and/or support B cell progenitors survival within the 
niche (Egawa et al., 2001, Tokoyoda et al., 2004, Nagasawa, 2006).  
 
 
 5.5 Developing B cell egress  
 Lymphocyte egress from primary and secondary lymphoid organs 
(SLO) is fundamental for a functional immune system. Lymphocytes 
continually recirculate by entering SLO from the blood, to then exit SLO into 
the lymph, and return to circulation via the thoracic duct (Gowans and Knight, 
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1964, Ford, 1968, Ford, 1969, Cyster, 2005).  If egress occurs prematurely 
during lymphocyte development, it can lead to development of autoimmune 
disease (Zachariah and Cyster, 2010); if it occurs inefficiently, it can lead to 
severe lymphopenia and immune deficiency.  
 Egress occurs when lymphocytes gradually reduce their retention in 
lymphoid organs while becoming increasingly attracted to exit sites 
(circulatory fluids, blood and lymph) (Pham et al., 2008). Therefore, egress is 
dependent on chemokine-mediated migration – chemotaxis, of immune cells. 
Chemokines bind to their receptor, engaging G-protein coupled receptors 
(GPCR), predominantly Gα
i
 proteins (Cyster, 2005). Expression of the ADP-
ribosylating subunit of pertuxis toxin (PTX) in thymocytes blocked their 
thymus egress, indicating that Gα
i
-coupled receptors are involved in immune 
cell egress (Chaffin and Perlmutter, 1991).  
 S1PR
1
 is the GPCR responsible for B and T lymphocyte egress from SLO, 
and T cell egress from the thymus (Cyster and Schwab, 2011).  These 
receptor binds to the bioactive lipid Sphingosine 1-phosphate (S1P). There 
are five known S1P receptors, named S1PR
1-5
. Naive T and B lymphocytes 
express high amounts of S1PR
1
 and lesser amounts of S1PR
2
, S1PR
3
, and 
S1PR
4 
(Cyster, 2005). S1P is a potent chemoattractant abundant in blood and 
lymph but less abundant in lymphoid tissue interstitium, creating a 
concentration gradient, which is fundamental to egress (Schwab et al., 2005, 
Pappu et al., 2007).  
 Egress from BM is thought to occur via the vast network of sinusoids. 
How cells enter the sinusoids is not fully understood. S1PR
1
 is unlikely to be 
the only regulator of B cell egress from BM (Pereira et al., 2010b, Allende et 
al., 2010). Deficiency in S1P/S1PR
1
 pathway leads to a more than one 
hundred fold reduction in T and B lymphocytes in the periphery (Matloubian 
et al., 2004). In contrast, if S1P
1
 is ablated in developing B cells, only a small 
decrease of immature B cells is seen in the periphery and a small but 
statistical significant accumulation of immature B cells in the BM parenchyma 
(Pereira et al., 2010b, Allende et al., 2010).  These observations suggest that 
S1PR
1 
may work together with other receptors to promote egress.  Other Gα
i
-
protein coupled receptors have been implicated in developing B cell 
positioning in BM. S1PR
3
 and CB2 retain immature B cells in the sinusoids, 
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together with the integrin α
4
β
1
 and its counterreceptor VCAM-1 (Pereira et al., 
2009, Donovan et al., 2010).  
 CXCR4 expression decreases from pro to pre-B and is further down-
regulated in immature B cells, which agrees with the increasing loss of 
retention. This raises the possibility that S1PR
1
 signaling overrides the 
CXCR4-mediated retention, thus promoting B lymphocyte egress. A study has 
shown that blockade of CXCR4 in S1PR
1
-deficient B cells did not release 
immature B cells to the periphery (Allende et al., 2010), supporting this 
hypothesis. Nevertheless, ablation of CXCR4 mobilizes immature B cells but 
the majority of pro and pre-B cells remains in the BM parenchyma (Pereira et 
al., 2009). In addition, overexpression of S1PR
1
 in pro and pre-B cells does 
not decrease their number in BM parenchyma (Pereira et al., 2010b). 
Together these data suggest that additional factors guide immature B cells to 
egress sites. Ultimately, how immature B cells egress from BM remains 
poorly understood.   
 
" 
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Chapter 2 | Aims 
 
 Despite their high complexity and variety, immune cells share two 
characteristics: they originate from a hematopoietic stem cell and they rely 
on cell migration and positioning to develop and also to carry on immune 
responses. Cell positioning and migration during immune responses and 
within secondary lymphoid organs has been broadly studied over the past 
three decades, but a huge gap lies on the understanding of cell positioning 
during hematopoiesis.  
 Except from T lymphocytes, all hematopoietic lineages develop in the 
bone marrow and are exported to the periphery. The BM stromal and 
sinusoidal compartment has been implicated in the maintenance of HSC and 
regulation of their quiescence. However, it is still unknown how 
hematopoietic progenitors interact and position relative to supporting cells. 
Hematopoietic lineage differentiation is regulated through the interplay of 
transcription factors. Besides transcription factors, cytokines have been 
found fundamental for lineage commitment. In particular, IL-7 is critical in B 
lymphopoiesis to maintain B lineage cell potential. Strikingly, IL-7 is a 
secreted cytokine but its levels in serum are very low, suggesting a tight 
regulation of IL -7 production and a local consumption of the cytokine 
(Guimond et al., 2009). This suggests that B cell progenitors and developing 
B lymphocytes have to be positioned in close proximity to IL-7-expressing 
cells. However, IL-7 producers in bone marrow are poorly characterized. 
Indeed, only the cellular components responsible for HSC maintenance in 
bone marrow niche were studied; cellular components of the niche 
responsible for lineage instruction remain unknown. It is critical to 
understand whether MPP require signals from HSC niches, or from other BM 
niches, for lineage differentiation.  
 CXCR4/CXCL12 is a key organizing chemokine receptor/ chemokine 
pair in the bone marrow, by controlling fundamental processes of HSC 
biology, such as quiescence, homing to bone marrow and maintenance in the 
hematopoietic niche. CXCR4 function on HSC is important for B 
lymphopoiesis (Nie et al., 2008, Sugiyama et al., 2006), so B lymphocytes are 
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an ideal immune cell type to understand hematopoietic differentiation niches 
within bone marrow. We dissociated the role of CXCR4 in HSC from a 
possible role in hematopoietic progenitors by conditionally deleting CXCR4 
in different stages of B lymphopoiesis.  
 
 In the present thesis, I sought to address the positional cues 
responsible for the positioning of hematopoietic progenitors and developing 
B cells within differentiation niches in bone marrow. Thus, I focused on: 
 1 – Defining the mechanism of immature B cell egress from the bone 
marrow (Chapter 3); 
 2 – Characterizing the lymphoid differentiation niche and the 
molecular mechanisms regulating the positioning of hematopoietic 
progenitors within the niche (Chapter 4). 
 Finally, by comprehending the function of the hematopoietic niches, 
we aim at solving how extrinsic cues affect lineage output and contribute to 
leukemogenesis and other hematopoietic disorders. 
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Chapter 3| CXCR4 and a cell-extrinsic mechanism 
control immature B lymphocyte egress from bone 
marrow 
 
 Previous studies had described that CXCR4 and its ligand CXCL12 
were critical for B lymphopoiesis (Egawa et al., 2001, Nie et al., 2008). 
However, deletion of CXCR4 specifically on B lymphocytes did not affect B 
cell development (Nie et al., 2004). I started my doctoral research by asking 
whether CXCR4 was required at early stages of B cell development.  For that 
purpose, we conditionally ablated Cxcr4 expression from the pro-B stage on, 
using Mb1cre/+. Fascinatingly, we found that B cell development proceeded 
normally even though the lack of the retention due to CXCR4-deficiency 
speeded up their egress from BM. Thus, we looked closer to the role of 
CXCR4 in the egress of developing B cells. We found that immature B cells 
down-regulate CXCR4 expression by twofold when they transit from BM 
parenchyma to the sinusoids. In addition, reduction of CXCR4 expression by 
using CXCR4 heterozygous immature B cells was sufficient to promote the 
egress of immature B cells. These data suggested that CXCR4 retention 
signaling is stronger than the weak egress-promoter signaling of S1P
1
 in 
immature B cells (Pereira et al., 2010b). Since egress is mediated by PTX 
sensitive-Ga
i
-coupled receptors (Cyster, 2005), we then proceeded to ask 
whether other Gα
i
-protein coupled receptor was involved in BM egress of 
immature B cells. For this purpose, we analyzed mice where all GPCR 
signaling is exclusively inhibited in developing B lymphocytes by crossing 
Rosa26PTX with Mb1cre/+ mice. It was surprising that in absence of Gαi function, 
developing B cells egress faster than wild-type cells, which indicates the 
existence of Gα
i
-independent mechanism of B cell egress. Simultaneously, in 
the lab, a fellow graduate student found that immature B cells retention 
within BM was strictly dependent on amoeboid motility mediated by CXCR4 
and CXCL12 and by α
4
β
1 integrin mediated-adhesion to VCAM-1. Moreover, 
immature B cells near the sinusoids had reduced motility, were 
predominantly round, and transversed the endothelium in a largely non-
amoeboid fashion. The passive mode of cell egress from BM also contributes 
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significantly to the export of other hematopoietic cells, such as NK cells.  
Together, our results challenged the paradigm that the BM egress of immune 
cells is dependent on the S1P/S1P
1
 pathway, highlighting the egress 
differences between B and T cells, and were published in the Journal of 
Experimental Medicine. This study also showed that antigen-induced BCR 
signaling antagonized CXCR4 down-regulation and therefore immature B cell 
egress from BM. 
 In this chapter I will present the data I obtained regarding the 
immature B cell egress project. The full publication can be found in the 
appendix section.  
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Abstract 
 In later stages of B cell development, immature B cells are 
partitioned between BM parenchyma and the sinusoids, from which they 
egress to the periphery. In order to egress, lymphocytes gradually 
reduce their retention in lymphoid organs while become increasingly 
attracted to exit sites. The bioactive lipid S1P and its receptor S1P
1
 are 
strictly required for T cell egress from thymus, and for T and B cell 
egress from SLOs. Even though immature B cells express abundantly 
S1P
1
 and are attracted to S1P gradients in in vitro chemotaxis assays, 
immature B cells still egress with high efficiency when they either lack 
S1P
1
, or when S1P is not produced (Pereira et al., 2010b). Here, we show 
that B cells residing in sinusoids reduced CXCR4 expression by 2-fold, 
and that a 2-fold reduction is sufficient for promoting B cell 
displacement from the BM parenchyma, suggesting that CXCR4 is the 
critical B cell retention chemoattractant in BM parenchyma. Other GPCRs, 
besides S1P receptors, may contribute to B cells export into the blood. By 
conditionally expressing PTX in developing B lymphocytes, we found that 
B-lineage cells were reduced in BM and enriched in peripheral blood and 
spleen, indicating that cells exited prematurely from BM. These findings 
show a novel mechanism regulating cell egress from BM that is 
independent of GPCR signaling.  We speculate that Gα
i
-dependent and 
independent egress mechanisms might occur simultaneously. 
 
1. Introduction 
 Leukocyte egress from lymphoid organs by active migrating toward 
exit sites, where they reverse transmigrate across endothelial barriers. 
Lymphocyte egress from thymus and lymph nodes is critically dependent on 
the chemoattractant lipid S1P. S1P is abundant in blood and lymph but 
limited in the lymphoid organs interstitium, creating a sharp concentration 
gradient. Lymphocytes express the S1PR
1
, which allows them to sense S1P 
gradient. Deficiency in S1PR
1
 reduces by ~50-1,000-fold T and B cell numbers 
in circulatory fluids, and significantly increases their numbers in lymphoid 
organs (Cyster and Schwab, 2012). S1PR1 signaling mediates lymphocyte 
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egress in part by overcoming lymphoid organ retention mechanisms (Pham 
et al., 2008). BM cell egress juxtaposes to thymus and lymph nodes egress. 
Genetic or pharmacologically induced S1P receptor deficiency causes an 
approximately two to three-fold reduction in immature B, NK cells and 
eosinophil export from BM (Walzer et al., 2007, Jenne et al., 2009, Allende et 
al., 2010, Pereira et al., 2010b, Sugita et al., 2010), suggesting that S1P and 
S1PR
1
 are not the exclusive mediators of BM egress. S1P
1 
may work together 
with other receptors to promote immature B lymphocyte egress from BM.  
 At the immature stage, B cells continue to redistribute away from IL-7+, 
and also from GAL1+ stromal cells, and become competent for export from 
bone marrow (Mourcin et al., 2011, Tokoyoda et al., 2004). Before exiting BM, 
immature B lymphocytes are transiently retained within BM sinusoids via a 
mechanism dependent on α
4
β
1
 integrin transactivation by CB2 and adhesion 
to VCAM-1 (Pereira et al., 2009). Within sinusoidal niches, immature B 
lymphocytes crawl, detach and re-attach with some cells homing back to the 
parenchyma while other cells are released into peripheral circulation175. S1RP
3 
has also been implicated in the retention of immature B cells within 
sinusoids (Donovan et al., 2010).  
 In late stages of B cell development, immature IgM+ lymphocytes are 
exported from BM via sinusoids into peripheral blood circulation. S1P/S1PR
1
 
pathway contributes minimally to immature and mature B lymphocyte egress 
(Pereira et al., 2010a, Allende et al., 2010). 
 In B cells, CXCR4 is expressed at highest levels in Pro-B cells and, even 
though its expression decreases as cells progress in B cell development, 
receptor activity significantly increases in a stepwise manner until the mature 
B cell stage (Glodek et al., 2003, Pereira et al., 2010b, Pereira et al., 2009). 
Likewise HSC, B lymphocytes are critically dependent on CXCR4 for homing 
to, and retention within BM parenchyma (Ara et al., 2003; Broxmeyer et al., 
2005; Nagasawa, 2006; Nie et al., 2008; Nie et al., 2004; Peled et al., 1999; 
Pereira et al., 2009; Sugiyama et al., 2006). CXCL12, the CXCR4 ligand, is a 
potent chemoattractant to various hematopoietic cells, and is abundantly 
expressed by non-hematopoietic cells in BM, including stromal cells, 
osteoblasts, endothelial, and perivascular cells (Sugiyama et al., 2006, Ding 
and Morrison, 2013a).  CXCR4/CXCL12 counteracts the activity of egress-
promoting cues in immature B lymphocytes, neutrophils, NK cells and in 
monocytes (Bernardini et al., 2008, Wang et al., 2009, Allende et al., 2010, 
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Eash et al., 2010), though how CXCR4 signaling antagonizes cell egress 
remains unknown. 
 It is puzzling why the export of T cells from the thymus is solely 
dependent on S1P/S1PR
1
 pathway whereas the export of different cells types 
in BM is not completely dependent on a single GPCR-mediated mechanism. 
For instance, CXCR2 and CCR2 mediate the BM egress of, respectively, 
neutrophils and monocytes. Deficiency in either receptor has a small effect in 
BM egress of these cells (Serbina and Pamer, 2006, Shi et al., 2011, Eash et 
al., 2010). Two models can be employed to explain BM egress. First, several 
GPCR play a redundant role in the egress of different cell lineages from BM. 
Second, alternative mechanisms control hematopoietic cell egress from BM. 
The second model is supported by the observation that millions of RBC are 
produced and exported daily from BM (Lichtman and Santillo, 1986), and that 
these cells lack mechanisms for interstitial amoeboid cell migration. 
 In this study, we demonstrate that down-regulation of CXCR4 is critical 
for immature B cell egress from BM. Remarkably, B cell exit from BM was 
accelerated by lymphocyte intrinsic PTX expression, indicating that the 
directed migration towards BM exit sites is largely controlled by a passive, 
GPCR-independent, mechanism. Finally, this passive mode of cell egress from 
BM is not restricted to developing B lymphocytes but also contributes 
significantly to NK cell egress from BM.  
 
 
2. Material and Methods 
 
Mice. Adult C57BL/6 (CD45.2+), Boy/J (CD45.1+) were obtained from The 
Jackson Laboratories. Cxcr4Fl/Fl, Rosa26FloxSTOP-PTX/+ transgenic mice were from 
internal colony. Cxcr4Fl/- and Rosa26FloxSTOP-PTX/+ mice were crossed with Mb1cre/+ 
mice (Pelanda et al., 2002) to generate Cxcr4Fl/- Mb1cre/+ and Rosa26FloxSTOP-PTX/+ 
Mb1cre/+ mice. Rosa26FloxSTOP-PTX/+ mice were crossed to Il7racre/+ to generate 
Rosa26FloxSTOP-PTX/+ Il7racre/+, and control littermates. Il7racre/+ mice were provided 
by Dr. Hans-Reimer Rodewald (German Cancer Research Center). Mice were 
maintained under specific pathogen-free conditions at Yale Animal Resources 
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Center, and used according to the protocol approved by the Yale University 
Institutional Animal Care and Use Committee. 
 
Tissue preparation, cell enumeration, and antibodies. BM cells were 
flushed from femurs and tibias in DMEM (Cellgro) containing 2% FBS 
(Invitrogen), 5% of antibiotics (Cellgro), and Hepes (Cellgro). PB was collected 
from the portal vein, and erythrocytes were lysed with NH4Cl, KHCO3, and 
EDTA. Spleen was dissociated in 5 ml DMEM containing 2% FBS, 5% of 
antibiotics, and Hepes using a cell strainer (Thermo Fisher Scientific). Cells 
were counted with a Coulter Counter (Beckman Coulter). B cells were 
identified by staining with anti-B220 (RA3-6B2) or CD19 (1D3), anti-IgM 
(11/41), anti-IgD (11-26c.2a), and anti-CD93 (AA4.1) antibodies. NK cells 
were stained with CD3e (145-2C11) and NK1.1 (PK136) antibodies. Dead 
cells were excluded by staining with DAPI. Cells were analyzed by FACS 
(LSRII; BD). 
 
In vivo labeling of BM sinusoidal B cell subsets. BM sinusoidal cells were 
labeled by injecting i.v. 0.3 μg phycoerythrin-conjugated rat anti-mouse 
CD19 in 200 μl PBS. 2 min after, mice were sacrificed in a CO
2
 chamber. 
 
BM chimeras. Approximately 1.5x106 total BM cells from Ly5.1+ donors were 
mixed with 1.5x106 total BM cells from adult Boy/J (Ly5.2+) mice and were 
transferred into adult Boy/J mice that had been exposed to two rounds of 
6.35 Gy separated by 3 h. Chimeras were analyzed at least 6 wk after 
reconstitution. 
 
Transwell migration assays. Chemotaxis assays were performed using 106 
BM or spleen cells incubated for 30 min with 1x DMEM containing 0.5% fatty 
acid–free BSA (EMD Biosciences), 5% of antibiotics, L-glutamine (Cellgro), and 
Hepes. Cells were then allowed to migrate through 5-µm-pore–sized 
transwells (Corning) toward soluble CXCL12 (R&D Systems), 2-AG (Cayman), 
or CXCL13 (PeproTech) for 3 h at 37C. Cells were collected, stained, and 
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resuspended in 40 µl of staining buffer and analyzed by flow cytometry for 
40 s. 
 
Statistics. Student’s two-tailed t test was performed using GraphPad 
Software Prism 6 or Microsoft Excel. A value <0.05 was considered significant. 
 
 
3. Results 
 
CXCR4 is essential for immature B cell retention in BM 
 To identify at which stage B developing cell require CXCR4 the most, 
we conditionally ablated CXCR4 expression in developing B cells by crossing 
Cxcr4Fl/- mice with Mb1cre/+ mice.  We found that Pro and Pre-B cell subsets 
were not affected in BM but immature B cells were significantly mobilized 
into the peripheral blood (Fig. 3.1a and b). CXCR4 is intrinsically required for 
immature B cell egress as CXCR4-deficient immature B cells are mobilized 
from BM parenchyma into sinusoids when in competition with CXCR4-
suficient cells (Fig. 3.1c). The data indicates that after commitment to B cell 
lineage, CXCR4 is mostly required to retain immature B cells in the BM 
parenchyma. 
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Figure 3.1| CXCR4 is intrinsically required in B lymphocytes for retention in bone marrow. 
a, Flow cytometic analysis of IgM and IgD expression in live-gated B220+ cells in BM and blood 
of Mb1Cre/+;Cxcr4+/+ (WT) and Mb1Cre/+;Cxcr4Fl/- (ΔX4) mice. b, Enumeration of B-lineage cells in BM, 
blood and spleen of Mb1Cre/+;Cxcr4+/+ (white) and Mb1Cre/+;Cxcr4Fl/- (green) mice. c, Frequency of 
Ly5.1+ developing B cell in BM (first panel), immature B cell subsets in parenchyma and 
sinusoids (middle panels), and developing B cells in blood (last panel). Data is representative 
of three independent experiments. Bars indicate average, and circles indicate individual mice.  
* P<0.05; ** P<0.005; by unpaired Student’s t test. 
 
 
Immature B cell egress is independent of chemotaxis mediated by 
Gα
i
-protein coupled receptor signaling  
 Lymphocyte egress from lymphoid organs is controlled by a tug of 
war between tissue retention signals and chemoattractants emanating from, 
or associated with, endothelial hot spot exit sites (Cyster and Schwab, 2012).  
As chemoattractants are sensed predominantly by PTX-sensitive GPCRs, we 
asked whether immature B lymphocyte egress from BM requires intrinsic 
GPCR signaling.  To address this question, we conditionally induced PTX 
expression in B-lineage cells by introducing Mb1Cre/+ alleles into mice carrying 
the ADP-ribosyl transferase S1 subunit of PTX within the Rosa26 locus 
preceded by a premature transcriptional stop codon flanked by loxP sites 
(Regard et al., 2007).   
 The number of Pro and Pre-B cells was slightly but significantly 
reduced in BM, which corresponded to a small, but highly significant 
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numerical increase in blood circulation (Fig. 3.2a and b).  Remarkably, IgM+ 
immature B cell subsets were reduced by 2-3 fold in BM and significantly 
increased in blood, indicating increased BM egress. In order to evaluate a 
possible leakiness of PTX expressed by developing B cells into the BM 
interstitium, we carefully analyzed the behavior of wild-type cells (Ly5.2) 
developing in the same environment as congenically marked wild-type or 
PTX-expressing B cells (Ly5.1).  As Pro and Pre-B cells are rare in the 
peripheral blood of wild-type animals, but are readily detected if expressing 
PTX (Fig. 3.2c; upper panels show Ly5.1 gated cells), we reasoned that 
significant PTX leakage would enforce Pro and Pre-B cell mobilization from 
BM irrespectively of the genotype.  As seen in panel d (lower panels show 
wild-type LY5.2 gated cells), the frequency of Pro and Pre-B cells in blood of 
WT/WT or PTX/WT mixed chimeras is indistinguishable.  The frequency of 
Ly5.1/Ly5.2 reconstitution was similar between both sets of mixed chimeras 
(Fig. 3.2d).  The frequency of Ly5.1+ PTX-expressing (orange) Pre-B cells in 
blood is significantly increased as compared to Ly5.1+ wild-type (black) Pre-B 
cells due to inefficient retention in BM, as expected (Fig. 3.2e). In contrast, 
the frequency of wild-type Ly5.2+ Pre-B cells in peripheral blood of mixed 
chimeras repopulated with PTX-expressing B-lineage cells is similar to that 
found in blood of mixed chimeras reconstituted with wild-type cells (Fig. 
3.2f).  From these data we conclude that PTX is not leaked to the BM 
interstitium in significant amounts. Furthermore, the faster egress of PTX-
expressing developing B cells were caused by Gα
i
-protein inhibition in B-
lineage cells as similar findings were obtained with B-lineage cells deficient 
in Gnai2 and Gnai3 (Hwang et al., 2013).  PTX-expressing B-lineage cells 
were also poorly retained within BM sinusoids (Fig. 3.2g and h), consistent 
with a role for Gαi-coupled CB2 and S1PR3 in this process (Donovan et al., 
2010, Pereira et al., 2009).  PTX-expressing B cells progressed normally 
throughout development (Fig. 3.2i) and showed largely similar kinetics of 
BrdU incorporation during B cell development as wild type cells (Fig. 3.2j).   
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Figure 3.2| B cells egress from bone marrow independently of GPCR-mediated migration. 
a, Flow cytometry analyses of IgM and IgD expression in live gated (DAPI-) B220+ cells in BM 
(upper panels) and peripheral blood (lower panels) of Mb1Cre/+ mice (WT, left panels) and 
Mb1Cre/+ Rosa26PTX/+ mice. b, Quantification of developing B cell subsets in BM (left) and 
peripheral blood (right) of Mb1Cre/+ mice (blue bars) and Mb1Cre/+ Rosa26PTX/+ mice (red bars).  
Bars indicate mean, and circles depict individual mice analyzed.  Data is representative of 
more than 3 independent experiments. c-j, Effects of intrinsic PTX expression in B cell 
development, and lack of evidence for PTX leakage into neighboring cells. c, Flow cytometric 
analyses of peripheral blood taken from lethally irradiated mice reconstituted with 50% of 
either Ly5.1+ Mb1Cre/+ Rosa26+/+ or Ly5.1+ Mb1Cre/+ Rosa26FloxSTOP-PTX/+ BM cells and 50% of congenic 
Ly5.2+ WT cells.  Left and right panels show WT/WT and WT/PTX mixed chimeras gated on 
B220+ Ly5.1+ cells (top) or on B220+ Ly5.2+ cells (bottom), respectively. d, Frequency of Ly5.2+ 
cells within the Pre-B cell gate in BM of WT/WT (black) and WT/PTX (orange) mixed chimeras.  
Note that both experimental groups had similar BM chimerism.  e, Frequency of Ly5.1+ Pre-B 
cells within the B220+ gate in peripheral blood of WT/WT (black) and WT/PTX (orange) mixed 
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chimeras.  Note that PTX-expressing Ly5.1+ Pre-B cells are significantly increased in blood.  f, 
Frequency of Ly5.2+ Pre-B cells within the B220+ gate in peripheral blood of WT/WT (black) and 
WT/PTX (orange) mixed chimeras.  Bars indicate average; circles indicate individual mice 
analyzed.  g, Distribution of immature CD93+ IgM+ IgD- cells in BM parenchyma, sinusoids and 
peripheral blood of WT/WT (black) and WT/PTX (orange) mixed chimeras.  h, Distribution of 
immature CD93+ IgM+ IgDlo cells in BM parenchyma, sinusoids and peripheral blood of WT/WT 
(black) and WT/PTX (orange) mixed chimeras.  i, Chimerism of developing B cell subsets in 
WT/WT (black) and WT/PTX (orange) mixed chimeras.  Y-axes display the frequency of Ly5.1+ 
cells in Pro-B cells divided by the frequency of Ly5.1+ cells within the granulocyte gate.  Cells 
within BM parenchyma and sinusoids were distinguished by intravenous administration of PE-
conjugated anti-CD19 antibodies 2 minutes before euthanasia.  Lines represent average; and 
error bars indicate SEM of 5 individual mice analyzed in each group.  j, Frequency of BrdU+ 
cells within Ly5.1+ developing B cell subsets of WT/WT (black) and WT/PTX (orange) mixed 
chimeras.  Bars indicate average; circles represent individual mice analyzed (n=5 in each 
group).  Data in all panels are representative of two independent experiments. ns, not 
significant; * P<0.05, ** P<0.005, **** P<0.00005 by unpaired Student’s t test. 
 
 We also observed that AMD3100 blocked the chemotaxis of wild type 
and PTX-expressing developing B cell subsets towards a CXCL12 gradient in 
vitro (Fig. 3.3a and b), whereas CXCR4-deficient B cells were unable to 
migrate in similar conditions (Fig. 3.3c-e). These observations suggest that 
CXCR4 can couple to PTX-insensitive G proteins in B cells, which in turn may 
also be involved in CXCR4-mediated retention in vivo.  
 
Figure 3.3| CXCR4 can promote B-lineage cell migration through a PTX-insensitive 
mechanism. a, In vitro transwell migration assay of untreated WT BM B cell subsets towards 
0.3mg/mL of CXCL12 untreated (left panel) or treated with the CXCR4 antagonist AMD3100 
(right panel).  b, In vitro transwell migration assay towards 0.3mg/mL of CXCL12 of PTX-
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expressing BM B cell subsets untreated (left panel) or treated with the CXCR4 antagonist 
AMD3100 (right panel).  c-e, In vitro transwell migration assay of CXCR4-deficient Pre-B (c), 
immature IgD- (d), and immature IgDlo (e) B cell subsets untreated (black) or treated with 
AMD3100 (white) towards 0.3mg/mL of CXCL12 (SDF-1), or towards 1mM 2-arachidonoyl 
glycerol (2-AG).  Bars indicate average; circles indicate independent experiments. ns, not 
significant.  * P<0.05; ** P<0.005; *** P<0.0005; **** P<0.00005 by unpaired Student’s t test. 
 
 
The GPCR-independent egress mechanism also mediates NK cells 
egress from BM  
 Next, we asked whether NK cells could also leave BM independently of 
PTX-sensitive GPCRs.  To address this question, we expressed PTX in NK cells 
by Cre-mediated recombinase driven by Il7ra (Schlenner et al., 2010), and 
quantified the egress of NK cells from BM into peripheral blood by flow 
cytometry.  Remarkably, NK cells, like B-lineage cells, were efficiently 
mobilized from BM into blood by PTX treatment (Fig. 3.4), even though PTX-
sensitive GPCRs can contribute to their export from BM (Eash et al., 2010, 
Allende et al., 2010, Jenne et al., 2009, Serbina and Pamer, 2006, Walzer et 
al., 2007, Pereira et al., 2010a).  
 
Figure 3.4| PTX mobilizes NK cells from BM into peripheral blood. Analysis of NK cells in 
BM and peripheral blood of lethally irradiated mice reconstituted with a mixture of bone 
marrow cells isolated from Ly5.1+/+ Il7racre/+ Rosa26+/+ (white), or from Il7racre/+ Rosa26PTX/+ mice 
(blue), with Ly5.2+/+ mice.  NK cells were gated as CD19- CD3e- NK1.1+.  Y axis shows the ratio 
of the frequencies of Ly5.1+ NK cells in blood and BM.   Bars indicate the mean; circles depict 
individual mice.  Data was pooled from 3 independent experiments.  * P<0.05; ** P<0.005; *** 
P<0.0005; and **** P<0.00005, by unpaired Student’s t test. 
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Gradual reduction in CXCR4 expression enforces immature B cell 
egress from BM 
 CXCR4 expression is highest at the Pro-B cell stage and decreases 
gradually during murine and human B cell development (Honczarenko et al., 
1999, Pereira et al., 2009). Therefore, it is possible that CXCR4 signaling is 
reduced in egress-competent cells. To investigate this possibility we 
compared CXCR4 expression on immature B lymphocyte subsets before and 
after BM egress, and found that it was reduced by approximately 2-fold in 
cells within sinusoids as compared to cells in parenchyma (Fig. 3.5a and b). 
To test if a 2-fold down-regulation of CXCR4 was sufficient to mobilize 
immature B cells from BM we compared the distribution of CXCR4 
haploinsufficient B-lineage cells in competition with wild type cells in BM 
mixed chimeras.  As expected, Cxcr4+/- immature B cells in BM parenchyma 
expressed comparable CXCR4 surface amounts as Cxcr4+/+ B cells positioned 
within BM sinusoids, whereas Cxcr4+/- immature B cells expressed ~ 2-fold 
lower CXCR4 than Cxcr4+/+ immature B cells in BM parenchyma (Fig. 3.5c).  
Furthermore, Cxcr4+/- immature B cells were significantly reduced in BM 
parenchyma, and increased in BM sinusoids and in blood when compared to 
Cxcr4+/+ immature B cells (Fig. 3.5d). 
 
Figure 3.5| CXCR4 expression in egress-competent immature B lymphocytes. a, CXCR4 
expression in B220+ immature IgM+ IgDlo B cells positioned in BM parenchyma (Par.) and 
sinusoids (Sin.). (left) IgM and IgD expression in B220+ BM cells. (middle) Distribution of B220+ 
CD93+ IgM+ IgDlo B cells in BM parenchyma (CD19-PE-) and sinusoids (CD19-PE+). (right) CXCR4 
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expression in B220+ immature IgM+ IgDlo B cells in parenchyma (gray) and sinusoids (black line). 
b, Geometric mean fluorescence intensity (MFI) of CXCR4 surface expression in BM 
parenchyma and sinusoid immature CD93+ IgM+ IgDlo B cells from C57BL/6 mice (n = 4). Bars 
indicate the mean; circles indicate individual mice. Data are representative of >10 
independent experiments. c, (left) CXCR4 surface expression in Mb1Cre/+;Cxcr4Fl/+ immature IgM+ 
IgDlo cells overlaid with Mb1Cre/+;Cxcr4+/+ immature IgM+ IgDlo in BM parenchyma. (right) CXCR4 
surface expression in Ly5.1+ Mb1Cre/+;Cxcr4Fl/+ immature IgM+ IgDlo in BM parenchyma overlaid 
with Ly5.2+ (Cxcr4+/+) immature IgM+ IgDlo cells residing in sinusoids. d, Distribution of B220+ 
CD93+ IgM+ IgDlo immature B cells in BM parenchyma, sinusoids, and PB of lethally irradiated 
mice reconstituted with a mixture of Ly5.1+ Mb1Cre/+;Cxcr4+l/+ and Ly5.2+ WT cells (gray) or with 
Ly5.1+ Mb1Cre/+;Cxcr4Fl/+ and Ly5.2+ WT cells (black). Error bars indicate ±SEM. Bars indicate 
mean; circles indicate individual mice. Data were pooled from three independent experiments. 
*, P < 0.05; **, P < 0.005; ***, P < 0.0005 by unpaired Student’s t test. 
 
 
4. Discussion  
 
 During B cell development, progression into the immature B cell stage 
is characterized by a significant change in positional distribution within BM. 
About 50% of immature B cells localize in BM sinusoids in a α
4
β
1
/VCAM-1, 
and CB2 and S1PR
3
 signaling-dependent manner (Donovan et al., 2010, 
Pereira et al., 2009).  Immature B cell movement towards sinusoids was 
independent of CB2 and S1PR
3
-mediated chemotaxis, and only minimally 
contributed by S1P and S1PR
1 
(Allende et al., 2010, Pereira et al., 2010a).  
Our studies reveal that CXCR4 down-regulation, which occurs gradually 
during mouse and human B cell development (Honczarenko et al., 1999, 
Pereira et al., 2009), was critical for immature B cell egress from BM. Rather 
than depending on the developmental expression of single or multiple 
egress-promoting GPCR, immature B lymphocytes egress BM by down-
regulating CXCR4 by approximately 2-fold. 
  It is surprising that in absence of Gα
i
 function, developing B cells 
egress faster than wild-type cells, which indicates the existence of a Gα
i
-
independent mechanism of B cell egress.  Erythrocyte egress from BM has 
been shown to be driven by pressure drop across the sinusoid wall. 
65"
Interestingly, the authors referred to it as vis-a-tergo from the Latin, a force 
from behind (Lichtman and Santillo, 1986). In agreement with these studies, 
it has been recently demonstrated using intravital imaging that 
megakaryocytes extend proplatelet-containing membrane protrusions into 
the sinusoidal compartment and these intravascular extensions appeared to 
be sheared from their transendothelial stems by flowing blood, resulting in 
the appearance of proplatelets in peripheral blood (Junt et al., 2007). These 
results highlight the possibility that blood flow–induced hydrodynamic shear 
stress is a biophysical determinant of BM egress. Therefore, we hypothesize 
that Gα
i
-independent mechanism of BM B cell egress might involve shear 
stress. Recent studies from our laboratory demonstrated that circulatory 
molecules rapidly perfuse BM parenchyma (Beck et al., 2014). Thus, it is 
possible that BM parenchyma has a high blood flow-induced hydrodynamic 
shear stress, which is sufficient to mobilize the cells out of BM in absence of 
Gα
i
-signaling. BM egress occurs through the vast sinusoidal network. In order 
to the cells reach the sinusoids, they have to transmigrate through the 
endothelium lining the sinusoidal compartment. Using TEM imaging, it has 
been observed that megakaryocytes and erythrocytes enter the lumen of the 
vascular sinus through the parajunctional zones of the endothelial cell. 
Although a passive role of the endothelium cannot be excluded, the 
observation of a radial and circumferential microfilaments associated with 
apertures in endothelial cell cytoplasm suggest an active participation of 
endothelial cells in the reverse transmigration of leukocytes from BM 
parenchyma to the sinus lumen. In addition, migration of cells occasionally 
occurs through thick areas of endothelial cytoplasm and the pores are 
formed at the time of migration and sealed when migration is complete. The 
authors also speculate that the formation of the aperture might also be 
related to specific interactions between the leukocyte and the endothelium 
(Chamberlain and Lichtman, 1978). Recent evidence has shown that 
neutrophils have a reverse transendothelial migration (Woodfin et al., 2011). 
Therefore, another possible Gα
i
-independent mechanisms might be specific 
lymphocyte-endothelium interactions that modulate the endothelium 
permeability.  
 The BM parenchyma is considerably perfused by an extensive network 
of sinusoids formed by a thin-walled endothelium (Tavassoli and Yoffey, 
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1983).  Some studies have demonstrated that most sinusoids are permeable 
to large molecules due to fenestrations between adjacent endothelial cell 
processes, and allow exchange of parenchymal interstitium and sinusoidal 
plasma (Tavassoli and Yoffey, 1983, Mazo et al., 1998).  The interstitial fluid 
flow generates considerable shear force and, under these conditions, 
developing B lymphocytes may be pushed to exit sites, and leave the BM in a 
GPCR-independent mechanism.  
 GPCR-independent egress mechanism also operates on NK cells, 
suggesting that this mechanism operates in the export of the different 
hematopoietic cells from the BM. For instance, inflammatory monocytes 
rapidly egress the BM (Shi et al., 2011, Serbina and Pamer, 2006); but RBC 
leave the BM carried by interstitial fluid flow in a passive manner into the 
blood (Lichtman and Santillo, 1986).  Considering that all blood cells 
produced in BM enter circulation via the sinusoids (Tavassoli and Yoffey, 
1983), we propose that the BM microanatomy evolved unique strategies for 
exporting highly heterogeneous cell populations.  The egress of non-motile 
and of slow moving cells is largely independent of egress-promoting 
chemoattractants near, or at, exit sites, and predominantly occurs via passive 
transport by interstitial fluid drainage into collecting sinusoids.  Large 
collecting venules receive blood from a network of smaller and irregular 
sinusoids linked by short anastomoses, and blood flows unidirectionally in 
these large venules (Mazo et al., 1998).  In contrast, smaller sinusoids often 
show unpredictable fluctuations in the direction of blood flow (Mazo et al., 
1998), and it is possible that interstitial fluid drainage from parenchyma into 
small sinusoids contributes to changes in flow direction. Whether smaller 
sinusoids with irregular blood flow constitute BM egress sites remains 
unclear.
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Chapter 4| Hematopoietic stem cell niches control 
multipotent progenitor differentiation 
 
 In the previous chapter, we demonstrated that CXCR4-deficiency does 
not compromise the later stages of B cell development, even though later 
stage developing B cells are prematurely exported into the periphery, 
suggesting that CXCR4 plays a role in B lymphopoiesis before lineage 
commitment occurs. Therefore, we ablated CXCR4 function at different early 
stages of hematopoiesis and found that CXCR4 is critical for the Ly6D+ CLP, a 
B lineage primed progenitor population. This phenotype resembled the 
phenotype observed in IL-7 or IL-7R deficiency. Thus, we determined the 
positioning of Ly6D+ CLP relative to IL-7 cells using reporter mice, and found 
that Ly6D+ CLP are positioned in close proximity to IL-7-expressing cells. 
Moreover, these progenitors rely on CXCR4 to consume IL-7, as CXCR4-
deficiency correlates with lower levels of STAT5 phosphorylation. 
 We also described that IL-7-expressing cells form a subset of CAR cells. 
Furthermore, we also ruled out osteoblast and the endosteum as a niche for 
B lymphopoiesis. Collectively, our findings provide groundbreaking evidence 
supporting a model in which HSC maintenance and multilineage 
differentiation are distinct cell lineages decisions locally controlled by HSC 
niche. Our results were submitted and are in revision at Immunity.     
  
"  
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Abstract 
Hematopoietic stem cells (HSC) self-renew in bone marrow niches 
formed by CXCL12+ mesenchymal progenitor and endothelial cells. Here, 
we show that hematopoietic multipotent progenitors (MPPs) encounter 
lineage-instructive differentiation signals in HSC niches. Conditional 
deletion of CXCR4 in MPPs profoundly reduced differentiation into 
common lymphoid progenitors (CLPs), which significantly decreased 
lymphopoiesis. CXCR4 was required for CLP positioning near IL-7+ cells 
and, consequently, for optimal IL-7R signaling. IL-7+ cells form a large 
subset of CXCL12-abundant reticular mesenchymal progenitor cells 
capable of differentiation into osteoblasts and adipocytes, and a minor 
subset of BM sinusoidal endothelial cells. Conditional Il7 deletion in 
mesenchymal progenitor cells dramatically reduced B-lineage committed 
CLPs, whereas Il7 deletion from endothelial cells specifically reduced 
preB cells. Our studies demonstrate that CLPs rely on positional cues to 
encounter short-range lymphopoietic signals provided by CXCL12+ 
mesenchymal progenitors. Thus, HSC maintenance and multilineage 
differentiation are distinct cell lineage decisions controlled by HSC 
niches. 
 
 
1. Introduction 
 In mammals, HSCs are maintained throughout life in specialized 
niches in bone marrow (BM). Upon cell division, HSCs either self-renew to 
maintain the HSC pool, or differentiate into diverse hematopoietic cell 
subsets. Over the past few years several studies have identified rare 
mesenchymal stem and progenitor cells as essential cellular components of 
HSC niches in BM that control HSC quiescence and long-term maintenance 
(Morrison and Scadden, 2014). However, the existence of a HSC 
differentiation niche remains unclear. 
 CXCR4 and its ligand CXCL12 form a chemokine/chemokine receptor 
pair that controls multiple essential fetal and adult hematopoietic processes. 
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Early studies using mice genetically deficient in CXCR4 or CXCL12 
demonstrated a severe reduction in B lymphopoiesis and a mild reduction in 
myelopoiesis in the fetal liver, and severe impairment in myeloid, lymphoid, 
and megakaryocyte cell development in fetal BM (E18.5) (Ma et al., 1998, 
Nagasawa et al., 1996, Zou et al., 1998). Some of these defects were in part 
explained by defective retention of hematopoietic precursors in BM, and by 
other findings indicating that CXCR4 is also required for hematopoietic stem 
cell homing and retention in BM (Ara et al., 2003b, Lapidot and Kollet, 2002, 
Ma et al., 1999, Peled et al., 1999). Furthermore, CXCR4 signaling in HSC 
was proposed to be critically required for HSC quiescence (Nie et al., 2008; 
Sugiyama et al., 2006). 
 CXCL12 is expressed abundantly by mesenchymal progenitor cells, 
named CXCL12-abundant reticular (CAR) cells (Omatsu et al., 2010; 
Sugiyama et al., 2006). CAR cells are essential organizers of HSC niches in 
BM because these cells regulate HSC quiescence and long-term maintenance 
(Ding and Morrison, 2013; Greenbaum et al., 2013; Omatsu et al., 2014), at 
least in part through the production of short-range signals such as stem cell 
factor (SCF) (Ding et al., 2012). Thus, a model emerges in which CXCR4 
enables HSCs to position near CAR cells in order to access critical factors 
controlling HSC decisions in BM. In favor of such a model, HSC have been 
found in proximity to Nestin-expressing mesenchymal stem and progenitor 
cells (MSPC) that also express CXCL12 (Kunisaki et al., 2013; Mendez-Ferrer 
et al., 2010). Indeed, MSPC share many morphological and functional 
similarities with CAR cells, including multipotent progenitor differentiation 
potential and expression of high amounts of SCF (Omatsu et al., 2010), 
suggesting a significant overlap between these cell types. 
 Amongst the many hematopoietic lineages, B lymphocytes are the 
most critically dependent on CXCR4 and CXCL12 (Nie et al., 2008; Sugiyama 
et al., 2006). This dependence is likely to be at an early hematopoietic stage 
given the fact that conditional deletion of CXCR4 in Pro-B cells did not impair 
B cell development in BM (Beck et al., 2014; Nie et al., 2008; Pereira et al., 
2009). These findings led us to ask the question of how could a single 
chemoattractant receptor (CXCR4) control HSC quiescence and 
lymphopoiesis. One possibility is that defects in HSC quiescence directly 
cause hematopoietic differentiation defects regardless of signals provided by 
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BM niches. Alternatively, CXCR4 and CXCL12 guide HSC and hematopoietic 
multipotent progenitors (MPP) to BM niches that not only support HSC 
quiescence but also sustain MPP differentiation. 
 B lymphopoiesis is dependent on interleukin -7 (IL-7; Carvalho et al., 
2001; von Freeden-Jeffry et al., 1995). IL-7 signals through a heterodimeric 
receptor composed by an IL-7Ra chain and a common g-chain (Corfe and 
Paige, 2012). IL-7 binding to IL-7Rα leads to phosphorylation and activation 
of Janus kinase 1 and 3 (JAK1 and JAK3), in addition to IL-
7Rα phosphorylation, which serve as docking sites for the recruitment of 
signal transducer and activator of transcription 5a and 5b (STAT5) (Corfe and 
Paige, 2012). Bound STAT5 is phosphorylated by JAK1 and JAK3, which 
results in its dissociation from IL-7Rα, and translocation to the nucleus where 
it activates gene transcription (Corfe and Paige, 2012). Despite these studies, 
very little is understood about the identity of IL-7-producing cells in BM. 
 Here in show that CXCR4 was intrinsically required in MPPs for 
differentiation into multiple downstream lineage-restricted hematopoietic 
precursors, most prominently to the earliest B cell-committed common 
lymphoid precursor (CLP) that expresses Ly6D (Inlay et al., 2009). We show 
that CXCR4 controlled the positioning of Ly6D+ CLPs in the vicinity of IL-
7+ cells in BM, and that defective positioning near IL-7+ resulted in reduced IL-
7R signaling in Ly6D+ CLPs. We further show that IL-7 is primarily made by a 
subset of CAR cells, which also contains multipotent mesenchymal 
differentiation capacity. Our studies demonstrate that positional cues play 
critical roles in enabling hematopoietic precursors to access short-range 
lineage-instructive cytokines. Furthermore, our studies favor a model in 
which HSC quiescence and multilineage differentiation are locally controlled 
by HSC niches in the BM. 
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2. Materials and Methods 
 
Mice. Adult C57BL/6 (CD45.2+), Boy/J (CD45.1+), Lepr-cre, Rosa26FloxSTOP-tdTomato/+, 
Tie2-cre, Prx1-cre, and Rosa26YFP/+ mice were purchased from The Jackson 
Laboratories. Cxcr4Fl/Fl and Il7Fl/Fl
 
mice were from internal colony. Il7racre/+ mice 
were kindly provided by Dr. Hans-Reimer Rodewald (German Cancer Research 
Center). Flk2-cre mice were a gift from Dr. E. Camilla Forsberg (University of 
California, Santa Cruz). Il7-ECFP mice were provided by Dr. Scott Durum 
(National Institute of Health). Some Il7GFP/+ mice were from our internal colony 
(Kyoto University); some Il7GFP/+ mice were obtained from Dr. Susan Kaech 
(Yale University). Cxcl12DsRed were a kind gift from Dr. Sean Morrison 
(University of Texas Southwestern Medical Center). Il7-cre mice were received 
from Dr. Ellen Richie (The University of Texas MD Anderson Cancer Center). 
Col2.3-cre mice were kindly provided by T. Nakamura (Kyoto University). Vav-
cre mice were kindly provided by Dr. Thomas Graf (Albert Einstein College of 
Medicine). All mice were maintained under specific pathogen-free conditions 
at Yale Animal Resources Center and in the Experimental Research Center for 
Infectious Diseases in the Institute for Virus Research, Kyoto University, and 
used according to the protocol approved by the Yale University Institutional 
Animal Care and Use Committee and by the Animal Research Committee at 
the Institute for Virus Research, Kyoto University. 
 
Bone marrow chimeras. Adult Boy/J (CD45.1) mice were exposed to two 
rounds of 6.35 Gy separated by 3h using an XRAD 320 X-ray irradiator 
(Precision X-ray Inc.). A mixture of CD45.2+ and CD45.1+ bone marrow cells 
were injected iv. Recipient mice were sacrificed 6 weeks after transplantation 
and bone marrow, blood, spleen, Peyer’s Patches, lymph nodes (inguinal, 
mesenteric, auxillary and brachial), thymus, liver and peritoneal cavity were 
harvested to analyze donor chimerism of Granulocytes, B, T and NK cells. 
 
Flow cytometry. Bone marrow cells were isolated by flushing long bones 
with DMEM (Lonza) containing 2% heat-inactivated fetal bovine serum (FBS), 
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HEPES, PenStrep and L-Glutamine (Cellgro). Red blood cells were lysed with 
ammonium chloride buffer. Spleen, lymph nodes, Peyer’s Patch, and thymus 
were mashed and cells were dissociated to single cell suspension and then 
filtered through a 70 µm nylon mesh. Liver leukocytes were isolated using 
Percoll gradients. For flow cytometric analysis of stromal cells, bone marrow 
was carefully flushed using HBSS supplemented with 2% of heat-inactivated 
fetal bovine serum. Whole bone marrow was digested with 200 U/mL 
Collagenase IV (Worthington Biochemical Corporation), and digested at 37ºC 
for 20 min. Cells clumps were dissociated by gentle pippeting, followed by a 
further incubation of 10 min at 37ºC. Cells were washed with 5 mL of 
HBSS/2%FBS, spun at 1000 rpm for 7 min, and stained with the respective 
antibodies. All stains were done for 20 min on ice, followed by 2 washes at 
1000 rpm, 7 min. For detection of pSTAT5a, bone marrow cells were flushed 
from long bones in DMEM containing 0.5% fatty acid free BSA (EMD 
Biosciences), antibiotics (50 IU/mL of ampicillin and 50 mg/mL of 
streptomycin), and 10 mM HEPES. Cells were fixed in 2% PFA for 10 min at RT 
and permeabilized with 90% Methanol for 30 min and washed with PBS. 
pSTAT5a was detected using Alexa Fluor 647-conjugated antipSTAT5a 
antibody (BD Pharmigen). Additional antibodies used are listed in table below. 
 
Table 7.1| List of antibodies and fluorochromes used, and vendors. 
Antibody Clone Conjugated Company 
anti-goat IgG 
 
Alexa Fluor 647 Jackson Immunoresearch 
anti-rat IgG 
 
Alexa Fluor 647 Jackson Immunoresearch 
anti-rabbit IgG 
 
AMCA Jackson Immunoresearch 
anti-rabbit IgG 
 
Biotin Jackson Immunoresearch 
CD3e 145-2C11 FITC Biolegend 
CD3e 145-2C11 Pe-Cy7 Biolegend 
CD3e 145-2C11 APC Biolegend 
CD3e 145-2C11 Biotin BD Biosciences 
CD4 RM4-5 FITC Biolegend 
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CD4 GK1.5 Pe-Cy7 Biolegend 
CD8a 53-6.7 Pe-Cy7 Biolegend 
CD11c N418 FITC Biolegend 
CD11c N418 Biotin Biolegend 
CD11b M1/70 FITC Biolegend 
CD11b RM2815 Biotin Invitrogen 
CD16/32 93 PE Biolegend 
CD19 1D3 FITC Biolegend/ BD Biosciences 
CD19 6D5 Pac. Blue Biolegend 
CD19 1D3 PerCP-Cy5.5 eBioscience 
CD19 MB19-1 Biotin eBioscience 
CD25 eBio74 Biotin eBioscience 
CD31 390 APC Biolegend 
CD34 RAM34 Alexa Fluor 700 BD Biosciences 
CD41 MWReg30 FITC Biolegend 
CD44 IM7 PerCP-Cy5.5 Biolegend 
CD45R (B220) RA3-6B2 PerCP-Cy5.5 eBioscience 
CD45.1 A20 FITC Biolegend 
CD45.1 A20 PE BD Biosciences 
CD45.1 A20 Pe-Cy7 eBioscience 
CD45.1 A20 Pac. Blue Biolegend 
CD45.2 104 FITC BD Biosciences 
CD45.2 104 PE eBioscience 
CD45.2 104 Pac. Blue Biolegend 
CD45.2 104 APC-Cy7 Biolegend 
CD45.2 104 Alexa Fluor 700 Biolegend 
CD93 (AA4.1) AA4.1 APC eBioscience 
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CD117 (cKIT) 2B8 Biotin Biolegend 
CD117 (cKIT) 2B8 APC-H7 BD Biosciences 
CD117 (cKIT) 2B8 APC BD Biosciences 
CD117 (cKIT) 2B8 BV421 Biolegend 
CD127 A7R34 PE Biolegend 
CD127 A7R34 eFlour450 eBioscience 
CD127 A7R34 Purified BioXCell 
CD135 (FLT3) A2F10 PE eBioscience 
CD144 BV13 Alexa Fluor 647 Biolegend 
CD150 mShad150 PerCP-eF710 eBioscience 
CD184 (CXCR4) 2B11 PerCP-eF710 eBioscience 
CD184 (CXCR4) 
 
Biotin BD Biosciences 
GFP 
 
purified Invitrogen 
Gr1 RB6-8C5 FITC Biolegend 
Gr1 RB6-8C5 Biotin eBioscience 
IgD 11-26c.2a PE Biolegend 
IgM II/41 Pe-Cy7 eBioscience 
LepR 
 
Biotin R&D 
Ly6A/E (Sca-1) D7 Pe-Cy7 eBioscience 
Ly6D 49-H4 FITC/ PE Biolegend 
NK1.1 PK136 FITC Biolegend 
NK1.1 PK136 PerCP-Cy5.5 BD Biosciences 
NK1.1 PK136 Biotin eBioscience 
Osteocalcin mOC(1-20) purified Clonotech 
Osteopontin 
 
purified R&D 
Perilipin D1D8 purified Cell Signaling 
pSTAT5 47/STAT5(pY694) Alexa Fluor 647 BD Biosciences 
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Streptavidin 
 
Alexa Fluor 488 Invitrogen 
Streptavidin 
 
PE BD Biosciences 
Streptavidin 
 
PerCP-Cy5.5 BD Biosciences 
Streptavidin 
 
Alexa Fluor 647 Invitrogen 
Streptavidin 
 
BV 605 Biolegend 
Streptavidin 
 
Qdot605 Invitrogen 
Ter-119 Ter119 FITC Biolegend 
Ter-119 Ter119 Biotin BD Biosciences 
 
 
Mesenchymal progenitor cell sorting. Long bones recovered from 3-4 
C57BL/6 mice (ages 6-12 week) were flushed and digested with Collagenase 
as described above. Cells were counted and stained with anti-LEPR antibody 
for 1 hour, on ice. LEPR staining was revealed with biotin-conjugated anti-
goat for 40 min. After washing, cells were incubated with anti-CD45, anti-
Ter119, anti-CD31, anti-CD144 antibodies, Streptavidin BV605, and DAPI for 
30 min. Cells were acquired and sorted on a BD FACS Aria II equipped with 
UV (355nm), Violet (405nm), Blue (488nm), Green (532nm) and Red (640nm) 
lasers, and with FACSDiva 7. 
 
Immunostaining of bone marrow sections. Freshly dissected long bones 
were fixed in a paraformaldehyde-based fixative at 4ºC for 6h or overnight. 
Then, bones were washed in PBS 1x, for 10 min, 3 times. Bones were 
dehydrated in a solution of 30% sucrose in PBS, at 4ºC overnight. Samples 
were embedded in OCT and snap-frozen in ethanol/dry ice bath. For 
wholemount staining, bones were shaved on a cryostat until the bone 
marrow cavity was fully exposed. Frozen sections were prepared according 
to the Kawamoto method (Kawamoto, 2003) or using CryoJane tape transfer 
system (Leica). 7-µm or 25-µm sections were dried overnight. Sections were 
rehydrated in PBS with 0.05% BSA for 10 min before staining. Goat serum 
(4%) in PBS with 1%BSA was used for blocking. Primary antibodies were 
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applied to the slides for 3h at room temperature or overnight at 4ºC, and 
this was followed by secondary antibody incubation by 1-2h at room 
temperature with repeated washes in between. Sections were incubated with 
a blocking solution of rat serum (4%), BSA (1%) in PBS at least for 30 min. 
Then, fluorochrome-conjugated antibodies were applied to the slides for at 
least 1h. Slides were mounted with Fluormount-G (SourthernBiotech) or with 
a 30% glycerin solution. Images were acquired on a Zeiss Z1 Observer 
fluorescent microscope equipped with Colibri LED light sources, or on a Leica 
SP8 confocal microscope.  
 
Chemotaxis assay. Total bone marrow cells were stained against lineage 
markers, and incubated with Dynabeads (Sigma). A Lin- cell enriched cell 
suspension was recovered and incubated for 30 min at 37ºC in DMEM 
containing 0.5% fatty acid free BSA (EMD Biosciences), antibiotics (50IU/mL of 
ampicillin and 50 mg/mL of streptomycin; Cellgro), and 10 mM HEPES 
(Cellgro). Cells were allowed to migrate through 5 μm-pore sized transwells 
(Corning) for 3h at 37ºC with 5% CO2. Cells were collected, stained, 
resuspended in 45μL of staining buffer and analyzed by flow cytometry for 
40s. 
 
CLP single cell differentiation in vitro assays. OP9 stromal cells were 
seeded in 96-well plates (2,500 cells/well), left overnight at 37 ºC, and 
irradiated (10 Gy) before plating of hematopoietic cells. Single live Ly6D+ CLP 
(Lin- CD127+ cKITint SCA1+ FLT3+ Ly6D+) were sorted to each well. RPMI 
(containing 10%FBS, HEPES, PenStrep, L-Glutamine, and 50µM β-
Mercaptoethanol) supplemented with saturating amounts of Flt3L, SCF, IL-7 
and IL-2 (final concentration of 50 ng/mL) was added to each well. On day 5, 
culture medium was replaced with RPMI supplemented with FLT3L and IL-
7only. On day 10 of culture, scores were assigned for B cells (CD19+), 
myeloid (CD11b+), NK cells (NK1.1+) and dendritic cells (CD11c+) by flow 
cytometry. 
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Adipocyte isolation. Bone marrow from long bones was gently flushed with 
HBSS/2% FBS supplemented with 200U/mL Collagenase IV and DNase I 
(Roche), and incubated at 37ºC for 15 min. After digestion, the cell 
suspension was washed and allowed to stand for 10 min, and then spun at 
500g for 5 min. Adipocyte layers were gently recovered from the upper 
phase. 
 
In vitro osteoblast differentiation. Neonatal calvaria osteoblasts were 
prepared from 3-5 day old C57BL/6 mice. Briefly, calvariae were treated with 
4mM EDTA in PBS and sequentially digested with collagenase (200 U/mL) for 
5 times. Fractions 3-5 were plated in α-MEM containing 10% FBS, 10 mM 
HEPES, and Penn/Strep. Media was changed every 3-4 days. Adult osteoblasts 
were differentiated as follows: BM cells flushed from femurs and the bones 
were incubated in DMEM containing 2% Collagenase A (Roche) and antibiotics 
at 37°C with agitation for 30 min (500 μl/bone), then washed with DMEM. 
Bones were incubated a second time in DMEM containing 2% Collagenase A 
and antibiotics at 37°C with agitation for 30 min and this fraction was 
collected. To remove contaminating hemaetopoietic cells, cells were 
incubated with biotin anti-CD45 (Clone 30-F11, Biolegend) at 1:100 dilution 
in 100 µl of DMEM containing 2% FBS for 20 min at 4°C then washed two 
times, cells were then resuspended in 100 µl of DMEM containing 10 µL 
strepavidin beads (Invitrogen) and incubated at 4°C with gentle shaking for 
45 min. Labeled hemaetopoietic cells were separated using a magnetic field 
and remaining cells were plated up to 1x106 per well on 6 well plates in α-
MEM containing 10% FBS, 10 mM HEPES, 50 μg/ml L-ascorbic acid 2-
phosphate (Sigma), 10 nM glycerophosphate (Sigma), and 10 nM 
dexamethasone (Sigma). Media was changed every 3-4 days. 
 
RNA isolation and Quantitative Real Time PCR. Total RNA was isolated 
from sorted stromal cells, adipocytes and cultured osteoblasts using 
mRNeasy kit (Qiagen). cDNA was synthetized from the isolated RNA and Q-
PCR was the SensiFASTTM SYBR Lo-ROX Kit (Bioline) and the CFX TouchTM 
Real-Time PCR detection system (BioRad). Hprt mRNA levels were used 
control. Murine PCR primer sequences: Bglap-Fw, GGG CAA TAA GGT AGT 
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GAA CAG; Bglap-Rv, GCA GCA CAG GTC CTA AAT AGT; Adipoq-Fw, TGT TCC 
TCT TAA TCC TGC CCA; Adipoq-Rv, CCA ACC TGC ACA AGT TCC CTT; Plin1-
Fw, CAT CTC TAC CCG CCT TCG AA; Plin1-Rv, TGC TTG CAA TGG GCA CAC 
T; Il7-Fw, GCT GCC TGT CAC ATC ATC TG; or GCC ACA TTA AAG ACA AAG 
AAG GT (for gene deletion); Il7-Rv, CAG CAC GAT TTA GAA AAG CAG C or 
TGG TTC ATT ATT CGG GCA AT (for gene deletion); Cxcl12-Fw, CGC CAA 
GGT CGT CGC CG; Cxcl12-Rv, TTG GCT CTG GCG ATGT GGC; Hprt -Fw, AGG 
TTG CAA GCT TGC TGG T; Hprt -Rv, TGA AGT ACT GAT TAT AGT CAA GGG 
CA. 
 
 
3. Results 
 
CXCR4 controls CLP development in BM 
 In order to dissociate the role played by CXCR4 in HSC quiescence 
from its role in MPP differentiation, we conditionally deleted Cxcr4 
exclusively in hematopoietic MPPs using a Flk2-cre transgene (Boyer et al., 
2011). To further restrict multilineage differentiation from adult BM niches 
we reconstituted lethally irradiated, congenically marked, wild-type (WT) mice 
(CD45.1+ C57BL/6) with a mixture of BM cells from Cxcr4Fl/Fl;Flk2-cre+ or Flk2-
cre- mice (both CD45.2+) with BM cells from WT mice (CD45.1+ C57BL/6), and 
analyzed hematopoietic cell lineages in BM and in the periphery six weeks 
after reconstitution. The frequency of hematopoietic cell subsets that 
differentiated from Cxcr4Fl/Fl;Flk2-cre- (WT, CD45.2+) or from competitor 
precursors (WT, CD45.1+) was similar to engrafted cells (not shown). In 
contrast, CXCR4-deficient MPP were reduced by 2-fold, multipotent CLP were 
reduced by 3-fold, B-lineage restricted Ly6D+ CLPs (Inlay et al., 2009) were 
reduced by more than 8-fold, and developing B cell subsets were nearly 
absent from BM (Fig. 4.1A, and for gating strategy see Figure S1). Using this 
approach CXCR4 deletion was detectable at the MPP and CLP stages, and was 
evident at the Pre-B cell stage (Figure S2A). CXCR4-deficient megakaryocyte 
and erythroid progenitors (MEP), and granulocyte and monocyte progenitors 
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(GMP) were also significantly reduced by 2-fold in BM (Fig. 4.1B). The 3-fold 
reduction in multipotent CLPs led to a similar reduction in early thymic 
precursors (ETP; Fig. 4.1C). We also detected reduced numbers of lymphoid 
precursors and lymphocyte subsets in non-irradiated Cxcr4Fl/Fl;Flk2-cre+ and 
Cxcr4Fl/Fl;Flk2-cre- adult mice, albeit the fold change was less prominent than 
that seen in mixed BM chimeras (Figure S2B and C). Although hematopoietic 
progenitors, including CLP and early B cell subsets, were mobilized to the 
periphery (Figure S2D) as expected (Nie et al., 2008), it nevertheless resulted 
in a profound reduction in total T, B and NK cell production (Fig. 4.1D). 
Because CXCR4 was required for MPP differentiation into CLP subsets (Fig. 
4.1A), the profound defect in lymphoid lineage production could have been 
caused by defective CLP differentiation. To address this possibility we 
conditionally deleted Cxcr4 from CLP using Il7raCre/+ mice (Figure S2A, E and 
F) and performed similar BM mixed chimeras. Although multipotent (Ly6D-) 
CLP were normally represented in BM (Fig. 4.1E), ETP were significantly 
reduced (Fig. 4.1F), and B-lineage committed Ly6D+ CLPs were significantly 
reduced by 3-fold in BM (Fig. 4.1E). These defects also resulted in a 
significant 2-3 fold reduction in total T, B and NK cells produced (Fig. 4.1G), 
despite the mobilization of lymphoid precursors into the spleen (Figure S2F). 
These data showed that CXCR4 was essential at the MPP and CLP stages for 
their retention in BM, and for the generation of a full lymphocyte 
compartment. These data also revealed a requirement for CXCR4 in MPP for 
their efficient differentiation into other hematopoietic cell lineage-restricted 
progenitors (e.g. MEP and GMP). 
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Figure 4.1| CXCR4 intrinsic expression in MPPs and CLPs is critical for lymphoid cell 
development. (A-D) Frequency of CD45.2+ hematopoietic cell subsets in BM (A and B), thymus 
(C), and in all lymphoid organs (D) of mice reconstituted with 90% CD45.2+ Flk2-cre-;Cxcr4Fl/Fl 
(black) or Flk2-cre+;Cxcr4Fl/Fl (blue) cells mixed with 10% CD45.1+ WT cells (data pooled from 
three independent experiments). (E) Frequency of CD45.2+ HSC, MPP and CLP subsets in BM of 
mice reconstituted with 90% CD45.2+ Il7raCre/+;Cxcr4Fl/Fl (purple) or Il7raCre/+;Cxcr4+/+ (black) cells 
and 10% WT CD45.1+ cells. (F) ETP number in Il7raCre/+;Cxcr4Fl/Fl (purple) and control mice (black). 
(G) Frequency of CD45.2+ in hematopoietic cells taken from all lymphoid organs (total 
chimerism). Data pooled from 3 independent experiments. Bars indicate the average; circles 
depict individual mice. * P<0.05, **P<0.01, ***P<0.001 (unpaired, two-tailed Student’s t-test). 
 
 
CXCR4 guides hematopoietic precursors towards IL-7+ cells in BM 
 Next, we asked how CXCR4 controls lymphoid lineage differentiation. 
The developmental block at the MPP to CLP transition, and particularly to the 
Ly6D+ CLP stage, was reminiscent of the phenotype of Il7 deficient mice 
(Carvalho et al., 2001; Dias et al., 2005; Tsapogas et al., 2011). This 
similarity led us to hypothesize that CXCR4 was required at the CLP stage for 
optimal IL-7/IL-7R signaling. To test this hypothesis we analyzed the 
distribution of Ly6D+ CLPs relative to IL-7-expressing cells. Even though IL-7 
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has been detected by immunofluorescence microscopy in situ (Tokoyoda et 
al., 2004, Tokoyoda et al., 2009), its visualization is difficult and may be 
restricted to cells that express IL-7 at highest levels. Thus, we visualized 
Ly6D+ CLPs in femur BM of Il7-ECFP transgenic mice (Mazzucchelli et al., 
2009), and of Il7GFP/+ knock-in mice (Miller et al., 2013). In both Il7 reporter 
mice, IL-7+ cells could only be visualized after signal amplification with anti-
GFP antibodies (data not shown), which strongly suggests that Il7 is 
expressed at very low amounts in vivo. B-lineage committed CLPs were 
identified in situ as being negative for hematopoietic cell lineage markers 
(see Materials and Methods for details), IL-7Rα+, and Ly6D+ (Fig. 4.2A), a cell 
gate that is ~93% enriched in Ly6D+ CLP (Figure S3A and B). Similar CLP 
frequencies were detected by immunofluorescence microscopy and by flow 
cytometry (Figure S3C and D). We found that more than 90% of Ly6D+ CLP 
were positioned within <15 µm from IL-7+ cells, whereas IgD+ B lymphocytes 
were predominantly distal to IL-7+ cells (Fig. 4.2B and C). Interestingly, Ly6D+ 
CLP proximity to IL-7+ cells was dependent on intrinsic CXCR4 expression 
(Fig. 4.2D and E) and, thus, their positioning was sensitive to a 3-day 
treatment with the CXCR4 antagonist AMD3100 (Fig. 4.2F and G). Defective 
CLP positioning near IL-7+ stromal niches resulted in a significant reduction 
in IL-7Rα signaling, as measured by STAT5a phosphorylation (Fig. 4.2H and I). 
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Figure 4.2| CXCR4 controls CLP positioning near IL-7+ cells in BM. (A) 7 µm-thick section of 
Il7-ECFP transgenic femur. Lin. (green) IL-7Rα (pink), Ly6D (red) and Il7 (blue). Scale bar, 20 µm. 
(B) Ly6D+ CLP (n=166), IgD+ (n=164), and IL-7+ cell distribution in BM. (C) Ly6D+ CLP and IgD+ 
cell frequency near IL-7+ cells (<15 µm). (D and E) distribution of Flk2-cre+;Cxcr4Fl/Fl (blue, ΔX4) 
or Flk2-cre-;Cxcr4Fl/Fl (black, CTR) Ly6D+ CLPs, and IL-7+ cells (D); cell frequency near IL-7+ cells 
(<15 µm) (E). (F and G) Distribution of Ly6D+ CLPs and IL-7+ cells after AMD3100 (AMD) or 
vehicle (Veh) treatment for 3 days (F). Cell frequency near IL-7+ cells (<15 µm) (G). (H and I) 
pSTAT5a in Il7raCre/+;Cxcr4Fl/+ (CTR) and Il7raCre/+;Cxcr4Fl/Fl (ΔX4) Ly6D+ CLPs. (H). pSTAT5a 
geometric mean intensity (I). Bars indicate mean; circles depict individual mice. Data pooled 
from 3 independent experiments. * P<0.05, **P<0.01, ***P<0.001 (unpaired, two-tailed 
Student’s t-test). 
 
 CXCR4 expression and function is increased at the CLP stage when 
compared to earlier HSC and MPP stages (Fig. 4.3A and B). As CXCR4 
signaling has been suggested to control HSC quiescence (in addition to its 
role as a chemoattractant receptor) we asked whether CXCR4 signaling was 
also required for CLP differentiation into B-lineage cells. To test this 
possibility, we measured the efficiency of CXCR4 sufficient and deficient 
single cell-sorted CLPs to differentiate into B and NK cells in vitro. We found 
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that CXCR4 sufficient and deficient CLP differentiated similarly into B and NK 
cells when cultured on OP-9 stromal cell layers with exogenous IL-7 (Fig. 
4.3C). As OP-9 cells express CXCL12 (Fig. 4.3D), the ability of CXCR4 
sufficient and deficient CLPs to differentiate equally into B and NK cells 
suggests that CXCR4 signaling is not required for lymphoid cell development 
from CLP per se. Combined, these data suggest that CXCR4 controls 
lymphopoiesis by promoting CLP positioning near IL-7+ cells in BM, which 
enables IL-7Rα signaling and STAT5a phosphorylation. 
 
 
Figure 4.3| CXCR4 expression and function in HSCs and hematopoietic progenitor cell 
subsets. (A) CXCR4 surface expression in HSC (blue), MPP (green), total CLP (orange, left), and 
in Ly6D- (pink) and Ly6D+ (cyan) CLP (right). (B) In vitro cell chemotaxis through 5 µm 
transwells: nil (black), CXCL12 (white; 300 ng/mL). Bars indicate mean, circles depict 
individual experiments. (C) In vitro single cell CLP differentiation on OP-9 stromal cells for 12 
days in the presence of IL-7 (50 ng/mL). (D) Il7 and Cxcl12 mRNA expression in non-irradiated 
(white) and irradiated (gray) OP-9 stromal cells. Expression is relative to Hprt. Data in all 
panels are representative of at least 3 independent experiments. * P<0.05, **P<0.01, 
***P<0.001 (unpaired, two-tailed Student’s t-test). 
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Osteoblast- and hematopoietic-derived IL-7 is not required for B-
lymphopoiesis 
 Previous studies suggested that osteoblasts form a specialized BM 
niche supporting B lineage cell development (Ding and Morrison, 2013; 
Visnjic et al., 2004; Wu et al., 2008; Zhu et al., 2007). Osteoblasts 
differentiated in vitro can express IL-7, and CXCL12 has also been detected 
in osteoblasts in vivo, albeit at very low amounts (Ding and Morrison, 2013; 
Sugiyama et al., 2006). Furthermore, a significant percentage of IL-7Ra+ 
lineage-negative cells, of which ~8% are CLP (Figure S4A), is positioned near 
the endosteum (Ding and Morrison, 2013). Thus, we asked whether Ly6D+ 
CLPs were preferentially distributed near the endosteum. To address this 
question, we quantified Ly6D+ CLP distance to the nearest bone surface and 
found that more than 80% of these cells were positioned > 30 µm away from 
the endosteum (Figure S4B and C). We then asked if Il7 was expressed in 
osteoblasts in vivo and in vitro. To address this question, we stained 25 µm-
thick femur whole mount sections from Il7 reporter mice or from control 
mice with anti-osteopontin or with anti-osteocalcin antibodies and found no 
evidence for Il7 expression in osteoblasts in situ (Fig. 4.4A, and Figure S5A, 
respectively). In order to analyze Il7 expression in osteoblasts in a 
quantitative manner we measured Il7 mRNA expression in cultured 
osteoblasts from adult femur BM precursors, and from neonatal calvaria BM 
precursors, by quantitative PCR. We found that Il7 expression is essentially 
undetectable in these cells, whereas osteocalcin (Bglap, a gene highly 
expressed in pre-osteoblasts and mature osteoblasts) was readily detected, 
and Cxcl12 expression was detected at low levels (Fig. 4.4B, and Figure S5B), 
as expected (Ding and Morrison, 2013; Sugiyama et al., 2006). To 
convincingly rule out the possibility that an undetectable amount of Il7 
expressed by osteoblasts contributes to B lymphopoiesis we conditionally 
deleted Il7 in osteoblasts using the Col1a1 2.3Kb promoter driven-cre 
recombinase approach (Col2.3-cre) (Liu et al., 2004). We found no evidence 
for a significant contribution of osteoblast-expressed IL-7 to B lymphopoiesis 
(Fig. 4.4C). Furthermore, we could not detect Il7 expression in hematopoietic 
cell subsets (not shown), nor did Il7 deletion from hematopoietic cells using 
the Vav-cre transgene resulted in measurable defects in B cell production 
(Fig. 4.4D). 
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Figure 4.4| Osteoblast-derived Il7 is not required for B lymphopoiesis. (A) Distribution of 
IL-7+ (green) and osteopontin+ (red) cells in BM. (B) Bglap (osteocalcin), Cxcl12, and Il7 
expression in osteoblasts by qPCR. Gene expression is relative to Hprt. (C) Total number of 
hematopoietic cell subsets in BM of Il7fl/-;Col2.3-cre+ (red) and control littermates (black). (D) 
Total number of hematopoietic cell subsets in BM of Il7fl/-;Vav-cre+ (gray) and control 
littermates (black). Bars indicate average, circles depict individual mice. Data in all panels are 
representative of 3-independent experiments, at least. 
 
 
IL-7+ cells are a subset of BM CAR cells and are critical for B-
lymphopoiesis 
 The fact that CXCR4 was critical for CLP positioning near or in contact 
with IL-7-producing reticular cells suggested that IL-7+ cells express 
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significant amounts of CXCL12. However, distinct stromal cell subsets were 
suggested to produce either CXCL12 or IL-7, but not both (Tokoyoda et al., 
2004). To gain insight on the BM niches that support lymphoid lineage 
differentiation, we analyzed the cellular composition and distribution of IL-7+ 
cells in BM of Il7GFP/+;Cxcl12DsRed/+ double reporter mice. We carefully extracted 
and digested BM cells with collagenase (see Materials and Methods for 
details) and analyzed cells by flow cytometry. We found that 0.05±0.01% of 
total BM cells express Il7 (Fig. 4.5A). Of these cells, 90.3±6.0% expressed 
Cxcl12 at very high levels (Fig. 4.5B), and were large reticular cells 
distributed in BM parenchyma and perivascular areas (Fig. 4.5D and E). 
Occasionally, we could find extremely large and elongated IL-7+ cells adjacent 
to arterioles, which resembled a population of Nestin-GFP bright cells 
(Nestinperi; data not shown) (Kunisaki et al., 2013). A few IL-7+ cells did not 
express Cxcl12 (2.8±3.2%, Fig. 4.5B and D), and these cells were also large 
reticular cells distributed in parenchyma and perivascular areas (not shown). 
Although >97% of IL-7+ cells expressed Cxcl12 (at intermediate and high 
amounts), only 61.5±3.9% of the CXCL12+ cells also expressed Il7 (Fig. 4.5C). 
 CAR cells share functional similarities with a subset of mesenchymal 
progenitor cells that expresses Leptin receptor (LEPR; Omatsu et al., 2010; 
Zhou et al., 2014). Interestingly, the majority of IL-7+ cells (88.3±8.6%) 
expressed LEPR, (Fig 4.5E); and Lepr-cre driven tdTomato expression marked 
IL-7+ BM cells (Fig. 4.5F). Next, we asked if Il7 expressed by LEPR+ cells was 
required for B lymphopoiesis. We found that conditional deletion of Il7 from 
LEPR+ cells resulted in a significant reduction in Ly6D+ CLP in BM (Fig. 4.5G), 
and reduced pSTAT5a in these cells (Fig. 4.5H and I). Consequently, the 
number of developing B cell subsets was dramatically reduced (Fig. 4.5J), 
which led to peripheral B lymphopenia (Fig. 4.5K). Finally, deletion of Il7 
from mesenchymal progenitor cells using PRX1 (a transcription factor 
expressed in the limb bud mesoderm, Prx1-cre (Logan et al., 2002)) also led 
to a dramatic (and significant) reduction in developing B cell subsets in BM 
(Figure S6). 
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Figure 4.5| Most IL-7+ cells are a subset of CXCL12-abundant reticular cells. (A) Frequency 
of IL-7+ cells in BM. (B) Cxcl12 expression in IL-7+ CD45- cells. (C) Cxcl12 and Il7 expression in 
CD45- cells (left and middle). Il7 expression in Cxcl12Hi cells (right). (D) 25 µm-thick section of 
Il7GFP/+;Cxcl12dsRed/+ mouse femur stained to detect IL-7+ (green) cells. CXCL12+ cells were directly 
visualized. Scale bar is 50 µm. Insert, example of an IL-7+ CXCL12- cell, and of an IL-7+ CXCL12+ 
cell. (E, Left) gated IL-7+ cells; (right) LEPR expression in gated IL-7+ cells. (F) Lineage mapping 
of Il7 expressing cells using Lepr-cre transgenic mice. 8 µm-thick femur section of Lepr-
cre+;Rosa26tdtomato/+ Il7GFP/+ mice. Scale bar is 50 µm. Arrow and arrowhead indicate Lepr-cre-
derived IL-7+ cells and Lepr-cre-derived IL-7− cells respectively. Yellow arrow indicates IL-7+ 
Lepr-cre- cells. (G) HSC, MPP, and CLP number in BM of Lepr-cre+;Il7fF/Fl (red) and Lepr-cre-;Il7fF/Fl 
(black) mice. (H) Histogram of pSTAT5a in Ly6D+ CLPs from Lepr-cre+;Il7fF/Fl (blue) and Lepr-cre-
;Il7fF/Fl (filled). (I) pSTAT5a geometric mean intensity in Ly6D+ CLPs in Lepr-cre-;Il7fF/Fl mice (gray) 
and in Lepr-cre+;Il7fF/Fl (red) mice. (J and K) Developing B cell numbers in BM (J); splenic B cells 
(K) in Lepr-cre+;Il7fF/Fl (red) and Lepr-cre-;Il7fF/Fl (black). In panels G, I, J and K, bars indicate mean, 
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circles depict individual mice. Data are pooled from 3 independent experiments. * P<0.05, 
**P<0.01, ***P<0.001 (unpaired, two-tailed Student’s t-test). 
 
 
Endothelial cell-derived IL-7 contributes to B lymphopoiesis 
 A previous study indicated that some IL-7+ cells in BM express 
endothelial cell markers (Hara et al., 2012). Likewise, we found that a smaller 
fraction (20.6±7.2%) of IL-7+ cells expressed CD31 (PECAM-1), Sca1, and VE-
Cadherin (Fig. 4.6A and B). To rule out the possibility of an in vitro staining 
artifact, we analyzed IL-7+ cells in relation to BM endothelial cells by confocal 
microscopy. We found that in some BM sinusoids, CD31 and CD144 (VE-
Cadherin) co-localize with GFP expression driven by Il7 (Fig. 4.6B). We then 
sorted CD144+ CD31+ CD45- Ter119- BM endothelial cells, and LEPR+ CD144- 
CD31- CD45- Ter119- MSPC, and compared Il7 and Cxcl12 expression by 
qPCR. We found that even though Il7 (and Cxcl12) was mostly expressed by 
MSPC, Il7 expression could also be readily detected in BM endothelial cells 
(Fig. 4.6C). Importantly, Il7 deletion from endothelial cells using a Tie2-Cre 
transgene resulted in a small, selective, but significant reduction in Pre-B cell 
numbers in BM (Fig. 4.6D), suggesting that Pre-B cell proliferation is sensitive 
to endothelial sources of IL-7. 
Figure 4.6| Endothelial cell-derived IL-7 
contributes to B cell development. (A) Flow 
cytometry analysis of Sca1 and CD31 
expression in IL-7+ BM cells. Blood endothelial 
cells (BECs). (B) Il7 co-localization with CD31 
and VE-Cadherin. Scale bar: 50 µm. (C) Il7 and 
Cxcl12 expression in FACS sorted CD45-Ter119-
CD144-CD31-LEPR+ MSPC and endothelial cells 
(ECs, CD45-Ter119-CD144+CD31+LEPR-). Gene 
expression is relative to Hprt. Bars indicate 
average ± SD of 3-independent cell sorting 
experiments. (D) Total number of 
hematopoietic cell subsets in BM of Il7Fl/- ;Tie2-
cre+ (red) and control littermates (black). Bars 
indicate average, circles depict individual mice. 
* P<0.05, (unpaired, two-tailed Student’s t-test). 
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IL-7+ cells are mesenchymal progenitor cells 
 CAR cells are mesenchymal progenitor cells that can differentiate into 
multiple cell lineages including osteoblasts, osteocytes, chondrocytes and 
adipocytes, and possibly stromal cells (Omatsu et al., 2010). As most IL-7+ 
cells form a subset of CAR cells it raised the possibility that IL-7+ cells also 
overlap with mesenchymal progenitor cells. Alternatively, IL-7+ CAR cells 
could represent a differentiated mesenchymal subset that no longer retains 
multipotent differentiation potential. To distinguish between these 
possibilities we traced cell lineages that differentiated from IL-7+ cells by 
crossing Il7-cre transgenic mice (Repass et al., 2009) with Rosa26YFP mice 
(YFP expression driven by Rosa26 repressed by a loxP-flanked transcriptional 
repressor), and examined the cellular composition and distribution of YFP+ 
cells in BM. We found that a large fraction of bone-lining osteocalcin+ 
osteoblasts were YFP+, and a few bone-embedded osteocytes were also YFP+ 
(Fig. 4.7A). To determine if adipocytes could differentiate from IL-7+ cells, we 
induced adipogenesis by sub-lethal irradiation (Bryon et al., 1979) and 
examined femurs and tibias of Il7-cre+;Rosa26YFP mice for YFP expression in 
perilipin+ adipocytes. We found that irradiation-induced adipogenesis 
occurred partly from IL-7+ cells (Fig. 4.7B), while adipocytes expressed 
marginal amounts of Il7 and high amounts of adipocyte-specific adiponectin 
and perilipin (Fig. 4.7C). Combined, these data show that IL-7+ CAR cells are 
mesenchymal progenitor cells with multilineage differentiation capacity. 
These data also showed that Il7 expression is down-regulated when IL-7+ CAR 
cells undergo differentiation. 
93"
  
Figure 4.7| IL-7+ BM cells are mesenchymal progenitor cells. (A) Osteoblasts and osteocytes 
differentiate from IL-7+ cells. Arrow indicates osteoblasts, arrowhead indicates osteocyte. (B) 
adipocytes differentiate from IL-7+ cells. (A and B) 25 µm-thick section of Il7-cre+;Rosa26YFP/+ 
mouse femur (top panels), or of control mouse femur (bottom panels), stained to detect 
osteocalcin+ cells (red, A); perilipin+ cells (red, B). YFP+ cells (green). (C) Adipoq, Plin1, Cxcl12, 
and Il7 mRNA expression in adipocytes. mRNA expression is relative to Hprt. 
 
 
4. Discussion  
 Here we showed that the BM niche formed by CXCL12+ cells represents 
a common niche for hematopoietic progenitors at multiple stages of 
differentiation. CXCR4 was critically required in hematopoietic progenitor 
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cells for positioning in the vicinity of IL-7+ cells in BM, and that proximity to 
IL-7 enables optimal IL-7R signaling and B cell developmental progression. 
The majority of IL-7+ cells form a subset of mesenchymal progenitor CAR cells 
capable of multilineage differentiation, and a minor fraction of IL-7+ cells are 
BM sinusoidal endothelial cells. 
 HSC require short-range extrinsic factors, such as angiopoietin, SCF, 
and CXCL12 amongst several others, produced by rare mesenchymal 
progenitor cells in BM for their long-term maintenance. SCF-producing 
mesenchymal progenitor cells overlap entirely with CAR cells (Ding et al., 
2012), and IL-7 expression marks the mesenchymal progenitor subset that 
expresses the highest amounts of CXCL12. Furthermore, Nestin-expressing 
mesenchymal cell subsets (namely NestinBright and NestinDim) are also critical 
components of HSC niches in BM, and these cells also express essential HSC 
maintenance factors and largely overlap with IL-7+ and IL-7- CAR cells. 
Importantly, NestinBright cells play a critical role in HSC quiescence and long-
term maintenance most likely because these cells express higher amounts of 
HSC maintenance factors (e.g. angiopoietin, SCF) than NestinDim cells 
(Kunisaki et al., 2013). Importantly, NestinBright cells also express significantly 
higher amounts of CXCL12 and IL-7 (Kunisaki et al., 2013). As HSC are highly 
dependent on CXCR4 signaling for quiescence and long-term maintenance 
(Nie et al., 2008; Sugiyama et al., 2006), our studies suggest that HSC 
quiescence and lymphopoiesis are distinct cellular decisions controlled by 
highly overlapping mesenchymal niches. 
 Mesenchymal progenitor cells also respond to long-range signals, 
such as cytokines and hormones, which regulate mesenchymal progenitor 
cell activity. For example, adrenergic signals controlled by circadian rhythms 
are sensed by beta 3 adrenergic receptors expressed on mesenchymal 
progenitor cells and reduce CXCL12 production (Mendez-Ferrer et al., 2008). 
Consequently, HSC are displaced from HSC niches and exit the BM in a 
circadian manner (Mendez-Ferrer et al., 2008). Although the physiological 
role for HSC recirculation remains unknown (Wright et al., 2001), we suggest 
that circadian fluctuations in CXCL12 production enable HSC to divide 
periodically, and possibly allow a few HSCs to differentiate into MPP. As our 
data showed that hematopoietic cell lineages are differentially sensitive to 
CXCR4 (lymphoid lineages being more dependent on CXCR4 than myeloid 
and erythro-megakaryocyte lineages, see Fig. 1B and 1D), we suggest that 
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circadian fluctuations in CXCR4 signaling in MPP presumably alters their 
positioning in relation to mesenchymal progenitors, and thus enables the 
production of distinct hematopoietic lineages in a periodic manner.  
 Previous studies implicated osteoblasts as an essential component of 
BM niches supporting B lymphopoiesis (Visnjic et al., 2004, Wu et al., 2008, 
Zhu et al., 2007). Furthermore, a recent study found that conditional deletion 
of Cxcl12 in osteoblasts using the Col2.3-cre transgene, led to a small but 
significant reduction in BM CLP that did not cause Bl ymphopenia (Ding and 
Morrison, 2013). Our findings are in apparent contrast with these studies, 
but are in agreement with the finding that the low Cxcl12 expression in 
osteocalcin+ osteoblasts is not required for B lymphopoiesis (Greenbaum et 
al., 2013). However, the strategies used for assessing the role played by 
osteoblasts in lymphopoiesis bear considerable limitations. For example, the 
use of conditional approaches for inducing osteoblast apoptosis result in 
synchronized cell apoptosis within BM that may not be efficiently cleared by 
phagocytic macrophages. Consequently, the release of intracellular 
components, such as genomic and mitochondrial DNA, can elicit a significant 
inflammatory response, including the production of IL-1, TNFα, and type I 
IFNs (Chen and Nunez, 2010). In turn, inflammatory signals not only reduce 
B lymphopoiesis (Ueda et al., 2004, Ueda et al., 2005), but also affect HSC 
numbers (Glatman Zaretsky et al., 2014), and these changes were evident in 
both studies (Visnjic et al., 2004; Zhu et al., 2007). Given that most, if not all, 
studies using cell ablation approaches did not include appropriate control 
experiments (e.g. ablation of an irrelevant and numerically equivalent cell 
population), their conclusions remain subject to such limitations. Using an 
Osterix-driven cre recombinase approach, another study reported that Gα
s
 
protein signaling in osteoblasts regulates B lymphopoiesis (Wu et al., 2008). 
However, CAR cells also express Osterix (Omatsu et al., 2010), and Osterix-
driven cre recombinase expression marks mesenchymal progenitor cells 
(Greenbaum et al., 2013; Mizoguchi et al., 2014), which implicates Gα
s
 
protein signaling in MSPC as a significant regulator of B-lymphopoiesis. 
Furthermore, although the Col2.3-cre approach has been widely used for the 
genetic manipulation of osteoblast-lineage cells, it should be noted that 
Col1a1 expression has also been detected in MSPC (Ding et al., 2012; 
Kunisaki et al., 2013; Mendez-Ferrer et al., 2010). Therefore, it is possible 
that the Col2.3-cre transgene is already active at the MSPC stage, albeit 
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inefficiently. 
 B cells develop through multiple developmental stages in which entry 
and exit from cell cycle and Rag protein expression are tightly controlled. 
Interestingly, some evidence supports the notion that this process relies on 
distinct BM niches. Specifically, the large majority of Pre-proB cells have been 
found in proximity to CAR cells, Pro-B cells were mostly found near IL-7+ cells 
that did not express CXCL12, and Pre-B cells seem to localize near poorly 
defined Galectin+ cells (Mourcin et al., 2011; Tokoyoda et al., 2004). B-
lineage cell movement towards and away from IL-7+ cells has been proposed 
to regulate Rag protein expression and activity (Clark et al., 2014, Johnson et 
al., 2008, Ochiai et al., 2012). Our results indicated that endothelial-derived 
Il7 contributed primarily to Pre-B cell development. Our data also clearly 
demonstrated that Il7 is mostly expressed by a subset of CAR cells, while 
only very few IL-7+ cells were CXCL12-. In fact, our data suggests that Il7 is 
expressed at very low amounts as we could barely visualize IL-7+ cells 
without signal amplification with anti-GFP antibodies. The fact that 
supraphysiological levels of IL-7 lead to the development of Pre-B cell 
leukemias in mice (Fisher et al., 1993) also supports the notion that IL-7 
must be expressed in low amounts in BM. Given the notorious difficulty we, 
and others (Mazzucchelli et al., 2009), had in visualizing IL-7+ cells in situ, it 
is possible that the previous studies that identified IL-7+ cells in BM 
(Tokoyoda et al., 2004; Tokoyoda et al., 2009) were able to visualize IL-7+ 
CXCL12- cells only. Thus, it will be important to determine the distribution of 
early B cell developmental subsets and of memory T cell subsets relative to 
such distinct IL-7+ cell subsets. 
 In summary, our studies revealed that IL-7 is produced in BM by a rare 
and heterogeneous cell subset composed of mesenchymal cells with 
multilineage differentiation potential, and by a few sinusoidal endothelial 
cells. The majority of IL-7+ cells expressed the highest amount of CXCL12 in 
BM. Consequently, MPP and CLP rely on CXCR4 signaling for positioning in 
proximity to IL-7+ cells, which is essential for accessing limiting IL-7 and for 
receiving sufficient IL-7R signaling. Although IL-7 is essential for B and T cell 
development in adult mice (Carvalho et al., 2001; von Freeden-Jeffry et al., 
1995), and likely in adult humans (Bendall et al., 2014, Parrish et al., 2009), 
NK cell development is mostly dependent on IL-15 (Kennedy et al., 2000). NK 
cells also developed poorly from CXCR4-deficient MPP and CLP, and CAR cells 
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express IL-15 (Noda et al., 2011). Combined, these data demonstrate that 
the control of cell positioning in BM niches is an essential checkpoint in 
lymphopoiesis as it enables hematopoietic precursor access to limiting 
lymphoid-instructive cytokines. The clear similarities that we have shown 
between lymphoid-supportive niches and HSC niches in BM favor a model in 
which HSC maintenance and multilineage differentiation are distinct cell 
lineage decisions controlled by overlapping BM niches. The functional, 
evolutionary, advantage(s) for the local control of HSC maintenance and 
multilineage differentiation remain(s) to be determined.   
  
 
Supplementary Figures 
 
 
Figure S1| Gating strategy for analyzing HSCs and hematopoietic progenitor cell subsets. 
(A) Common lymphoid progenitor subsets. (B) Long-term HSC and MPP. Cells shown were 
gated on the indicated live (DAPI-) LSK gate. (C) MEP, CMP and GMP. Cells shown were gated on 
live (DAPI-) IL7R- L-S-K+ gate. (D) ETP. Data are representative of more than 10 independent 
experiments. 
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Figure S2| CXCR4 deficiency at MPP and CLP stage reduces lymphoid celldifferentiation. 
(A) Histogram of CXCR4 expression in gated MPP (left), CLP (middle), and Pre-B (right) cells 
isolated from control (filled), Flk2-cre+;Cxcr4Fl/Fl (blue), and Il7racre/+;Cxcr4Fl/Fl (pink) mice. Data 
are representative of more than 3 independent experiments. (B-D) Analysis of Flk2-
cre+;Cxcr4Fl/Fl (blue) and Flk2-cre-;Cxcr4Fl/Fl (black)mice. (B) Number of hematopoietic progenitor 
cell subsets, developing B cell subsets, and NK cells in the femur and tibia. (C) Total number 
of granulocytes (gran.), mature B cells, NK and T cells in combined primary and secondary 
lymphoid organs, peritoneal cavity, and in liver. D, Number of hematopoietic cell subsets in 
the spleen. (E and F) Analysis of Il7raCre/+;Cxcr4Fl/Fl mice (purple) and Il7raCre/+;Cxcr4+/+ mice 
(black). (E) Number of hematopoietic progenitor cell subsets, developing B cell subsets, and 
NK cells in the femur and tibia. (F) Number of CLP subsets in the spleen. Bars indicate mean; 
circles depict individual mice. Data are pooled from at least 3 independent experiments. 
*P<0.05, **P<0.01, ***P<0.001 (unpaired, two-tailed Student’s t-test). 
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Figure S3| Strategy for in situ detection of Ly6D+ CLP cells. (A) FLT3 expression in live 
(DAPI-) lineage (lin-) negative BM cells gated on Ly6D+ and Ly6D- cells. (B) FLT3 expression in 
total Ly6D+ and IL7Ra+ BM cells. Left panel shows Lin- gated BM cells. Right panel shows FLT3 
expression in gated population. (C) Distribution of IL-7+ cells in femur 7-µm sections stained 
with anti-GFP antibodies. Left, control (CTR); right, Il7-ECFP transgenic. (D) 7-mm femur 
section of Il7-ECFP transgenic mice stained with anti-GFP (blue), lineage antibody cocktail 
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(green), anti-IL-7Rα (purple), and with anti-Ly6D antibodies. Scale bar is 200 µm. White box in 
large panel indicates insert; individual fluorescence channels of magnified inserts are shown 
below. Data are representative of more than 10 independent experiments. Table, cell 
frequencies determined by immunofluorescence (IF) and by flow cytometry (FACS). 
 
 
Figure S4| CLP gating strategy used by Ding et al 2, and CLP distribution in situ. (A) Left 
panel, frequency of total IL-7Rα+ Lin- cells in BM. Right panel, FLT3 expression in gated IL-7Rα+ 
Lin- cells. Numbers indicate average ± SD (n=8 mice pooled from 3 independent experiments). 
(B) Distribution of Ly6D+ IL-7Rα+ Lin- CLP and IL-7+ cells in a 7 µm-thick section of Il7-ECFP 
transgenic femur. Dotted line indicates bone surface. Scale bar is 200 µm. (C) Frequency of 
Ly6D+ IL-7Rα+ Lin- CLP positioned at <30 µm from bone surface. Bars indicate average, circles 
depict individual mice. Data was pooled from 3 independent experiments. 
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Figure S5| Distribution of IL-7+ cells in relationship with osteoblasts. (A) Distribution of IL-
7+ cells and osteocalcin+ cells in 25 µm-thick femur whole mount. Scale bar is 50 µm. (B) Il7, 
Cxcl12, and Bglap expression in neonatal-derived calvaria osteoblasts cultured over a 4 week 
period (x-axis). Expression is relative to Hprt (y-axis). Lines indicate average ± SD of 3-
independent experiments. 
 
 
Figure S6| IL-7 expressed by MSPC is critical for B lymphopoiesis. (A) Flow cytometric 
analysis of BM from 4-wk-old Il7Fl/-;Prx1-cre+ and control littermate mice. Numbers indicate the 
percentages of each fraction. (B) Absolute numbers of indicated cells in the femur and tibia. 
Bars indicate average, circles depict individual mice. *** p <0.001 (unpaired, two-tailed 
Student’s t-test). 
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Chapter 5 | Discussion 
 The experimental data was discussed throughout chapters 3 and 4. 
Therefore, the following discussion aims to puzzle together the data, 
highlighting the novel findings, the open and/ or unanswered questions on 
defining/ characterizing hematopoietic differentiation niches, with emphasis 
on the B lymphopoiesis niche and on the mechanisms regulating the 
positioning of hematopoietic progenitors within the niche.   
 
 
1. Re-Defining the Hematopoietic Niche 
 Transcription factors dictate cell lineage choices, but the signals 
controlling their expression and/or activity remain poorly understood. 
Therefore, it was initially hypothesized that HSC reside within a niche. Over 
the last decade, the effort of many research teams shed light on defining 
which cell types regulate the HSC niche. However, how the niche constituents 
are organized within bone marrow, and to what extent they interface with 
each other is still poorly understood. Moreover, the hematopoietic output is 
diverse, and several different cues are required to generate the different 
blood lineages. Furthermore, ablation of CXCR4 function on HSC themselves 
affected more B lymphopoiesis than myelopoiesis (Nie et al., 2008), 
suggesting that the positional cues are fundamental for lineage 
differentiation.  
 CXCR4 /CXCL12 pathway is the major organizing chemokine/ 
chemokine receptor in bone marrow. We (Beck et al., 2014) and others 
(Pereira et al., 2009, Nie et al., 2008, Nie et al., 2004) have shown that B 
lymphopoiesis proceeds normally in the absence of CXCR4. Deficiency in 
CXCR4 after commitment to the B lymphoid lineage accelerates the egress of 
developing Immature B cells to the periphery, but not the egress of Pro and 
Pre-B cells at the same extent. Another retention mechanism may act on Pro 
and Pre-B cell stages to maintain them within the bone marrow parenchyma 
and thus, further work is required to define this CXCR4-independent 
retention of Pro and Pre-B cell stages. Pro and Pre-B cells might be incapable 
to transendothelial migration. 
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 Immune cell migration and chemoattraction are mostly dependent on 
Gα
i 
protein coupled receptors (Cyster and Schwab, 2012). Interestingly, when 
we ablated Gα
i 
function in developing B lymphocytes, B lymphopoiesis 
proceed normally in bone marrow, being immature B cell egress accelerated 
albeit to a less extent due to the lack of the egress active mechanism. This is 
explained because S1P
1
R/ S1P pathway is also affected by the lack of Gα
i 
function in developing B cells. Even though bone marrow B lymphopoiesis 
proceeds normally in absence of Gα
i
 function, immature B in the periphery 
show a survival defect, suggesting that GPCR function is required for the 
survival of immature B cells in the periphery.   
 Two major findings arise from these data. First, we revealed a passive 
egress mechanism, which we further characterized in (Beck et al., 2014). 
Second and most remarkably is that later stages of B lymphopoiesis are not 
critically dependent on positional cues, thus, challenging the concept of a 
differentiation niche, and favoring the initial niche concept where lineage 
differentiation occurs distantly to the maintenance HSC niche. A few studies 
have supported the existence of different hematopoietic niches, being HSC 
maintenance niche a distinct and separated entity to the B lineage 
differentiation niche (Ding and Morrison, 2013b, Zhu et al., 2007, Bai et al., 
2007). The HSC niche have been described as perivascular and the B 
lymphoid niche to be close to endosteal regions and regulated by 
osteoblasts. These studies present some caveats. Their conclusions need to 
be rigorously determined on 1) the identity and abundance of the cell 
populations that are recombining and possible off-target effects, such as the 
deletion occurring in other cell types; 2) the efficiency of recombination in 
the targeted cell type; and 3) effects related to the kinetics of the induced 
deletion. It is important to retain that these considerations are critical to 
genetic models in which a specific cell population is ablated through Cre-
mediated expression of a suicide gene (such as diphtheria toxin). In these 
models, the elimination of a cell population also affects its progeny, causing 
a compensatory feedback response in its precursor cells, or generating local 
inflammatory responses that may alter other cell populations secondarily 
(Mendez-Ferrer et al., 2015). Moreover, several Cre lines, such as Col2.3-cre, 
were incompletely characterized and instead of marking specific cell types, 
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may recombine in broader cell populations, leading to misunderstanding 
about which cell type is responsible for the phenotype observed.   
 The B lineage differentiation niche is not fully characterized. A 
strategy to define a lineage differentiation niche is to focus on factors critical 
for certain lineages, namely cytokines. Cytokines stimulate the survival and 
proliferation of hematopoietic stem and progenitor cells and also influence 
their lineage output. Whether lineage commitment occurs due to cell intrinsic 
mechanisms, such as fluctuating transcription factor networks, followed by a 
selective cytokine function, or is directly instructed by cytokines through the 
induction of lineage specific transcriptional programs has been technically 
challenging to demonstrate and distinguish. Adult murine B lymphopoiesis 
has been extensively reported as critically dependent on IL-7 (Carvalho et al., 
2001, Dias et al., 2005, von Freeden-Jeffry et al., 1995, Vosshenrich et al., 
2004, Vosshenrich et al., 2003).  IL-7 is a soluble cytokine whose production 
is tightly regulated, implying that IL-7 consumption has to occur locally, i.e., 
close to its source. The arguments supporting the local consumption of IL-7 
have been outlined in the discussion section of Chapter 4. IL-7 is required at 
the CLP stage to maintain the B lymphoid potential, arguing for an instructive 
role of IL-7 in B lymphopoiesis. The requirement for local consumption of an 
instructive cytokine in B lymphopoiesis allows to better identify and 
characterize a differentiation niche, namely, the B lymphopoiesis niche and 
molecular mechanisms regulating it.    
 In chapter 4, we showed that B lineage primed CLP localize 
preferentially close to IL-7-expressing BM cells. Moreover, CLP rely on the 
chemokine receptor CXCR4 signaling to position in proximity to IL-7-
expressing cells, which is essential for accessing limiting IL-7 and for 
receiving optimal IL-7R signaling. Therefore, our studies revealed a 
contribution in vivo of a concerted action of chemokines and cytokines in the 
lineage differentiation of hematopoietic progenitors. Moreover, we 
demonstrated that different hematopoietic lineages have a differential 
requirement on CXCR4 at the progenitor level to access instructive cytokines, 
being lymphoid lineages highly dependent on CXCR4 on hematopoietic 
progenitors. Taken together, our data supports the model that in vivo 
cytokines and chemokines have an instructive role in hematopoiesis, and are 
major players in the hematopoietic niche.  
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 Previous observations have reported that MPP represent a highly 
‘instructable’ progenitor population whose lineage output can be 
reprogrammed in response to external cues, namely inflammatory cytokines 
(Maeda et al., 2005). Interestingly, lineage differentiated cells have been 
shown to modulate the hematopoietic niche by direct activation of 
mesenchymal progenitor cells, during stress responses, such as viral 
infections (Maeda et al., 2005), and by direct action on hematopoietic 
progenitors also during steady state (Mondal et al., 2011). Niche stromal 
cells express different cytokine receptors (Ding et al., 2012), and most likely 
they are capable of sensing extracellular cues and respond. As a 
consequence, the type of factors produced by these cells, namely instructive 
cytokines, may fluctuate, affecting lineage differentiation output. More 
studies are needed to understand how the hematopoietic niche senses 
external cues, under steady and stress states, and responds, and whether 
the responses affect lineage choice of progenitor cells.  
 
 
2. The B lymphopoiesis niche as part of the HSC maintenance 
niche  
 Besides identifying it, we further characterized the B lymphopoiesis 
niche (Chapter 4), by thoroughly describing IL-7 sources in BM. IL-7-
expressing cells share several features with the stromal cells implicated on 
the maintenance of HSC. Both cell types are shown to be mesenchymal 
progenitor cells (with adipogenic and osteogenic potential), which express 
LEPR, CXCL12. In addition, Cxcl12, Il7, and Scf mRNA was detected in Nestin-
expressing mesenchymal stem cells (Mendez-Ferrer et al., 2010b). Our 
results provide a strong evidence of overlapping between lymphoid-
supportive niches and hematopoietic stem cell niches in BM. Yet, the types of 
niche supporting cells remain unsolved. Different types of stromal cells and 
some hematopoietic cells, like macrophages (Chow et al., 2011) and 
megakaryocytes (Bruns et al., 2014), may constitute a niche unit. Further 
studies will have to determine whether different types of supporting cells 
constitute a niche unit. Considering that the niche has four (A, B, C, D) types 
of supporting cells, cell A, B and C express CXCL12. Cell A expresses SCF but 
109"
not IL-7; B expresses IL-7, but not SCF, and cell C expresses both IL-7 and 
SCF. Cell D expresses only IL-7. HSC may be positioned close to either cell A 
or cell C. CLP are either in close contact with cell B or C. It is possible that 
HSC are maintained by cell A and differentiate close to cell C. Therefore, it is 
imperative to determine the positioning of HSC (and MPP) relative to IL-7 cells, 
and to CLP, and determine whether IL-7+ and SCF+ stromal cells overlap. The 
identification of a HSC in close contact with the same IL-7 cell is strong 
indication but it is not sufficient to demonstrate an overlap between HSC 
maintenance and lineage differentiation niches. It will be necessary to 
demonstrate that HSC reside close to IL-7 cells and CLP differentiate into the 
B cell lineage, which is a challenging quest. For this purpose, G1 phase 
FUCCI reporter mice (Sakaue-Sawano et al., 2008, Hitoshi et al., 1991), in 
which FUCCI+ LSK cells are enriched for HSC (Shangqin Guo, Yale Univeristy, 
personal communication), are being crossed with cKitGFP/+ (Zhu et al., 2009). 
FUCCI+ cKitGFP/+ mice will be crossed with transgenic mice ubiquitously 
expressing the green-to-red, irreversibly photoconvertible protein KikGR 
mice (Tsutsui et al., 2005, Nowotschin and Hadjantonakis, 2009), and triple 
reporter mice will be crossed with IL-7-ECFP mice. Intravital 2-photon imaging 
of calvaria BM will allow to identify HSC in proximity to IL-7+ cells. The area 
will be then exposed to violet light to induce photo-conversion. FACS 
analysis of the photo-converted cells will allow to identify which 
hematopoietic cells reside in proximity to HSC. Detection of Ly6D+ CLP within 
the photo-converted cells would indicate that HSC and CLP reside in close 
proximity. A strategy to determine that the same supporting cell regulates 
HSC maintenance and lineage differentiation is to specifically ablate Cxcl12 
expression using Il7cre/+ mice. Alteration in HSC pool and CLP would decree 
that CXCL12+ IL-7+ cells support HSC maintenance and B lymphopoiesis.    
 The fact that some supporting cells in the niche are MSC may also 
affect the lineage output, varying with the stages of the mesenchymal 
differentiation program. When the supporting cells are mainly primitive MSC, 
the niche maintains the HSC and supports B lymphopoeisis. We 
demonstrated that mature osteoblasts and adipocytes express low amounts 
of IL-7 then, with maturation of MSC into adipocytes and/or osteoblasts, the 
niche loses the capability of supporting B lymphopoiesis. This could account 
to the decreasing B lymphopoieisis with age.  
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 The highlight of the hematopoietic niche (HSC maintenance and 
lineage-instructive niche) allows dissecting the poorly known structural 
organization of the bone marrow. For instance, it has been observed that 
bone marrow transits from red (hematopoiesis active) to yellow 
(hematopoiesis inactive) with age due to the accumulation of adipocytes, 
which have been implied as negative regulators of hematopoiesis (Naveiras 
et al., 2009). In the adult human, the red marrow is found mainly in the flat 
bones, such as the pelvis, sternum, cranium, ribs, and in the cancellous 
material at the epiphyseal ends of long bones (eg, femur and humerus). Why 
these changes in bone marrow structure occur is not completely understood. 
One possibility is that bone marrow parenchyma and the bone crosstalk to 
maintain the homeostasis of the marrow, and therefore regulate 
hematopoiesis. Shedding light on the mechanisms will be important to 
prevent/ cure pathologies such as osteoporosis. Moreover, hematopoietic 
failure is usually a consequence of overproduction of pro-inflammatory 
cytokines in pathologies such as chronic inflammatory diseases, 
hematological malignancies, and bone marrow failure syndromes (Bryder et 
al., 2001, Ishihara and Hirano, 2002). Hence, how the bone marrow 
comportment is regulated and how its regulation affects hematopoiesis are 
unanswered fundamental questions. It is feasible that HSC are the only 
important player in the regulation of hematopoiesis and therefore lineage 
output is only dependent on these multipotent cells. However, our studies 
show that multipotent hematopoietic progenitors are positioned in close 
proximity with specific types of bone marrow stromal cells, which argues 
that lineage differentiation is not a stochastic process determined exclusively 
at the HSC level, but instead the accessibility of multipotent progenitors to 
instructive cytokines is fundamental in hematopoietic output. It is still 
unknown whether multipotent hematopoietic progenitors regulate the niche 
and HSC maintenance and/or quiescence. If they do, do multipotent 
progenitors act directly on HSC in a paracrine fashion? Or do they directly 
crosstalk with the niche supporting cells? Addressing these questions will 
open important lines of investigation. 
 
 
111"
3. Implications of overlapping HSC maintenance and lineage 
differentiation in the same niche 
 If the same niche regulates both HSC maintenance and quiescence 
and lineage differentiation how do these fundamental but very different 
processes co-exist and are regulated is a major unknown.  
 HSC recirculation may affect lineage output. Circadian rhythms control 
HSC recirculation and leukocyte trafficking (Lucas et al., 2008, Mendez-Ferrer 
et al., 2008, Scheiermann et al., 2012). The fact that HSC recirculate 
antagonizes the notion that such important cell type has to be kept 
quiescent and protected within a niche. HSC release from the bone marrow is 
due to circadian fluctuation of CXCL12 (Mendez-Ferrer et al., 2009, Mendez-
Ferrer et al., 2008). HSC recirculation due to circadian fluctuations may 
control lineage differentiation. On one hand, CXCL12 reduction attenuates 
CXCR4 signaling, which can have two outcomes. First, lower levels of CXCL12 
reduce HSC quiescence, inducing the proliferation of the HSC, and as a 
consequence of less CXCR4 mediated retention, some HSC are released to 
the circulation, and home back to bone marrow when CXCL12 levels increase. 
When homing back to bone marrow, HSC may encounter different niches, 
which may dictate lineage choices. Second, lower CXCR4 signaling on MPP 
and CLP reduces IL-7 and presumably IL-15 consumption. Thus, the lack of 
this instructive cytokine impairs lymphoid differentiation, resulting in an 
increase of other lineages production. This model argues in favor of lineage 
decisions being made at the progenitors level but does not completely 
exclude the possibility of stochastic lineage decisions at the stem cell level, 
which leads to a second potential scenario. 
 Several studies have shown polyclonal output from HSC differentiation 
assays in vitro. In addition, HSC are also heterogeneous with respect to the 
ratio of myeloid to lymphoid cells that they generate upon transplantation 
into irradiated mice (Muller-Sieburg et al., 2004, Dykstra et al., 2007, Kent et 
al., 2009, Beerman et al., 2010, Challen et al., 2010, Morita et al., 2010) and 
with respect to their self-renewal potential upon transplantation (Ema et al., 
2005, Morita et al., 2010, Benveniste et al., 2010). These findings suggest 
that HSC are imprinted with different lineage potential and thus, lineage 
differentiation/ commitment occurs at the stem cell level. The circadian 
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recirculation of HSC removes the stem cells from their maintenance niche, 
which along with possible sensing of extramedullary signals may affect 
lineage differentiation.  
 Besides HSC and hematopoietic multipotent progenitors, the bone 
marrow also harbors lineage-committed cells, such as developing B cells, 
recirculating mature B cells, NK cells, CD8+ memory T cells, and granulocytes. 
Hence, how is the bone marrow organized to maintain and support all the 
different cell types? Our findings shed light on the existence of specialized 
hematopoietic niches, which combine multiple functions in order to 
maximize the efficiency of the hematopoietic output. In agreement with this 
possibility, computational modulation studies found that coupling together 
niche lineages allows the organism to regulate blood cell numbers as closely 
as possible to the homeostatic optimum (Szekely et al., 2014). 
 Bone marrow has to be organized to support the differentiation of 
different hematopoietic cells. Therefore, it is possible that different 
hematopoietic differentiation/ maintenance niches overlap. Moreover, fully 
differentiated hematopoietic cells, such plasma cells and memory T cells 
home back to bone marrow, and also require similar factors as developing 
hematopoietic cells. Indeed, memory T cells require IL-7 to survive and have 
been shown to reside in close proximity to IL-7 expressing bone marrow 
stromal cells (Sercan Alp et al., 2015, Mazzucchelli et al., 2009, Tokoyoda et 
al., 2009). IL-7 signaling in CD8 T cells must be intermittent and not 
continuous to promote cell survival (Kimura et al., 2013). CXCR4 is required 
to the homing of CD8 T memory cells to the bone marrow. Also, keeping the 
CD8 T cells in the marrow in a resting stage is important for secondary 
recalling (Chaix et al., 2014), and antigen is transported to bone marrow to 
be presented to CD8 T memory cells (Duffy et al., 2012).  Hence, CD8 T cells 
may recirculate and home back to bone marrow when they require IL-7. Thus, 
T lymphocytes and CLP may compete for IL-7 in bone marrow, and in 
homeostasis, CD8 T cells may regulate/ modulate B lymphopoiesis by 
scavenging IL-7 from Ly6D+ CLP. In addition, during inflammatory states, 
such as infections, B lymphopoeisis might be reduced because together with 
the decrease in the production of CXCL12 (Ueda et al., 2004), IL-7 is 
consumed by T cells residing in bone marrow and CLP are out competed. 
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 Once formed the differentiated cells have to be exported from the 
bone marrow to the periphery. In Chapter 3, we demonstrate that CXCR4 
signaling retains developing B cells in bone marrow parenchyma, but 
developing B cell egress from bone marrow was surprisingly independent of 
egress promoting chemoattractants sensed by PTX-sensitive GPCRs. These 
observations lead to a deeper analysis of the role of CXCR4 in B 
lymphopoeisis after B lineage commitment. CXCR4 signaling mediated an 
haptokinectic (dependent on α
4
β
1
-VCAM1), amoeboid migration in developing 
B lymphocytes (Beck et al., 2014). Moreover, CXCR4 down-regulation 
enforced B cells to distribute into perisinusoidal e intrasinusoidal 
compartments and was critical for immature B cell egress from bone marrow, 
together with a passive egress mechanism (Beck et al., 2014). The 
mechanical forces responsible for the passive egress mechanism are not 
entirely clear, but such mechanisms likely involve shear stress, as the BM is a 
highly vascularized compartment. Besides the effects on hematopoietic cell 
egress, a potential effect of shear stress in the hematopoieitic niches, for 
instance, by affecting the extracellular matrix (Gattazzo et al., 2014), should 
be accessed.  
 
 
4. A Model for B Lymphopoiesis in bone marrow 
 Our research highlighted how B lymphopoeisis occurs in vivo within 
bone marrow (Figure 5.1). Before commitment to B cell lineage, CXCR4 
positions CLP in proximity of perivascular LEPR-expressing mesenchymal 
progenitor cells, which highly overlap with the HSC niche. This positioning 
allows an optimal consumption of IL-7, which is fundamental for the 
maintenance of the B lineage potential, most likely through the modulation 
of EBF levels (Dias et al., 2005). After commitment, CXCR4 retains developing 
B cells within bone marrow parenchyma by mediating their motility. CXCR4-
mediated migration on B cells may allow the different stages of B cell 
development to encounter key factors. For instance, Pre-B cells have been 
described to reside in close proximity to Galectin-1-expressing bone marrow 
stromal cells, which do not express IL-7 (Mourcin et al., 2011). Interestingly, 
conditional Il7 deletion from bone marrow endothelial cells did not affect B 
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cell progenitors but significantly reduced the number of Pre-B cells. These 
data suggests that IL-7 provided from different cellular sources may be 
important for different stages of B cell lymphopoeisis, which needs to be 
further determined.  
 At the immature stage, developing B lymphocytes significantly change 
their positioning within bone marrow, with up to 50% of immature B cells 
localizing within BM sinusoids in an α
4
β
1
-VCAM-1 – and CB2 and S1PR
3
 
signaling-dependent manner (Pereira et al., 2009, Donovan et al., 2010). 
Immature B cells egress bone marrow by down-regulating CXCR4 by about 
twofold, simultaneously mechanical forces purge sessile B cells. It was 
described that CXCR4 down-regulation in immature B cells was antagonized 
by antigen-induced BCR signaling, presumably after negative selection has 
occurred (Beck et al., 2014). It will be valuable to analyze the cellular 
composition and biological significance of the BM niches that attract self-
reactive immature B cells.   
 
Figure 5.1| Model of positional 
regulation of B cell development. 
We found that CXCR4 mediates 
CLP positioning in the proximity to 
CAR cells, which express IL-7 and 
constitute most likely the B 
lymphopoiesis niche. The close 
proximity of CLP to CAR cells is 
critical for B lymphopoiesis 
because it allows optimal 
consumption of IL-7. Later on the 
development, immature B cells 
decrease CXCR4 expression and 
egress from BM. 
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Chapter 6 | Conclusion and Future Perspectives 
 
 The major scientific contribution made in this thesis was the 
observation that hematopoietic multipotent progenitor differentiation is 
controlled by positional cues that enable the access to short-range lineage 
instructive cytokines produced by hematopoietic niches in bone marrow. 
Specifically, our research allowed us to conclude the following: 
1. Hematopoietic multipotent progenitors require CXCR4 mediated 
chemoattraction to access short-range lineage-instructive cytokines 
produced by hematopoietic niches in bone marrow; 
2. IL-7 acts as a short-range signal for CLP differentiation into B 
lymphocyte lineage; 
3. IL-7-expressing cells are CXCL12-abundant reticular mesenchymal 
progenitor cells; 
4. HSC maintenance and lymphopoiesis are controlled by overlapping 
bone marrow niches; 
5. After commitment to B cell lineage, CXCR4-mediated haptokinectic 
migration retains developing B lymphocytes within bone marrow 
parenchyma. 
6. Down-regulation of CXCR4 on immature B cells, and consequently 
reduction of their migration (active egress mechanism), together with 
action of mechanic forces (passive egress mechanism) allow the 
egress from bone marrow to the periphery where the final stages of B 
lymphopoiesis occur.  
 
 Our findings challenge not only the current model for HSC niche but 
also the current paradigm of early B lymphopoiesis, opening important lines 
of investigation. The positioning of developing B cells relative to IL-7-
expressing cells needs to be further analyzed. In addition, it is fundamental 
to determine the molecular regulators of IL-7 expression. Ablation of Gα
s 
in 
mesenchymal stem cells, such as CAR cells, osteoprogenitors, and 
osteoblasts severely affected pro- and pre-B cells in a fashion that could be 
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mitigated with IL-7 (Wu et al., 2008), suggesting that Ga
s 
signaling may be a 
potential regulator of IL-7 expression in bone marrow.  
 
 Our data also changed the concept of immature B cell egress from 
bone marrow. The critical CXCR4 down-regulation before immature B cell 
egress was antagonized by antigen-induced BCR signaling, suggesting that 
immature B cell egress ensues after negative selection has occurred. These 
data creates a line of investigation of the cellular composition and biological 
significance of the BM niches that attract self-reactive immature B cells.  
 Understanding B lymphopoiesis is important but the actual 
breakthrough is to understand what determines the choice of a specific 
lineage pathway under homeostasis and how the niche responds to changes 
in homeostasis, such as inflammation and/or leukemia.  
 As far as I am concerned, a lot of effort should be invested in 
determining the mechanisms that control the niche size to avoid exhaustion 
of the stem cell pool and over proliferation of the multipotent progenitors. 
The niche is a dynamic unit, where all cell types must interact and 
communicate with each other. Determining the existence of feedback 
mechanisms between progenitors at different stages of differentiation and 
the upstream more pluripotent progenitors is critical to understand how 
lineage differentiation is controlled at the organ level.  
 The niche has two different types of stem cells – the HSC and the MSC. 
Most likely, the relationship between these two types of stem cells is 
symbiotic. HSC and progenitors require MSC to self-renewal and/or 
differentiate. It is still unknown whether HSC and progenitors have an 
influence on MSC fate and whether MSC require HSC and progenitors to 
maintain their multipotent potential and avoid differentiation. In addition, 
the molecular mechanisms regulating the symbiotic relationship between 
HSC and MSC will be important players in designing therapeutic approaches 
to modulate hematopoiesis, in a far ahead future.  
 The understanding of niche regulation is not only important for 
immunology and/or development biology but also to biology in general 
because it will shed light on maintenance of tissue homeostasis.   
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Leukocyte egress from lymphoid organs is a 
multistep process characterized by active cell 
migration mediated by pertussis toxin (PTX)–
sensitive GAi protein–coupled receptors (GPCRs) 
toward exit sites, followed by reverse transmi-
gration across endothelial barriers. Lymphocyte 
egress from thymus and lymph nodes is highly 
dependent on the chemoattractant lipid sphin-
gosine 1 phosphate (S1P), which is abundant in 
circulatory fluids (blood and lymph) while lim-
ited in the lymphoid organ interstitium. The 
S1P gradient is sensed by lymphocytes through 
intrinsic expression of the PTX-sensitive GPCR 
S1P receptor 1 (S1PR1). S1PR1 deficiency causes 
Y50–1,000-fold reduction in T and B lympho-
cyte numbers in blood and lymph concomitant 
with their significant accumulation in lym-
phoid organs (Cyster and Schwab, 2012). S1PR1 
mRNA expression is driven by the transcription 
factor Krüppel-like factor-2 (KLF2) in devel-
oping thymocytes and in naive T lymphocytes 
(Carlson et al., 2006; Bai et al., 2007). Of note, 
KLF2 transcription is dependent on the FOXO1 
transcription factor (Fabre et al., 2008; Gubbels 
Bupp et al., 2009; Kerdiles et al., 2009), and in 
T cells FOXO1 is sequestered in the cytoplasm 
and rendered transcriptionally inactive via phos-
phorylation mediated by the serine/threonine 
kinase AKT (Fabre et al., 2005). This molecular 
circuitry seems to ensure that only the negatively 
selected thymocytes undergoing low TCR sig-
naling achieve sufficient S1PR1 expression for 
exiting the thymus. In contrast, S1P and its 
receptors play a modest role in mediating cell 
egress from BM, as genetic or pharmacologically 
induced S1P receptor deficiency only accounts 
for approximately two- to threefold reduction 
in immature B lymphocyte, NK cell, and eosino-
phil export from BM (Walzer et al., 2007; Jenne 
et al., 2009; Allende et al., 2010; Pereira et al., 
2010; Sugita et al., 2010). S1PR1 mRNA ex-
pression is largely independent of KLF2 ex-
pressed in developing and mature B lymphocytes 
(Hart et al., 2011), thus making it unlikely that 
the S1P/S1PR1 egress pathway is under the 
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Leukocyte residence in lymphoid organs is controlled by a balance between retention and 
egress-promoting chemoattractants sensed by pertussis toxin (PTX)–sensitive GAi protein–
coupled receptors (GPCRs). Here, we use two-photon intravital microscopy to show that 
immature B cell retention within bone marrow (BM) was strictly dependent on amoeboid 
motility mediated by CXCR4 and CXCL12 and by A4B1 integrin–mediated adhesion to 
VCAM-1. However, B lineage cell egress from BM is independent of PTX-sensitive GPCR 
signaling. B lineage cells expressing PTX rapidly exited BM even though their motility within 
BM parenchyma was significantly reduced. Our experiments reveal that when immature  
B cells are near BM sinusoids their motility is reduced, their morphology is predominantly 
rounded, and cells reverse transmigrate across sinusoidal endothelium in a largely non-
amoeboid manner. Immature B cell egress from BM was dependent on a twofold CXCR4 down-
regulation that was antagonized by antigen-induced BCR signaling. This passive mode of cell 
egress from BM also contributes significantly to the export of other hematopoietic cells, includ-
ing granulocytes, monocytes, and NK cells, and is reminiscent of erythrocyte egress.
© 2014 Beck et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
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licenses/by-nc-sa/3.0/).
T
he
 J
ou
rn
al
 o
f 
E
xp
er
im
en
ta
l 
M
ed
ic
in
e
 on June 15, 2015
jem
.rupress.org
Downloaded from
 
Published November 17, 2014
http://jem.rupress.org/content/suppl/2014/11/14/jem.20140457.DC1.html 
Supplemental Material can be found at:
2568 CXCR4 controls immature B cell egress | Beck et al.
RESULTS
CXCR4 controls B lineage cell movement within BM
We examined how CXCR4 inhibits BM egress by visualizing 
the dynamic behavior of developing B lymphocytes within 
calvarial BM of Rag1GFP/+ mice by two-photon intravital mi-
croscopy (IVM) before and after disruption of CXCR4 signal-
ing. Mice were injected i.v. with fluorescently labeled dextrans 
to allow distinguishing BM parenchyma from sinusoids. Ap-
proximately 99.8% of GFP+ cells in BM are B lineage cells 
(99.5% B220+ cells and 0.3% B220lo CD93+ early B lineage 
progenitors), Y0.1% are CD3e+ T cells (presumably recent 
thymic emigrants), and CD3e NK1.1+ cells were all found 
to be GFP (not depicted). GFP+ B lineage cells displaced 
throughout the 30-min imaging period (Fig. 1, A and B) at a 
median velocity of 2.4 µm/min (Fig. 1 C), as expected (Pereira 
et al., 2009). However, cells rapidly stopped their migration 
1–2 min after treatment with 80 µg of the CXCR4 antago-
nists AMD3100 or TN14003 (Tamamura et al., 2001) i.v. or 
1 h after treatment with CXCL12 blocking antibody (Fig. 1, 
A and B; and Video 1). The sudden arrest led to a significant re-
duction in the median velocity (Fig. 1 C) and mean displace-
ment (Fig. 1 D), which were reflected in a 6–10-fold reduction 
of the mean motility coefficient (Fig. 1 B). CXCR4 signaling 
blockade also changed B cell morphology from an amoe-
boid/elongated form to a significantly rounded shape (Fig. 1, 
E and F; and Video 1). The effects of AMD3100 were revers-
ible after 2–3 h, with most cells regaining an amoeboid shape 
and motility (not depicted), which is in agreement with its 
rapid decay rate in vivo (Hendrix et al., 2000). These data sug-
gested an intrinsic requirement for CXCR4 for B cell migra-
tion in vivo. Indeed, B cells conditionally deficient in CXCR4 
moved within BM with a significantly reduced median veloc-
ity (Fig. 1 H and Video 2) and were more rounded than WT 
B cells (Fig. 1 I). However, most cells were not entirely stopped 
(Video 2), and their mean motility coefficient was only re-
duced by Y40% (Fig. 1 G). Treatment with AMD3100 (80 µg 
i.v.; Video 3) further reduced the velocity and mean motility 
coefficient of CXCR4-deficient B cells and increased their 
roundness (Fig. 1, G–I). The similar activities of the three 
CXCR4 signaling inhibitors reduced the probability that 
B cell motility defects were caused by off-target effects. Also, 
in vitro B cell migration toward the chemokine CXCL13 
was unaffected by treatment with AMD3100 (not depicted). 
Genetic and pharmacological CXCR4 deficiency also led to 
the significant mobilization of developing B cell subsets from 
BM into blood (Fig. 1 J), as expected (Nie et al., 2004; Pereira 
et al., 2009). As CXCR4 is critically required for B lineage 
cell retention in BM, it is possible that the few GFP+ B lin-
eage cells observed in calvaria BM of CXCR4 condition-
ally deficient mice had residual CXCR4 signaling that was 
sufficient for promoting BM retention and migration. In-
deed, some CXCR4 conditionally deficient B lineage cells 
exhibited low CXCR4 surface expression (not depicted). 
Nevertheless, these data do not exclude the possibility that 
lymphocyte-extrinsic CXCR4 contributes to B lineage cell 
motility in BM.
control of BCR signaling induced in immature B lympho-
cytes during negative selection in BM. The mechanism or 
mechanisms used by immature B lymphocytes for exiting 
BM thus remain essentially unknown.
Whereas T cells comprise the vast majority of cells exported 
from the thymus, all other hematopoietic cells, and several 
nonhematopoietic cells, are produced in and exported from 
the BM. Neutrophils and monocytes use the GPCRs CXCR2 
and CCR2 for BM egress, respectively; however, deficiency 
in either receptor reduced BM export by less than sevenfold 
(Serbina and Pamer, 2006; Eash et al., 2010; Shi et al., 2011). 
Why are lymphocytes highly sensitive to S1PR1-dependent 
mechanisms for exiting thymus and lymph nodes, whereas 
other hematopoietic cells, including lymphocytes, are mar-
ginally dependent on single GPCR-dependent mechanisms 
for egress from BM? One possibility is that redundancy with 
multiple GPCRs controls egress of different cell lineages from 
BM. Alternatively, the fact that millions of red blood cells are 
produced and exported daily from BM (Lichtman and Santillo, 
1986), and that these cells lack mechanisms for interstitial 
amoeboid cell migration, raises the possibility that alternative 
mechanisms control hematopoietic cell egress from BM.
CXCR4 is a PTX-sensitive GPCR that signals the BM 
homing and retention of multiple hematopoietic cell lineages, 
including hematopoietic stem and progenitor cells, mono-
cytes, neutrophils, NK cells, B cells, and plasma cells (Ma et al., 
1999; Hargreaves et al., 2001; Lapidot and Kollet, 2002; Liles 
et al., 2003; Broxmeyer et al., 2005; Bernardini et al., 2008; 
Pereira et al., 2009; Wang et al., 2009b; Eash et al., 2010). 
CXCL12, the CXCR4 ligand, is a potent chemoattractant to 
various hematopoietic cells and is abundantly expressed by 
stromal cells, osteoblasts, and endothelial and perivascular cells 
in BM (Sugiyama et al., 2006; Ding and Morrison, 2013). 
CXCR4/CXCL12 counteracts the activity of egress-promoting 
cues in immature B cells, neutrophils, NK cells, and monocytes 
(Bernardini et al., 2008; Wang et al., 2009b; Allende et al., 2010; 
Eash et al., 2010), though how CXCR4 signaling antagonizes 
cell egress remains unknown.
In this study, we demonstrate that CXCR4 signaling con-
trols B lineage cell motility within BM parenchyma. Further-
more, developing B cell migration is strictly dependent on A4B1 
integrin–mediated adhesion to VCAM-1. The BM parenchyma 
is extensively perfused by blood flow, which presumably im-
poses significant shear stress on BM-resident cells. Deficiency in 
CXCR4-mediated B lineage cell motility in BM parenchyma 
resulted in their acute mobilization from BM into periphery. 
Likewise, B lineage cells expressing PTX are predominantly 
nonmotile in BM parenchyma and are efficiently mobilized into 
the periphery. Our experiments revealed that the critical mech-
anism regulating B lineage cell egress from BM is a twofold 
down-regulation of CXCR4 in immature B cells, which depo-
larizes their amoeboid shape, reduces cell movement in perisi-
nusoidal niches, and facilitates export into BM sinusoids and 
peripheral organs. Notably, antigen engagement by immature 
B cells prevents CXCR4 down-regulation, increases B lineage 
cell motility in BM parenchyma, and blocks egress from BM.
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signaling increases A4B1 integrin affinity for its ligand VCAM-1, 
and both contribute to B lineage cell retention in BM (Koni 
et al., 2001; Leuker et al., 2001; Glodek et al., 2003; Pereira 
et al., 2009). To test this hypothesis, we analyzed B cell motil-
ity within BM parenchyma of Rag1GFP/+ mice by IVM before 
and after i.v. administration of 200 µg anti-A4 (clone PS/2) 
or anti–VCAM-1 (clone M/K-2) blocking antibodies. B cell 
migration was largely blocked after treatment with anti-A4 
or anti–VCAM-1 antibodies (Fig. 2 A and Video 4). There 
was a sixfold reduction of the mean motility coefficient 
(Fig. 2 B), reduced cell velocity (Fig. 2 C), and increased cell 
roundness (Fig. 2 D). The requirement for A4B1 integrin– 
mediated haptokinesis was intrinsic to B lineage cells as similar 
Integrin-dependent B lineage cell migration in BM
Leukocyte migration is independent of integrin-mediated 
adhesion within lymphoid organ interstitium (Woolf et al., 
2007; Lämmermann et al., 2008). In contrast, leukocytes re-
quire integrins for migration on two-dimensional surfaces 
(haptokinetic migration), such as migration along luminal en-
dothelium toward the site of diapedesis (Alon and Feigelson, 
2009). The cell shape changes that occurred immediately after 
treatment with CXCR4 inhibitors suggested that CXCR4 
was involved in promoting B cell adhesion to the BM extra-
cellular matrix and raised the possibility that B lymphocyte 
migration within BM interstitium was haptokinetic (i.e., in-
tegrin dependent). Consistent with this possibility, CXCR4 
Figure 1. CXCR4 antagonism inhibits B lineage cell migration in BM. (A–F) Rag1GFP/+ mice were injected i.v. with AMD3100, TN14003, or anti-
CXCL12 antibody. Blood vessels were labeled with 2,000-kD dextran-rhodamine injected i.v. Cell movement was tracked by IVM of calvaria immediately 
before and after treatment. (A, left) Distribution of GFP+ B cells (green) in BM. (middle and right) Movement of GFP+ B cells tracked for 30 min before and 
after AMD3100 treatment, respectively. Colored lines represent cell trajectories. Data are representative of three individual experiments. (B) Mean motility 
coefficient of B lineage cells before (blue) and after (red) treatment with CXCR4 antagonists. Cell displacement from starting coordinates is plotted against 
the square root of time. Lines depict the average mean motility coefficient calculated from three individual experiments. (C) Median velocity (µm/min).  
(D) Displacement (µm). (E) Morphology of GFP+ B lineage cells before (left) and after (right) AMD3100 treatment. Dotted lines depict the cells’ borders.  
Bars: (A) 20 µm; (E) 30 µm. (F) Measurement of cell axis ratio of GFP+ B lineage cells before (blue) and after (red) treatment with CXCR4 inhibitors.  
(G–I) WT (Mb1Cre/+) and CXCR4 KO (Mb1Cre/+ Cxcr4Fl/) were treated as in A–F. (G) Mean motility coefficient of WT (blue) and CXCR4 KO (red) B lineage cells 
before (red) and after (green) treatment with AMD3100. Colored lines depict average mean motility coefficient calculated from three independent datasets. 
(H) Median cell velocity of WT (blue) and CXCR4 KO (red) B lineage cells before (red) and after (green) treatment with AMD3100. (I) Cell axis ratio of GFP+ 
(Mb1Cre/+, blue) and CXCR4 KO (Mb1Cre/+ Cxcr4Fl/, red) B lineage cells. (G–I) Data are representative of two independent experiments. (C, D, F, H, and I) Lines 
indicate mean. (J) Enumeration of B lineage cells in BM, blood, and spleen of Mb1Cre/+ Cxcr4+/+ (open bars) and Mb1Cre/+ Cxcr4Fl/ (green bars) mice. Bars 
indicate mean, and circles indicate individual mice. Data are representative of three independent experiments. *, P < 0.05; **, P < 0.005; ***, P < 0.0005; 
****, P < 0.00005 by unpaired Student’s t test.
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reduced in BM, which corresponded to a significant increase 
in peripheral blood (PB; not depicted), as expected (Pereira et al., 
2009). Electron microscopy analyzes of the BM sinusoidal endo-
thelium demonstrated that it is highly fenestrated (Tavassoli and 
Yoffey, 1983). Consistent with these observations, the BM vas-
culature was permeable to large-molecular-mass, FITC-coupled 
observations were made in Itgb1-deficient B lymphocytes 
(Video 5). Treatment with anti-A4 blocking antibody did not 
change the dynamic behavior of Itgb1-deficient B cells (not 
depicted). Interestingly, loosely adherent and rounded cells 
were seen occasionally moving short distances for a brief period 
(Video 6). The number of developing B cells was significantly 
Figure 2. Developing B cell motility in BM parenchyma is strictly dependent on A4B1 integrin–mediated adhesion to VCAM-1. (A–D) Rag1GFP/+ 
were injected (i.v.) with integrin A4 or VCAM-1 blocking antibodies, and calvarial BM was imaged before and immediately after treatment. Blood vessels 
were labeled with 2,000-kD dextran-rhodamine injected i.v. (A, left) Distribution of GFP+ B cells (green) in BM. (middle and right) Movement of GFP+  
B cells tracked for 30 min before and after treatment with anti–VCAM-1 antibody. Colored lines represent cell trajectories. (B) Mean motility coefficient of 
B lineage cells before (blue line) and after VCAM-1 (red) and A4 blockade (green). Lines depict the average mean motility coefficient calculated from three 
independent experiments. (C) Median velocity (µm/min). (D) Cell axis ratios before (blue) and after treatment with VCAM-1 (red) and A4 (green) blocking 
antibodies. The data are representative of three independent experiments. (C and D) Lines indicate mean. (E) Mice were injected with 50 µg of 500-kD 
FITC-conjugated dextran (i.v.), and calvaria BM was imaged before and after treatment. BM vasculature (S) and parenchyma (P) are indicated. White boxes 
delineate regions of interest used for measurements of dextran perfusion. Time is shown in each panel (mm:ss). (A and E) Bars, 20 µm. (F) FITC-conjugated 
dextran perfusion of BM parenchyma and vasculature (red fluorescent voxels; y axis) over 30 min (time; x axis). Data are representative of >10 independent 
experiments. (G) Interstitial fluid flow rate (µm3/s) determined after injection (i.v.) of FITC-dextran (500 kD; green) or BSA–Texas red (red). Lines indicate 
the mean; symbols represent regions of interest obtained from three mice (FITC-dextran) or from two mice (BSA–Texas red). (H) In vivo staining of pro-B 
and pre-B cells in BM and of marginal zone (MZB) and follicular (FOB) B cell subsets in spleen with biotin–anti-CD19 antibody administered i.v. for 2 (red) 
or 10 (blue) min. Saturation with anti-CD19 antibody was determined by ex vivo staining with excess antibody (green). Data are representative of three 
independent experiments. **, P < 0.005; ***, P < 0.0005 by unpaired Student’s t test.
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retained within BM sinusoids (not depicted), consistent with 
a role for GAi-coupled CB2 and S1PR3 in this process 
(Pereira et al., 2009; Donovan et al., 2010). Mature B lympho-
cytes were also reduced in BM (Fig. 3 A) because CXCR4 
coupling to GAi proteins is PTX sensitive, and mature B cells 
require CXCR4 for homing back to BM (Nie et al., 2004; 
Pereira et al., 2009).
To investigate whether B lineage cell motility within BM 
was dependent on PTX-sensitive GPCRs, we visualized the 
behavior of PTX-expressing B cells marked with a Rag1GFP/+ 
allele in calvaria BM by IVM. We found that PTX-expressing 
B cells were predominantly nonmotile (Fig. 3, C and D; and 
Video 8) and exhibited rounded morphology (Fig. 3 E). Oc-
casionally, we found BM pockets with some PTX-expressing 
B cells moving in an amoeboid manner with similar kinetics 
as WT cells (Video 9), but their migration was sensitive to 
CXCL12 blocking antibody treatment (Fig. 3 F). These find-
ings suggest that CXCR4 can couple to PTX-insensitive G pro-
teins in B cells and promote interstitial migration in vivo. In 
agreement with these observations, AMD3100 blocked the 
chemotaxis of WT and PTX-expressing developing B cell 
subsets toward a CXCL12 gradient in vitro, whereas CXCR4-
deficient B cells were unable to migrate in similar conditions 
(not depicted). Finally, we asked whether other hematopoietic 
cells could leave BM independently of PTX-sensitive GPCRs. 
To address this question, we treated mice with 1 µg PTX i.v. 
for 24 h and quantified hematopoietic cell egress from BM 
into PB by flow cytometry. NK cells, neutrophils, and inflam-
matory monocytes, like B lineage cells, were efficiently mobi-
lized from BM into PB by PTX treatment (Fig. 3 G), even 
though PTX-sensitive GPCRs can contribute to their export 
from BM (Serbina and Pamer, 2006; Walzer et al., 2007; Jenne 
et al., 2009; Allende et al., 2010; Eash et al., 2010; Pereira et al., 
2010). Similar results were obtained by cre recombinase– 
mediated PTX expression in granulocytes and monocytes and 
in NK cells, driven by Lyz2 (Clausen et al., 1999) or by Il7r 
(Schlenner et al., 2010), respectively (not depicted).
The increased rate of BM B cell egress seen in CXCR4-
deficient mice, or in PTX-expressing B cells, suggested that 
defective motility within parenchyma enforced B lineage cells 
to position near BM sinusoids. To address this possibility, we 
measured the distance between WT, CXCR4-deficient, and 
PTX-expressing B lineage cells and BM sinusoids and found 
that both CXCR4-deficient and PTX-expressing cells were 
significantly accumulated in proximity to sinusoids (perisinu-
soidal space was defined as the area that is <10 µm distal 
from sinusoids; Fig. 4, A and B). As CXCR4 controls the move-
ment of B lineage cells in parenchyma and the lack of CXCR4 
signaling positions cells around sinusoids (Fig. 4, A and B) and 
within sinusoids (Pereira et al., 2009), we hypothesized that 
B lineage cells moving within perisinusoidal niches had reduced 
motility. Thus, we analyzed the dynamic behavior of B lineage 
cells that moved within 10-µm distance to sinusoids and com-
pared them with cells moving in parenchymal areas of the same 
imaging volume. Even though there was a trend toward re-
duced median velocity that did not reach statistical significance 
dextrans (Y500 kD) present in circulatory fluids (Fig. 2, E and F; 
and Video 7), and blood plasma perfusion reached an intersti-
tial fluid flow rate of Y2 µm3/s (Fig. 2 G). The extensive per-
fusion of the BM parenchyma within minutes of injection of 
intravascular dyes is consistent with BM-resident cells being 
continuously exposed to shear stress generated by fluid flow. 
Indeed, considering that the femur volume is <100 µm3 (our 
unpublished estimates), we hypothesized that circulatory mol-
ecules access the entire femur BM parenchyma in <2 min. To 
test for this possibility, we injected 5 µg biotin-conjugated 
anti-CD19 antibody i.v., allowed it to equilibrate for 2 or 
10 min, and measured the extent of binding to pro-B and 
pre-B cells in BM. For comparison we examined labeling of 
splenic follicular and marginal zone B cells of the same mouse. 
Our data show that the large majority of pro-B and pre-B cells 
are readily labeled with anti-CD19 within 2 min, and by 10 min 
100% of each B cell subset is saturated with circulatory anti-
body (Fig. 2 H). In contrast, a significant fraction of mature 
follicular B cells in the spleen is poorly stained even after 10 min 
of exposure to biotin anti-CD19 antibody in circulation. As 
expected, the marginal zone B cell subset was readily stained 
with anti-CD19 antibodies after 2 min (Cinamon et al., 2008), 
but saturation was only achieved after 10 min (Fig. 2 H). These 
data demonstrate that circulatory molecules rapidly perfuse 
BM parenchyma. Whether lymphocytes access BM exit sites 
by forces induced upon cells, such as interstitial fluid flow, or 
exclusively by active migration guided by chemoattractants 
sensed by GPCRs intrinsically expressed on lymphocytes was 
not clear.
B lineage cell egress from BM is independent  
of GPCR-guided amoeboid motility
The findings that CXCR4 blockade significantly reduced 
B lineage cell motility in parenchyma while accelerating egress 
into sinusoids and PB raised an interesting and unprecedented 
possibility: that BM egress could be achieved in the absence 
of amoeboid migration toward BM exit sites. To test this hy-
pothesis, we conditionally induced PTX expression in B lin-
eage cells by crossing Mb1Cre/+ mice with mice encoding the 
ADP-ribosyl transferase S1 subunit of PTX within the Rosa26 
locus, preceded by a premature transcriptional stop codon 
flanked by loxP sites (for simplicity referred as Rosa26PTX/+ 
mice; Regard et al., 2007). Using this strategy, >99% of B lin-
eage cells conditionally express genes under Rosa26 promot-
ers from the pro-B cell stage and throughout subsequent stages 
of development (not depicted). The number of pro-B and 
pre-B cells was slightly but significantly reduced in BM, which 
corresponded to a small, but highly significant numerical in-
crease in blood circulation (Fig. 3, A and B). However, IgM+ 
immature B cell subsets were reduced by two- to threefold in 
BM and significantly increased in blood, indicating increased 
BM egress. We did not find evidence of bystander effects, such 
as PTX leakiness into neighboring cells in BM mixed chime-
ras (not depicted). Furthermore, similar findings were obtained 
with B lineage cells deficient in Gnai2 and Gnai3 (Hwang 
et al., 2013). PTX-expressing B lineage cells were also poorly 
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the total number of B lineage cells remaining in BM (Fig. 3, 
A and B; and not depicted, respectively). Furthermore, the 
relatively small number of B lineage cells visualized and the lim-
ited volume of imaging fields make it difficult to capture B cells 
transmigrating across sinusoidal endothelial barriers. How-
ever, in Y18 h of IVM of untreated WT (Rag1GFP/+) mice and 
in 3 h of IVM of PTX-expressing B cells, we were able to 
observe reverse transmigration of 11 and 2 B lineage cells, 
(Fig. 4 C), their motility coefficient was reduced by 35% (Fig. 4 D), 
and cells within perisinusoidal niches were significantly less 
amoeboid (Fig. 4 E). B cells were only rarely observed migrat-
ing across sinusoidal endothelium before or after CXCR4 
blockade, or in B cells genetically deficient in CXCR4 or in 
GAi protein–dependent receptors. This was not surprising be-
cause the numerical increase of GAi protein– or CXCR4-
deficient B cell subsets in blood is Y10–100-fold lower than 
Figure 3. B cells egress BM independently of GPCR-mediated migration. (A) IgM and IgD expression in live gated (DAPI) B220+ cells in BM 
(top) and PB (bottom) of Mb1Cre/+ (WT, left) and Mb1Cre/+ Rosa26PTX/+ mice (PTX, right). (B) Quantification of developing B cell subsets in BM (top) and 
PB (bottom) of Mb1Cre/+ mice (blue bars) and Mb1Cre/+ Rosa26PTX/+ mice (red bars). Bars indicate mean, and circles depict individual mice analyzed. Data 
are representative of more than three independent experiments. (C) IVM of PTX-expressing B lineage cells in calvaria BM. Blood vessels were visual-
ized with BSA–Texas red. (top) Distribution of GFP+ B cells (left) and the movement of GFP+ B cells tracked for 30 min in BM (right) of Mb1Cre/+ mice 
(WT). (bottom) Distribution of GFP+ B cells (left) and the movement of GFP+ B cells tracked for 30 min in BM (right) of Mb1Cre/+ Rosa26PTX/+ mice (PTX). 
Colored lines represent cell trajectories. The data are representative of at least three independent experiments. Bars, 20 µm. (D) Mean motility coef-
ficient of WT and PTX-expressing B lineage cells. Lines depict the average mean motility coefficient calculated from three independent mice. (E) Cell 
axis ratios of WT and PTX-expressing cells. (F–H) Analysis of the mean motility coefficient (F), median velocity (µm/min; G), and displacement (µm; H) 
of PTX-expressing B lineage cells before (blue) and after treatment with 250 µg anti-CXCL12 antibody (ASDF, red). M indicates mean motility coefficient 
in µm2/min. Lines depict the average mean motility coefficient calculated from datasets obtained by IVM of three different mice. (E, G, and H) Lines indi-
cate mean. (I) Numbers of pre-B cells, NK cells, granulocytes (Gran.) and inflammatory monocytes (Mon.) in BM and PB of WT mice treated with saline 
(open bars) or with 1 µg PTX for 24 h (gray bars). Data are representative of more than three independent experiments. *, P < 0.05; **, P < 0.005, 
***, P < 0.0005; ****, P < 0.00005 by unpaired Student’s t test.
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during reverse transmigration, which strongly suggests that 
reverse transmigration across BM sinusoidal endothelium is 
an active process that is independent of GPCR signaling.
Gradual reduction in CXCR4 expression reduces motility  
and enforces immature B cell egress from BM
Previous studies have shown that CXCR4 expression is high-
est at the pro-B cell stage and decreases gradually during mu-
rine and human B cell development (Honczarenko et al., 1999; 
Pereira et al., 2009). The finding that perisinusoidal B lineage 
cells exhibited reduced motility and increased roundness sug-
gested that CXCR4 signaling was reduced in egress-competent 
cells. To investigate this possibility, we compared CXCR4 ex-
pression on immature B lymphocyte subsets before and after 
respectively. In all examples observed, B lineage cells that ex-
ited BM parenchyma into sinusoids did not approach BM 
exit sites in an amoeboid manner, were poorly motile, and re-
sided adjacent to sinusoids (Video 10). Consistent with our 
previous findings, we did not observe morphological differ-
ences between WT and PTX-expressing B cells in the process 
of exiting into sinusoids (Fig. 4, F and G; and Video 10), even 
though PTX-expressing B cells were rapidly displaced into 
circulation after entry into sinusoids, whereas WT B lineage 
cells were retained in this compartment, as expected (Pereira 
et al., 2009; Donovan et al., 2010). Interestingly, reverse trans-
migration occurred exclusively in areas where the sinusoidal 
endothelial barrier exhibited intense vascular leakage (Video 10). 
In some cases, WT and PTX-expressing cells deformed 
Figure 4. Morphology and motility of developing B cells during BM egress. (A) Distribution of B lineage (Rag1GFP/+) cells in BM of Mb1Cre/+ 
Rosa26+/+ mice (WT, left), Mb1Cre/+ Rosa26PTX/+ mice (PTX, middle), and Mb1Cre/+ Cxcr4Fl/ mice (X4$, right). Dotted lines indicate border between sinusoids 
and parenchyma. (B) Ratio of B lineage cells proximal (<10 µm) and distal (>10 µm) to BM sinusoids. Data depicted were from >90 B lineage cells ana-
lyzed in three WT, PTX, and X4$ mice. Bars indicate mean (±SEM). (C–E) Cell motility parameters of developing B cells in parenchyma and in perisinusoidal 
space. (C) Median velocity (µm/min). (D) Mean motility coefficient of Rag1GFP/+ B lineage cells in inner parenchyma (Inner Par. blue) and in perisinusoidal 
areas (Per. red). Mean cell displacement from starting coordinates is plotted against the square root of time. Lines depict the average mean motility coef-
ficient of >70 inner parenchyma and 40 perisinusoidal areas GFP+ B cells. (E) Axis ratio (x/y). Dotted line depicts the mean axis ratio of Mb1Cre/+ Rosa26PTX/+  
B cells in BM parenchyma (1.2). (C and E) Lines indicate means. (F and G) Two WT GFP+ B cells (F) and one PTX-expressing GFP+ B cell (G) exiting from  
BM parenchyma (P) into sinusoids (S). Arrowheads point to cell egress. Time is shown in mm:ss. WT and PTX-expressing cell egress examples were cap-
tured from more than 10 and 4 independent experiments, respectively. Bars: (A) 19 µm; (F and G) 5 µm. *, P < 0.05; **, P < 0.005 by unpaired Student’s  
t test. Unpaired Student’s t test with Welch’s correction was used in E.
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To accomplish this, we reconstituted lethally irradiated mice 
with a 50% mixture of BM cells isolated from Cxcr4+/ or 
Cxcr4+/+ CD45.1 mice with Cxcr4+/+ CD45.2 mice. As ex-
pected, Cxcr4+/ immature B cells in BM parenchyma expressed 
comparable CXCR4 surface amounts as Cxcr4+/+ B cells 
positioned within BM sinusoids, whereas Cxcr4+/ immature 
B cells expressed approximately twofold lower CXCR4 than 
Cxcr4+/+ immature B cells in BM parenchyma (Fig. 5 D). 
Furthermore, Cxcr4+/ immature B cells were significantly re-
duced in BM parenchyma and increased in BM sinusoids and 
blood when compared with Cxcr4+/+ immature B cells (Fig. 5 E). 
Antagonizing CXCR4 down-regulation by retroviral transduc-
tion of hematopoietic stem cells with a desensitization-deficient 
BM egress and found that it was reduced by approximately 
twofold in cells within sinusoids as compared with cells in pa-
renchyma (Fig. 5, A and B). This reduction was evident even 
after treatment with AMD3100 (not depicted), suggesting that 
it was not mediated by CXCR4 desensitization from expo-
sure to perisinusoidal sources of CXCL12 (Ding and Morrison, 
2013). A twofold reduction in CXCR4 was sufficient to re-
duce immature B lymphocyte migration toward a gradient 
of CXCL12 established in vitro (Fig. 5 C). To test whether a 
twofold down-regulation of CXCR4 was sufficient to mobi-
lize immature B cells from BM, we compared the distribution 
of CXCR4 heterozygous B lineage cells in direct competition 
with CXCR4 WT cells in BM parenchyma, sinusoids, and PB. 
Figure 5. CXCR4 expression in egress-competent immature B lymphocytes. (A) CXCR4 expression in B220+ immature IgM+ IgDlo B cells positioned 
in BM parenchyma (Par.) and sinusoids (Sin.). (left) IgM and IgD expression in B220+ BM cells. (middle) Distribution of B220+ CD93+ IgM+ IgDlo B cells in 
BM parenchyma (CD19-PE) and sinusoids (CD19-PE+). (right) CXCR4 expression in B220+ immature IgM+ IgDlo B cells in parenchyma (gray) and sinusoids 
(black line). (B) Geometric mean fluorescence intensity (MFI) of CXCR4 surface expression in BM parenchyma and sinusoid immature CD93+ IgM+ IgDlo  
B cells from C57BL/6 mice (n = 4). Bars indicate the mean; circles indicate individual mice. Data are representative of >10 independent experiments.  
(C) Cell migration through 5-µm transwells. Cxcr4+/+ (gray bars) and Cxcr4+/ (black bars) immature CD93+ IgMhi IgD (left) and IgDlo (right) cells were 
allowed to migrate toward 0.3 µg/ml CXCL12 for 3 h. Bars indicate mean, and circles indicate replicates. Data were pooled from two independent ex-
periments. (D, left) CXCR4 surface expression in Mb1Cre/+ Cxcr4Fl/+ immature IgM+ IgDlo cells overlaid with Mb1Cre/+ Cxcr4+/+ immature IgM+ IgDlo cells in 
BM parenchyma. (right) CXCR4 surface expression in Ly5.1+ Mb1Cre/+ Cxcr4Fl/+ immature IgM+ IgDlo cells in BM parenchyma overlaid with Ly5.2+ (Cxcr4+/+) 
immature IgM+ IgDlo cells residing in sinusoids. (E) Distribution of B220+ CD93+ IgM+ IgDlo immature B cells in BM parenchyma, sinusoids, and PB of le-
thally irradiated mice reconstituted with a mixture of Ly5.1+ Mb1Cre/+ Cxcr4+/+ and Ly5.2+ WT cells (gray) or with Ly5.1+ Mb1Cre/+ Cxcr4Fl/+ and Ly5.2+  
WT cells (black). Error bars indicate ±SEM. (F) Overexpression of truncated CXCR4 (R334X WHIM mutation) in BM cell subsets reported by GFP expression. 
(left) GFP expression in gated B220+ CD93+ IgM+ IgDlo immature B cells. (middle) CXCR4 surface expression in gated GFP (gray) and GFP+ (black line) 
B220+ CD93+ IgM+ IgDlo immature B cells. (right) Distribution of CXCR4-transduced (GFP+) B220+ CD93+ IgM+ IgDlo immature B cells in BM parenchyma 
and sinusoids. (G) Ratio of the frequencies of GFPhi immature IgDlo and mature B cells in PB and in BM. Bars indicate mean; circles indicate individual 
mice. Data were pooled from three independent experiments. *, P < 0.05; **, P < 0.005; ***, P < 0.0005 by unpaired Student’s t test.
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BM chimeras by IVM 4 wk after reconstitution, a time point 
where Y75% of ZsGreen+ B lineage cells were immature B 
lymphocytes, as measured by CD93 surface expression (not 
depicted). In agreement with these findings, the amoeboid 
polarity and motility of MD4+ B lymphocytes increased sig-
nificantly after exposure to HEL, whereas the movement and 
morphology of MD4 B lineage cells was unaffected by HEL 
treatments (Fig. 6, I and J). We also noted that MD4+ B cells 
were less motile and more rounded than MD4 B cells (Fig. 6, 
I and J). However, this difference was likely caused by the very 
limited size of pro-B and pre-B cell compartment in MD4 trans-
genic mice as compared with that in WT mice (not depicted). 
In summary, these data demonstrate that immature B cell mo-
tility and retention within BM parenchyma are significantly 
increased by BCR signaling.
DISCUSSION
Recent studies provided substantial mechanistic insight into 
the multistep process of lymphocyte egress from secondary 
lymphoid organs: as B and T lymphocytes randomly move via 
the activity of distinct chemoattractants, lymphocytes make 
frequent contacts and probe lymphoid organ sinuses. The avail-
ability of the egress-promoting chemoattractant S1P, presumably 
at sinusoidal exit sites, and signaling through the lymphocyte-
intrinsic PTX-sensitive S1PR1 are both required for lympho-
cyte reverse transmigration across sinusoidal endothelium and 
egress (Cyster and Schwab, 2012). Here, we demonstrate that 
developing B cell retention in BM parenchyma was dependent 
on lymphocyte-intrinsic amoeboid motility, predominantly 
mediated by CXCR4 signaling and by A4B1–VCAM-1. 
However, BM egress was surprisingly independent of egress-
promoting chemoattractants sensed by PTX-sensitive GPCRs. 
PTX treatments in vivo have been shown to mobilize B 
cells and hematopoietic stem/progenitor cells from BM 
(Papayannopoulou et al., 2003; Ueda et al., 2004). In the work 
presented here, we now show that cell-intrinsic PTX expres-
sion not only reduces B lineage cell movement within BM 
parenchyma, but also mobilizes B lineage cells, NK cells, mono-
cytes, and granulocytes from BM into the periphery.
The immature B cell stage is characterized by a significant 
change in positioning within BM, with up to 50% of immature 
B cells localizing within BM sinusoids in an A4B1–VCAM-1– 
and CB2 and S1PR3 signaling–dependent manner (Pereira et al., 
2009; Donovan et al., 2010). However, immature B cell move-
ment toward sinusoids was independent of CB2- and S1PR3-
mediated chemotaxis and only partially contributed by S1P 
and S1PR1 (Allende et al., 2010; Pereira et al., 2010). Our ex-
periments now reveal that CXCR4 down-regulation enforced 
B cells to distribute into perisinusoidal and intrasinusoidal 
compartments and was critical for immature B cell egress from 
BM. Furthermore, these experiments also suggest that A4B1-
mediated adhesion is temporally reduced when cells are in 
perisinusoidal compartments, before it is increased again within 
sinusoids, likely through CB2-induced transactivation (Pereira 
et al., 2009). It is possible that B cell–intrinsic A4B1 and VCAM-1 
expressed on sinusoidal endothelial cells may antagonize reverse 
CXCR4 (R334X mutation that causes the WHIM syndrome 
in humans [Hernandez et al., 2003]) was sufficient to prevent 
immature B lymphocyte egress from BM parenchyma into si-
nusoids and into PB (Fig. 5, F and G).
BCR signaling antagonizes CXCR4 down-regulation  
in immature B cells and prevents BM egress
In late stages of B cell development, newly generated imma-
ture B cells undergo negative selection against systemic self-
antigens predominantly in BM (Goodnow et al., 2005). This 
process is likely promoted by immature B cell migration 
within BM by facilitating cellular interactions and screening 
for self-reactive BCRs. As B lineage cell migration in BM is 
controlled by CXCR4 and reduced CXCR4 signaling is es-
sential for BM export, we hypothesized that BCR signaling 
intensity controlled CXCR4 expression in immature B cells. 
To test this hypothesis, we analyzed CXCR4 surface expres-
sion in immature B cells before and after inducing BCR 
stimulation. For this purpose, we isolated BM cells from WT 
mice (C57BL/6), MD4 BCR transgenic mice (B cells specifi-
cally recognize hen egg lysozyme [HEL]), and B1-8 BCR 
transgenic mice (nitrophenyl hapten–specific B cells) and in-
duced BCR signaling with cognate antigens for various periods 
of time. We found that immature B cells increased CXCR4 
surface expression as early as 3 h after treatment with stimula-
tory anti-IgM antibodies or with cognate antigens and peaked 
at 12 h after BCR stimulation (Fig. 6, A and B). We then 
asked whether self-antigen engagement was sufficient to pre-
vent immature B cell egress from BM. We treated MD4 trans-
genic mice with 10 mg HEL for 6 h i.v. and measured immature 
B cell subsets in BM parenchyma, sinusoids, and PB. We found 
that HEL treatment not only significantly increased CXCR4 
expression in immature B cells in vivo (Fig. 6 C), but also 
prevented immature B lymphocyte egress into sinusoids and 
PB by almost 10-fold (Fig. 6, D and E). The effects of HEL on 
CXCR4 expression and B cell egress blockade were strictly 
dependent on an HEL-specific BCR (Fig. 6 F). The periph-
eral reduction in immature B lymphocyte subsets was not 
caused by BCR signaling–induced cell death because these 
cells significantly accumulated in BM parenchyma (Fig. 6 E). 
Furthermore, similar results were obtained with MD4 imma-
ture B lymphocytes that overexpressed antiapoptotic BCL2 
(Fig. 6 H). These results predicted that antigen engagement 
altered B lineage cell movement in BM parenchyma. To test 
this hypothesis, we crossed MD4 BCR transgenic mice with 
mice expressing cre recombinase driven by Cd19 and with mice 
encoding the ZsGreen fluorescent protein driven by the chicken 
albumin and rabbit B globin promoter within the Rosa26 locus, 
preceded by a premature transcriptional stop codon flanked by 
loxP sites (for simplicity referred as Rosa26ZsGreen/+; Madisen 
et al., 2010). Using this strategy, Y99% of ZsGreen+ cells were 
IgM+ B lineage cells (not depicted). We lethally irradiated 
C57BL/6 recipient mice and reconstituted them with BM cells 
taken from MD4+ and MD4 Cd19Cre/+ Rosa26ZsGreen/+ mice. 
To measure the effect of antigen engagement mostly in imma-
ture B lymphocyte motility in BM, we analyzed the calvaria of 
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measured in parenchyma-restricted pro-B and pre-B cell sub-
sets (Koni et al., 2001). Thus, these data are in agreement with 
the finding that A4B1–VCAM-1 is specifically required for 
sinusoidal retention (Pereira et al., 2009) and disfavor a prom-
inent role played by A4B1–VCAM-1 in impeding migration 
across sinusoidal endothelium.
transmigration of developing B cell subsets and prevent their 
egress from BM. However, conditional deletion of VCAM-1 
from endothelial (and hematopoietic) cells induced the selective 
mobilization of immature B cell subsets, most prominently 
immature IgM+ IgDlo cells (which are distributed between 
BM parenchyma and sinusoids), without significant effects 
Figure 6. BCR signaling increases CXCR4 expression, promotes B lymphocyte motility, and prevents BM egress. (A) IgM and IgD expression in 
unstimulated and BCR-stimulated B220+ cells (left and right gates, respectively). (B) CXCR4 mean fluorescence intensity (MFI) in IgM+ IgDlo CD93+ MD4  
B cells untreated (black) or stimulated with 1 mg/ml HEL (gray) for the indicated time periods. Lines indicate mean (±SEM) of three independent experi-
ments. (C) CXCR4 surface expression in unstimulated (black) and in vivo HEL-stimulated (6 h; gray) immature (CD93+) MD4 B cell subsets. (D) MD4  
immature IgM+ IgDlo CD93+ B cell distribution in BM before and after HEL i.v. treatment for 6 h. (E) Quantification of immature B cell subsets in BM pa-
renchyma (Par.), sinusoids (Sin.), and PB of MD4 mice treated with HEL for 6 h. (F) CXCR4 surface expression in WT immature IgM+ IgDlo CD93+ B cells 
stimulated with PBS (black) or with HEL i.v. (gray). (right) CXCR4 MFI on unstimulated (black) and HEL-stimulated (gray) immature IgM+ IgDlo CD93+  
B cells from WT mice. (G) Quantification of immature B cell subsets in BM parenchyma, sinusoids, and PB of WT mice treated with HEL for 6 h. (H, left) 
Distribution of immature IgM+ IgDlo CD93+ MD4 B cells overexpressing Bcl2 in BM parenchyma (CD19-PE) and in sinusoids (CD19-PE+). (right) Immature 
CD93+ IgM+ IgDlo B cell numbers in BM parenchyma, sinusoids, and PB of MD4.BCL2 transgenic mice treated with HEL. (E, G, and H) Bars indicate mean, 
and circles depict individual mice. Data are representative of two independent experiments. (I) Mean motility coefficient of MD4+ and MD4 Cd19Cre/+ 
Rosa26ZsGreen/+ B lineage cells before and 6 h after treatment with HEL i.v. Lines depict the average mean motility coefficient calculated from datasets 
obtained by IVM of two to three mice. (J) Axis ratio (x/y) of MD4+ and MD4 Cd19Cre/+ Rosa26ZsGreen/+ B lineage cells before and 6 h after HEL treatment i.v. 
Circles, unstimulated MD4+ B cells; squares, HEL-stimulated MD4+ B cells; triangles, HEL-stimulated MD4 B cells; diamonds, MD4 unstimulated B cells. 
Lines indicate mean. Data are representative of three independent experiments. *, P < 0.05; **, P < 0.005; ****, P < 0.00005 by unpaired Student’s t test.
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between blood-bathed splenic red pulp and bloodless follicles 
in the white pulp and also rely on integrin-mediated adhesion 
for their retention in this compartment (Arnon et al., 2013). 
The observation that B lineage cell exit occurred from areas 
of intense parenchymal perfusion, and that several B cells were 
largely nonmotile and remained rounded during reverse trans-
migration, suggests that drainage of interstitial fluids back into 
circulation via collecting sinusoids facilitates BM export of 
B lineage cells and possibly other hematopoietic cell types, 
including red blood cells. In agreement with this model, neu-
trophils are also poorly motile in BM and are stationed near 
or at BM exit sites for several minutes before exiting into the 
sinusoidal lumen (Devi et al., 2013).
Whereas CXCR4-deficient pro-B and pre-B cells were 
easily detected in blood and spleen, as expected (Ma et al., 1999; 
Ueda et al., 2004), their numbers in BM were only slightly 
reduced when compared with immature B cell subsets. These 
data indicate that early B cell subsets are less efficiently mobi-
lized from BM than immature B cells and suggest that they use 
other retention mechanisms. However, the majority of GFP+ B 
lineage cells (which include pro-B and pre-B cells) remained 
predominantly sessile, exhibited a rounded morphology, and 
seemed largely nonadherent to the extracellular matrix when 
they lacked A4B1-mediated adhesion to VCAM-1. An alterna-
tive and attractive possibility is that pro-B and pre-B cells cannot 
undergo efficient reverse transmigration. Electron microscopy 
studies of femoral marrow of rats, rabbits, and guinea pigs doc-
umented extensive evidence of intimate interactions between 
immature lymphocyte pseudopodia and cell processes between 
adjacent sinusoidal endothelial cells (Tavassoli and Yoffey, 1983). 
In some instances, though not infrequent, lymphocyte pseu-
dopodia were seen extending through endothelial cells (Hudson 
and Yoffey, 1966). We also observed few examples of WT and 
PTX-expressing B cells elongating during reverse transmigra-
tion through sinusoids. These observations suggest that reverse 
transmigration across some areas of the sinusoidal endothelial 
wall requires an active process. Our study reveals that it is inde-
pendent of GPCR signaling.
Thymocyte egress is directly linked to TCR signaling in-
tensity through AKT/FOXO1 inhibition of KLF2-dependent 
S1PR1 expression (Hart et al., 2012), which likely prevents 
premature egress of autoreactive T lymphocytes (Zachariah 
and Cyster, 2010). Similarly, immature B lymphocyte egress is 
sensitive to BCR signaling intensity as it controlled CXCR4 
expression. However, even when CXCR4 was overexpressed 
in developing B cells, a few immature B cells expressing high 
amounts of CXCR4 were detected in blood and spleen. 
Likewise, small numbers of B cells and neutrophils can be 
found in PB of WHIM patients, in which CXCR4 is consti-
tutively active because of mutations that prevent its desensiti-
zation. Finally, autoreactive immature B cells can still egress 
from mouse and human BM, albeit inefficiently (Hartley et al., 
1993; Wardemann et al., 2003). Combined, these data suggest 
that the BM architecture and its fenestrated vasculature gen-
erate a cell egress–permissive environment that contrasts with 
rather impermeable egress sites from the thymus. We suggest 
Immature B cells egress BM by down-regulating CXCR4 
by approximately twofold through a mechanism that was 
antagonized by antigen-induced BCR signaling, presumably 
after negative selection has occurred. In vitro studies using 
mouse primary immature B cells and a chicken B cell line re-
ported that antigen-induced BCR signaling reduced B cell 
chemotaxis toward CXCL12, while having no detectable ef-
fect on CXCR4 surface expression (Guinamard et al., 1999; 
Brauweiler et al., 2007). Here, using two independent BCR 
transgenic mouse strains and WT (polyclonal) mice, we reli-
ably measured BCR-induced CXCR4 expression in imma-
ture B cells in vitro and in vivo and a corresponding increase 
in B lineage interstitial motility and retention within BM pa-
renchyma. The discrepancy between these findings could be 
related to an inadequacy of the in vitro systems for measuring 
antigen-coated immature B cell chemotaxis. However, our 
experiments are consistent with the observation that CXCR4 
expression was increased in immature B cells in multiple mu-
rine models of lupus (Wang et al., 2009a), given that these 
cells encounter self-antigens during development in BM (Li 
et al., 2002). It will be valuable to analyze the cellular compo-
sition and biological significance of the BM niches that attract 
self-reactive immature B cells.
Even though the S1P pathway contributes to promote 
hematopoietic cell egress from BM, namely NK cells, mono-
cyte/osteoclast precursors, eosinophils, and immature B cells 
(Walzer et al., 2007; Jenne et al., 2009; Allende et al., 2010; 
Pereira et al., 2010; Sugita et al., 2010), its relatively minor 
contribution is in agreement with a marginally detectable 
S1P gradient between BM parenchyma and sinusoids ( Jenne 
et al., 2009). The BM sinusoids are fenestrated and allow pas-
sive flow of circulatory fluids into the parenchyma (Tavassoli 
and Yoffey, 1983; Mazo et al., 1998). Interestingly, the few ob-
served examples of B lineage cell egress from BM parenchyma 
into sinusoids occurred exclusively in areas where vascular leak-
age was readily observed. This observation raises the possibility 
that S1P receptors promote BM egress from areas in paren-
chyma that are less perfused. Whether the fenestrated nature 
of the BM sinusoidal endothelium is a constitutive feature or 
a regulated process remains unknown.
The mechanical forces responsible for purging sessile B cells 
from BM are not entirely clear, but such mechanisms likely 
promote the egress of other hematopoietic cell subsets, in-
cluding poorly motile red blood cells. The dependency on 
integrin-mediated adhesion for motility in BM demonstrates 
that developing B cells adopt similar mechanisms to those 
used by leukocytes during migration on luminal endothelial 
surfaces under shear stress generated by blood flow (Alon and 
Feigelson, 2009). The sudden morphological changes ob-
served immediately after CXCR4 and/or A4 integrin block-
ade are also reminiscent of the cell shape changes seen in T cells 
exposed to lymph flow in lymphatic sinuses (Grigorova et al., 
2009). Immature B cells likely adapted to haptokinetic migra-
tion for retention and controlled migration in shear-rich three-
dimensional environments such as BM, and possibly the spleen. 
Consistent with this model, marginal zone B cells move 
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Measurement of FITC-conjugated dextran dye perfusion into the 
parenchyma. Dye perfusion was measured by selecting two regions of in-
terest in the BM parenchyma and FITC-conjugated labeled sinusoids using 
Imaris. A surface was applied to the green channel to generate voxels in re-
gions of interest within the BM parenchyma and sinusoids over the course of 
the video. Perfusion of FITC-dextran into the parenchyma was assessed by 
measuring the number of voxels that appeared in the regions of interest over 
the course of a 29-min video.
Calculation of interstitial flow rate of dye perfusion into the BM 
parenchyma. Analyses of interstitial fluid flow were performed as described 
previously (Iliff et al., 2012; Egawa et al., 2013). In brief, flow rate within 
BM parenchyma was measured by injecting FITC-dextran (500 kD) or BSA–
Texas red i.v. into anesthetized mice. Mice were then immediately imaged by 
two-photon IVM. The volumetric flow rate in the BM parenchyma was quan-
tified by first applying a surface to the appropriate channel. Next, a three- 
dimensional box of a fixed volume was applied to three regions of interest. The 
instantaneous flow rates (on average six time points) of dye before the three-
dimensional box was filled were used to calculate the mean instantaneous 
flow rate. The instantaneous flow rate (µm3/s) was calculated by taking the 
difference between volumes from consecutive time points and dividing this 
difference by time (60 s).
In vivo labeling of BM sinusoidal B cell subsets. BM sinusoidal cells 
were labeled by injecting i.v. 0.3 µg phycoerythrin-conjugated rat anti–
mouse CD19 (1D3) in 200 µl PBS. 2 min after, mice were sacrificed in a CO2 
chamber.
BrdU and PTX treatment. Mice were treated with 1 mg/ml BrdU (BD) 
i.v. and administered 1 mg/ml BrdU (Sigma-Aldrich) in drinking water 24 h 
before analysis. 1 µg PTX (List Bio Labs) was injected i.v. 24 h before analysis. 
BrdU-labeled cells were identified staining with anti-BrdU FITC according 
to the manufacturer’s protocol. B cells were identified by staining with anti-
B220 (RA3-6B2) or CD19 (ebio1D3), anti-IgM (11/41), anti-IgD (11-26.c.2a), 
and anti-CD93 (AA4.1). Monocytes, NK cells, and granulocytes were identi-
fied by staining for anti-Ly6c (HK1.4), anti-CD11b (M1/70), anti-CD3d 
(145-2C11), anti-NK1.1 (PK136), and anti-CD115 (AFS98). After staining, 
cells were analyzed by FACS (LSRII).
BM chimeras. Approximately 1.5 × 106 total BM cells from Ly5.1+ donors 
were mixed with 1.5 × 106 total BM cells from adult Boy/J (Ly5.2+) mice 
and were transferred into adult Boy/J mice that had been exposed to two 
rounds of 6.35 Gy separated by 3 h. Chimeras were analyzed at least 6 wk 
after reconstitution.
Transwell migration assays. Chemotaxis assays were performed using 106 
BM or spleen cells incubated for 30 min with 1× DMEM containing 0.5% 
fatty acid–free BSA (EMD Biosciences), 5% of antibiotics, l-glutamine (Cell-
gro), and Hepes. Cells were then allowed to migrate through 5-µm-pore–
sized transwells (Corning) toward soluble CXCL12 (R&D Systems), 2-AG 
(Cayman), or CXCL13 (PeproTech) for 3 h at 37°C. Cells were collected, 
stained, and resuspended in 40 ml of staining buffer and analyzed by flow cy-
tometry for 40 s.
Retroviral BM transduction. The R334X mutation in CXCR4 cytoplas-
mic tail was cloned into mammalian retroviral vector (pMSCV) upstream of 
an IRES-truncated GFP cassette as a reporter. Sanger DNA sequencing reac-
tion verified truncated CXCR4 sequences. Phoenix 293T cells were trans-
fected with MSCV retroviral constructs with Lipofectamine 2000 (Invitrogen) 
according to the manufacturer’s protocol. For mutant Cxcr4 (R33x) trans-
duction of hematopoietic stem cells, BM cells were harvested 5 d after i.p. 
injection of 5-fluoracil (Sigma-Aldrich) and cultured with IL-3, IL-6, and 
100 ng/ml mSCF (PeproTech). BM cells were then spin-infected twice with 
a retroviral constructs and injected i.v. into lethally irradiated Boy/J recipients. 
Mice were analyzed at least 5 wk after reconstitution.
that the passive mode of leukocyte egress from BM evolved 
to facilitate the release of highly heterogeneous leukocyte sub-
sets that include nonmotile cells, at the expense of some pre-
mature exit of developing B lymphocytes. This fundamental 
difference between T and B lymphocyte egress strategies from 
primary lymphoid organs possibly imposed an evolutionary 
pressure for additional extramedullary B cell developmental 
checkpoints (Carsetti et al., 2004).
MATERIALS AND METHODS
Mice. Adult C57BL/6 (CD45.2), Boy/J (CD45.1), Itgb1Fl/Fl, Lyz2Cre/+, 
Cd19Cre/+, and Rosa26FloxSTOP-ZsGreen/+ (Madisen et al., 2010) mice were from 
obtained from The Jackson Laboratory. MD4 and MD4.Bcl2 transgenic mice 
were from an internal colony (J.G. Cyster). B1-8 transgenic mice were pro-
vided by A. Haberman (Yale University, New Haven, CT). Cxcr4Fl/ and 
Rosa26FloxSTOP-PTX/+ (Regard et al., 2007) mice were crossed with Mb1Cre/+ mice 
(Pelanda et al., 2002) to generate Cxcr4Fl/ Mb1Cre/+ and Rosa26FloxSTOP-PTX/+ 
Mb1cre/+ mice (all provided by J.G. Cyster). Rosa26FloxSTOP-PTX/+ mice were 
crossed to Lyz2Cre/+ and Il7rCre/+ to generate Rosa26FloxSTOP-PTX/+ Il7rCre/+, 
Rosa26FloxSTOP-PTX/+ Lyz2Cre/+, and control littermates. Il7rCre/+ mice were 
provided by H.-R. Rodewald (German Cancer Research Center, Heidelberg, 
Germany). For intravital imaging, Cxcr4Fl/, Itgb1Fl/Fl, and Rosa26FloxSTOP-PTX/+ 
Mb1Cre/+ were crossed with Rag1GFP/+ mice (Kuwata et al., 1999). Mice were 
maintained under specific pathogen–free conditions and used according to 
the protocols approved by the Yale University Institutional Animal Care and 
Use Committee.
Two-photon intravital imaging. Mice were anesthetized with ketamine/
xylazine and immobilized on a custom-built stage. Laser-scanning microscopy 
images were collected using a BX61WI fluorescence microscope (Olympus) 
and a 20× 0.95NA water immersion objective (Olympus) and dedicated single-
beam TriM Scope II (LaVision Biotec) controlled by IMSpector software. 
The microscope was outfitted with a Chameleon Vision II Ti:Sapphire laser 
(Coherent) with pulse precompensation. For 4D analysis of cell migration, 
stacks of 13–17 optical sections with 3-µm z spacing were acquired every 20 
or 30 s for 30 min with the laser tuned to a wavelength of 845–875 nm. Phar-
macological antagonists AMD3100 (Tocris Bioscience), 4F-benzoyl-TN14003 
(a gift from H. Tamamura, Tokyo Medical and Dental University, Tokyo, Japan), 
and anti–VCAM-1 (clone M/K2; Bioexpress Inc.), anti-A4 (clone PS/2; 
LygoCyte Pharma Inc.), and anti-CXCL12 (clone 79014; R&D Systems) 
blocking antibodies were injected i.v. 1–5 min before imaging. Videos in 
which significant tissue drifting was detected were excluded from analyses. 
A few videos showed small tissue drifting, which was computationally cor-
rected with Imaris software tool “Correct Drift” (Bitplane).
The axis ratio of parenchymal GFP+ cells was calculated by measuring 
the distance between the two furthest GFP+ points on the x and y planes of 
individual cells after collapse of the z plane using Imaris. Parenchymal GFP+ 
cells that were distinguishable from neighboring cells were selected for analy-
sis to avoid miscalculation of the axis ratio of a single GFP+ cell.
Tissue preparation, cell enumeration, and antibodies. BM cells were 
flushed from femurs and tibias in DMEM (Cellgro) containing 2% FBS (In-
vitrogen), 5% of antibiotics (Cellgro), and Hepes (Cellgro). PB was collected 
from the portal vein, and erythrocytes were lysed with NH4Cl, KHCO3, and 
EDTA. Spleen was dissociated in 5 ml DMEM containing 2% FBS, 5% of 
antibiotics, and Hepes using a cell strainer (Thermo Fisher Scientific). Cells 
were counted with a Coulter Counter (Beckman Coulter). B cells were 
identified by staining with anti-B220 (RA3-6B2) or CD19 (1D3), anti-IgM 
(11/41), anti-IgD (11-26c.2a), and anti-CD93 (AA4.1) antibodies. Mono-
cytes and granulocytes were stained with Ly6C (HK1.4), CD11b (M1/70.15), 
and CD115 (AFS98) antibodies, and NK cells were stained with CD3e (145-
2C11) and NK1.1 (PK136) antibodies. Dead cells were excluded by staining 
with DAPI. Cells were analyzed by FACS (LSRII; BD).
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In vitro antagonist treatments. 106 BM or spleen cells were treated with 
saline (0.9% NaCl) or AMD3100 for 1 h at 37°C. Cells were then removed 
from incubation and used in transwell migration assays.
BCR stimulations in vivo and in vitro. BM cells isolated from femurs 
and tibias were prepared at 107 cells/ml in DMEM containing 10% FBS, 
10 mM Hepes, and a cocktail of penicillin and streptomycin (50 U/liter and 
50 µg/liter, respectively). Approximately 2 × 106 cells were left unstimulated 
or stimulated with 20 µg/ml F(ab)2 fragment goat anti–mouse IgM (Jackson 
ImmunoResearch Laboratories, Inc.), with 20 µg/ml HEL (Sigma-Aldrich), 
or with 1 mg/ml NP-BSA (Biosearch Technologies, Inc.), at 37°C and 5% 
CO2 for the indicated time points in the Fig. 6 legend.
MD4 and MD4.Bcl2 transgenic mice were stimulated with 10 mg HEL 
for 6 h. Mice were injected with 0.3 µg phycoerythrin-conjugated rat anti–
mouse CD19 (1D3) in 200 µl PBS before sacrifice. Cells isolated from femur 
and tibia BM, PB (portal vein), and spleen were counted in a Coulter Coun-
ter and stained to detect B cell subsets, as previously described in Tissue 
preparation, cell enumeration, and antibodies.
Statistics. Student’s two-tailed t test or X2 test was performed using GraphPad 
Software Prism 6 or Microsoft Excel. A value <0.05 was considered significant.
Online supplemental material. Video 1 shows intravital imaging of devel-
oping B cell migration before and after treatment with AMD3100 (25 min). 
Video 2 shows intravital imaging of Cxcr4-deficient developing B cell migra-
tion (30 min). Video 3 shows intravital imaging of Cxcr4-deficient developing 
B cell migration before and after treatment with AMD3100 (30 min). Video 4 
shows intravital imaging of developing B cell migration before and after 
treatment with anti–VCAM-1 (30 min). Video 5 shows intravital imaging of 
Itgb1-deficient developing B cell migration (30 min). Video 6 shows intravital 
imaging of developing B cell migration before and after treatment with anti–
VCAM-1 (30 min). Video 7 shows intravital imaging of FITC-conjugated 
dextran perfusion into the BM parenchyma (29 min). Video 8 shows intravital 
imaging of PTX-expressing B lineage cell migration in BM (30 min). Video 9 
shows intravital imaging of motile PTX-expressing B lineage cell migration 
in BM (30 min). Video 10 shows intravital imaging of WT and PTX-expressing 
B lineage cell egress from BM. Online supplemental material is available at 
http://www.jem.org/cgi/content/full/jem.20140457/DC1.
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Abstract !
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease 
that primarily affects the joints.  Self-reactive B and T lymphocytes cooperate to 
promote antibody responses against self proteins and are major drivers of 
disease.  T lymphocytes also promote RA independently of B lymphocytes 
mainly through the production of key inflammatory cytokines, such as IL-17, that 
promote pathology.  While the innate signals that initiate self-reactive adaptive 
immune responses are poorly understood, the disease is predominantly caused 
by inflammatory cellular infiltration and accumulation in articular tissues and by 
bone erosions driven by bone-resorbing osteoclasts.  Osteoclasts are giant 
multinucleated cells formed by the fusion of multiple myeloid cells that require 
short-range signals for undergoing differentiation. The recruitment and 
positioning of osteoclast precursors to sites of osteoclast differentiation is an 
important point of control for osteoclastogenesis and bone resorption and are 
reviewed. Furthermore, the pathways of osteoclast differentiation under 
homeostasis and driven by inflammatory signals are also reviewed.!!!
Index entries/Keywords: Rheumatoid arthritis, osteoclasts, osteoclast precursors, 
cell migration!!
Introduction 
Risk for inflammatory autoimmune diseases, like rheumatoid arthritis (RA), 
is influenced by genetic variation and environment. Genetic risk loci for 
autoimmune diseases have been identified by GWAS [1] and recently genetic 
fine mapping studies coupled with epigenomic analyzes have begun to identify 
putative causal variants [2,3].  Multiple disease-associated single nucleotide 
polymorphisms (SNPs) were mapped to genes and regulatory regions that are 
active in a cell-specific manner. These analyses revealed RA-associated SNP 
enrichment in genes and regulatory regions active in B cells, T cells, and to a 
lesser extent, monocytic cells [2,3].  This work provides a contextual framework 
for understanding the genesis of human autoimmune disease that can be applied 
to present and future studies in animal models.  It also places the adaptive 
immune system front and center in the pathogenesis of RA. 
 
Pathogenesis of RA 
Rheumatoid arthritis is a chronic inflammatory disease characterized by 
an accumulation of inflammatory leukocytes in the synovium and articular 
tissues, and autoantibodies (rheumatoid factor and anti-citrullinated protein 
antibodies (ACPA)).  The disease is also comprised of bone and cartilage tissue 
destruction and by other systemic features presumably caused by flares of 
inflammation.  Even though RA is a common autoimmune disease that has been 
studied for several decades now, it is still unclear why articular tissues are 
predominantly attacked.  The cellular components of the articular space include 
cells of the innate and adaptive immune system, chondrocytes, fibroblast-like 
synoviocytes, and bone remodeling cells, i.e. osteoclasts and osteoblasts.  The 
accumulation of inflammatory leukocytes in articular tissues is a hallmark feature 
of RA, but this accumulation is thought to occur primarily because of cellular 
recruitment into inflamed tissues rather than as a consequence of local leukocyte 
proliferation [4].  
The adaptive immune response in RA has been a focus of intense 
research over the last several decades. The strongest genetic link to RA involves 
SNPs in the Human Leukocyte Antigen (HLA)-DRB1 gene that likely alter T cell 
repertoire selection and antigen presentation, amongst other possibilities.  The B 
cell repertoire is also constrained in RA patients, in which defects in early B cell 
tolerance checkpoints have been described [5], but for which there is still little 
mechanistic insight.  Numerous antigens have been described in RA patients and 
in RA mouse models, and they include antibodies against the immunoglobulin Fc 
region (rheumatoid factor) and against citrullinated proteins (ACPA). Citrullination 
is a post-translational modification in which arginines are deiminated by 
peptidylarginine deiminases.  ACPA are not only prevalent biomarkers for RA 
diagnosis, they also predict the development of the more debilitating erosive 
aspects of the disease.  To date, it still remains unclear if specific autoantigen 
epitopes are key for the pathogenesis of RA, but autoantigens are clearly 
essential for the adaptive immune response in the pathogenesis of RA.  
Numerous citrullinated polypeptides have been detected in the synovium 
of RA patients, populating a “citrullinome” that is comprised of both intracellular 
and extracellular antigens ranging in size from ~14-100 KDa [6]. ACPAs can be 
detected years before disease onset and are likely important for shaping the 
development of disease [7-9].  In support of this possibility it was recently shown 
that immune complexes with citrullinated histones are potent activators of 
myeloid cells (macrophages and neutrophils) and induce TNFα secretion [10].  
Evidence from several mouse models of inflammation in the joint and of 
inflammatory arthritis provides valuable insight into the spatio-temporal dynamics 
of the antibody response [11].  The K/BxN transgenic mouse is a model that 
allows studying the mechanisms whereby autoantibodies drive inflammation in 
the joint. In K/BxN transgenic mice there is spontaneous inflammation in the 
articular space that presents synovial pannus formation and bone and cartilage 
erosions [12]. K/BxN mice spontaneously produce autoantibodies against 
glucose 6-phosphate isomerase (GPI) that selectively deposit in the joints as 
immune complexes and trigger complement fixation [13]. Transfer of serum 
containing arthritogenic anti-GPI antibodies from K/BxN transgenic mice into 
naïve wild-type mice leads to the development of inflamed joints clinically and 
pathologically similar to what is observed in K/BxN transgenic mice [14]. Given 
that the generation of autoantibodies in the K/BxN model is crucial for disease 
development, effort has been made to identify the anatomical location(s) and 
kinetics of anti-GPI antibody production. The anti-GPI antibody response initially 
localizes to draining LNs and persists until later stages of the disease [15].  This 
indicates that draining LNs are involved in the initiation and perpetuation of the 
inflammatory arthritis antibody response in this model.   Evidence in the clinical 
setting for LN involvement in RA patients has long been appreciated, including 
data showing that immune responses develop in draining LNs prior to the 
appearance of arthritis symptoms [16].  Importantly, B cell depletion from the 
draining LNs (popliteal) ameliorates inflammatory arthritis [17,18], and B cell 
depletion therapies significantly reduce RA symptoms in humans [19].  
The activation of the B cell antibody response in the LN requires two 
antigen-driven events that are segregated in distinct temporal and anatomical 
locations: 1.) antigen recognition by B cells in follicles 2.) antigen presentation by 
T-zone dendritic cells and subsequent T cell activation in the T cell zone.  
Relatively small soluble antigens <70 kDa can gain access to B and T cell areas 
of the LN by free diffusion via the follicular conduit network [20-22].  Larger 
antigens are transported into follicles through their initial capture by CD169+ 
subcapsular sinus macrophages from the incoming lymph, and relay to B cells in 
follicles in a complement receptor-dependent manner.  These large immune 
complexes become subsequently deposited on follicular dendritic cells (FDCs) 
where they persist for long periods of time [23-26]. The molecular sizes of 
autoantigens uncovered in arthritis patients suggests both mechanisms of 
antigen delivery to T and B cell niches in secondary lymphoid organs are likely to 
operate in RA.  But, T cells can also be activated by DCs that may sample 
antigens in inflamed articular spaces and migrate to the draining LN for T cell 
priming. In RA patients, both mature and immature DCs have long been 
identified in synovium and synovial tissue by histology [27-32].  Plasmacytoid 
DCs have also been identified in rheumatoid synovium and synovial fluid [33-35].  
Whether various DC subsets are recruited to the joints during the earliest stages 
of synovial inflammation remains unknown. 
Shortly after antigen-engagement, activated B cells increase the 
expression of the T-zone homing chemokine receptor CCR7, and migrate to the 
T-B border where they interact with a subset of activated (cognate) T cells [36].  
At this stage, activated B cells receive further differentiation signals from cognate 
T cells mostly through CD40/CD40L interactions.  Importantly, SNPs in CD40 
have been linked to RA [4].  Within 1-2 days after antigen engagement and CD40 
signaling B cells increase EBI2 (GPR183) expression [37-40] and!together with 
activated T cells, migrate to outer and inter-follicular areas in an EBI2-dependent 
manner.  The oxysterol ligands of EBI2 (mostly 7α, 25-hydroxycholesterol, (7α, 
25-OHC)) are presumably abundant in the follicle perimeter, including 
interfollicular regions [37-40].  Dendritic cells also express EBI2 and migrate to 
inter-follicular niches, and signals or cellular interactions occurring at these sites 
contribute significantly to the development of primary antibody responses by 
promoting plasmablast differentiation [41,42].  Later in the immune response a 
subset of activated T and B cells initiates germinal center responses where 
antibody affinity maturation, isotype switching, and long-lived plasma cell 
differentiation take place.   
The GC reaction is thought to play an important role in RA. Follicular 
dendritic cells (FDCs) are critical for the formation of autoreactive GC reactions 
and development of joint inflammation in the K/BxN model [43].  In RA patients, T 
and B cells form aggregates in the articular space and can form ectopic GCs in 
about 40% of patients [44].  Given that anti-B cell therapy (Rituximab) is 
inefficient at depleting antibody-secreting plasma cells, and variably affects 
antibody titers [19], its efficacy may be associated with other roles B cells play in 
the organization of ectopic lymphoid follicles and GCs, and in T cell activation 
through cytokine secretion and autoantigen presentation.  These tertiary 
lymphoid structures do not form in most experimental mouse models of 
inflammatory arthritis, the exception being in the collagen-induced arthritis (CIA) 
model [45]. The fact that CIA displays many similar histophathological features 
with human RA has made it one of the most widely studied models of 
inflammatory arthritis [46].  In this model, type II collagen (an abundant protein in 
cartilage), is used as an antigen for immunizing mice, which leads to the 
development of inflammatory arthritis.  CIA is often used to evaluate therapeutic 
interventions. 
 
Inflammation in the synovial compartment 
Despite many decades of intense research very little is still known about 
the kinetics of cell recruitment into synovial tissues in RA patients and in 
experimental inflammatory arthritis.  In a permutation of the K/BxN inflammatory 
arthritis model, LaBranche et al. transferred autoreactive KRN TCR transgenic T 
cells into T cell-deficient mice (B6.TCR.cα-/-H-2b/g7) and were able to induce 
arthritic lesions that were synchronized and chronic in nature [47].  Interestingly, 
T cells were not detected in the joint but were present in the draining popliteal 
LN.  Instead, monocyte/macrophage and neutrophil infiltration occurred early in 
disease progression, and correlated with bone and articular erosions.  The influx 
of monocytes and macrophages, whether by recruitment or local differentiation 
and activation, highly correlates with inflammation and tissue damage in RA 
patients [48-50].  Given that monocytes and macrophages secrete numerous 
chemokines and cytokines, they also could be involved in the recruitment of other 
inflammatory cells into the joint, such as neutrophils.  Neutrophils are abundant in 
synovial tissues and fluid, and mouse models provide clear evidence for 
neutrophil involvement in disease.  Neutrophil depleted mice are completely 
resistant to the K/BxN serum transfer model of inflammatory arthritis [51].  A 
study in an anti-type II collagen antibody induced inflammatory arthritis model 
reported that the initial cellular infiltrate to the synovium is mainly composed of 
neutrophils and macrophages [52], and depletion of neutrophils attenuates 
disease progression [52,53]. However, the mechanisms controlled by neutrophils 
that exacerbate disease remain poorly understood.  Furthermore, whether 
macrophages also contribute to the onset of disease remains unclear.  
 
Recruitment of innate immune cells  
In the synovium and synovial fluid of RA patients numerous homeostatic 
and inflammatory chemokines with the potential to influence the trafficking of 
leukocytes into the tissue are upregulated.  CCR7+ mature DC (CD83+ and DC-
LAMP+) present within synovial infiltrates of RA patients were found in close 
association with CCR7-ligand (CCL19 and CCL21) expressing cells, suggesting 
these chemokine pairs may play a role in the recruitment of DCs to the synovium 
[32].  In this study immature DC (CD1a+) expressed CCR6 and were in close 
association with CCL20-producing synovial cells [32].  In humans it was also 
recently reported that pDCs expressed CXCR3 and CXCR4 and accumulated in 
the inflamed joints of RA patients, [34].  Furthermore, the levels of CXCR3 
ligands CXCL10, CXCL11, and of the CXCR4 ligand CXCL12 in the synovial fluid 
of RA patients were significantly increased when compared to osteoarthritis (OA) 
patients [34], suggesting the involvement of CXCR3 and CXCR4 in pDC homing 
or retention in inflamed joints.  Besides pDCs, other DC subsets express 
functional CXCR4 [54], and CXCL12 was found to be highly expressed in 
synovial tissues [55,56] and synovial fibroblasts from RA patients [57].  
In the K/BxN serum transfer model, neutrophils are absolutely required for 
disease progression [51]. Neutrophils express CXCR2 and its ligand CXCL2 is 
abundant in arthritic tissues including CXCL2 [58]. Furthermore, CXCR2 was 
crucial for disease progression in this model [58]. Importantly, blockade of 
CXCR2 in other animal models of arthritis quantitatively reduces disease severity 
and the recruitment of neutrophils [59-61]. Given that CXCR2 promotes 
neutrophil egress from bone marrow cavities [62], it is unclear if CXCR2 
deficiency reduced inflammatory arthritis by impairing neutrophil recruitment to 
the synovium or by reducing their egress from bone marrow, or both.  Using 
intravital 2-photon imaging of LysM-GFP mice and the K/BxN serum transfer 
model of arthritis, Wang and colleagues were able to visualize neutrophil 
recruitment to the inflamed synovial space [63]. Intriguingly, they observed that 
neutrophils were often associated with monocytes at sites of extravasation, and 
global depletion of monocytes arrested neutrophil extravasation [63]. 
 
Recruitment of lymphocytes  
Th1, Th17, and Treg cell types are present in inflamed articular tissues in 
RA patients, with Th1 cells being the most prevalent T helper cell subset [64,65]. 
Studies from mouse models in combination with data obtained from RA patients 
have provided some insight into the trafficking mechanisms for T cells in arthritis.  
CXCR3 and CCR5 are abundantly expressed by T cells isolated from the 
synovial fluid and synovial tissues of RA patients, and both receptors are 
preferentially expressed on Th1 cells [66-68].  In adoptive transfer experiments in 
a mouse adjuvant arthritis model, T cells deficient in CXCR3 were poorly 
recruited to inflamed joints, and CXCR3 blockade using antibodies inhibited T 
cell recruitment and reduced disease severity [69].  Consistent with these 
findings, the CXCR3 ligands CXCL10 and CXCL9 are abundant in the synovial 
fluid of RA patients [66] and, interestingly, myeloid DCs isolated from the synovial 
fluid of RA patients express higher CXCL9 and CXCL10 amounts than myeloid 
DCs isolated from peripheral blood [70].  CCR5 has also been suggested to 
contribute to the recruitment of T cells to the synovium.  Several studies have 
reported that a single nucleotide polymorphism (SNP) resulting in a non-
functional CCR5 allele was negatively associated with RA [71-74], but this finding 
was not confirmed in other studies [75,76]. In animal models CCR5 deficiency 
had no effect on disease outcome [77].   
In RA patients, CXCR4 is expressed on memory CD4+ T cells (CD45RO+) 
infiltrating the synovium [68]. In mice, T cell specific deletion of CXCR4 impaired 
their infiltration into the joints and decreased the severity of collagen-induced 
arthritis [78].  
CX3CR1 is expressed on T cell subsets, and in RA patients the CX3CR1+ 
fraction of T cells is increased when compared to healthy controls [79].  The 
ligand for CX3CR1, fractalkine (CX3CL1), is expressed by synoviocytes and 
endothelial cells and is elevated in RA patients compared to OA patients 
[80,79,81]. In the collagen induced mouse model of arthritis, CX3CR1 is also 
expressed on T cells infiltrating the synovium and CX3CL1 is also upregulated 
[82].  Given that the depletion of CX3CL1 in synovial fluid in animal models of 
inflammatory arthritis reduced overall chemotactic potency [83], this chemokine 
receptor pair likely guides the recruitment of T cells to inflamed synovium. 
Th17 cells play a key role in the pathogenesis of RA and these cells 
express CCR6 [84].  CCR6-expressing cells were identified in synovial tissue 
from RA patients several years ago [85], and the CCR6 ligand CCL20 is robustly 
secreted by synovial fibroblasts isolated from arthritic joints (but not secreted by 
granulocytes and monocytes) [84,85].  CCR6 blockade suppressed the onset 
and severity of disease and reduced the number of CD4+ T cells that infiltrated 
the joint [84], although the numbers of Th17 cells were not specifically reported.   
Administration of FTY720, a high affinity agonist for sphingosine 1-
phosphate (S1P) receptors that induces receptor internalization and renders 
targeted cells unresponsive to chemotactic gradients of S1P, was protective in 
mouse models of inflammatory arthritis by reducing lymphocytic infiltration into 
the joints and bone erosions [86-88].  Lymphocytes (including T cells) [86-88] 
and monocytes [87] were sequestrated in secondary lymphoid organs and thus, 
were unavailable to egress into the circulation and migrate to arthritic tissues. 
Although bone marrow populations were not examined in either study, it 
highlights the importance of this pathway in lymphocyte circulation and trafficking 
in inflammatory arthritis.  S1P levels are elevated in the synovium and synovial 
fluid of RA patients (even higher than serum levels) and could contribute to 
cellular recruitment and retention [89,90]. 
An essential component of the pathogenesis of RA is B cells, highlighted 
by the efficacy of B cell depletion therapy [91,92].  In RA, B cell production of 
ACPA is strongly predictive of erosive bone disease [93].  B cells can be found in 
abundant numbers organized into follicular structures in the synovium, and in 
ACPA+ RA patients about 25% of IgG+ B cells isolated from articular space 
encode antigen receptors that are specific for citrullinated antigens [94].  Whether 
self-reactive B cells differentiate within ectopic follicles and germinal centers in 
the synovium, or are recruited from draining LNs is not entirely clear.  
The chemokine expression pattern on B cells isolated from the synovium 
of RA patients includes CCR5, CCR6, CCR7, CXCR3, CXCR4, and CXCR5 [95].  
The levels of CCL19, CXCL12, and CXCL13 are all increased in the serum of RA 
patients [96], CCL19 is increased in the synovium of RA patients [97], and 
CXCL13 is expressed in ectopic germinal centers in the synovium of RA patients 
[98].  This combination of homeostatic and inflammation-associated 
chemoattractant receptors suggests an active involvement in B lymphocyte 
recruitment and cell organization in synovial spaces. 
 
 Inflammation in the subchondral bone marrow 
The synovium, and more recently LNs, represent the main focus of the 
inflammatory response in RA, but nearby compartments also develop 
inflammation including the subchondral bone marrow.  The subchondral bone 
marrow is located under the subchondral bone that separates the articular 
cartilage from the bone marrow cavity.  The bone marrow cavity is an important 
site of hematopoiesis but the subchondral bone marrow is populated by 
adipocytes and lacking abundant hematopoietic activity under homeostatic 
conditions.  However, evidence indicates that subchondral bone marrow 
participates in the inflammatory response in RA. Magnetic resonance imaging 
data (MRI) from RA patients identifies edema throughout the bone marrow, even 
at stages where there is a low level of synovial inflammation [99,100].  Indeed, 
like synovitis, bone marrow edema is also predictive of subsequent pathologic 
bone erosion [101,102]. Subchondral bone marrow inflammation, including 
ectopic germinal center-like structures, has been found in the CIA mouse model 
[45,103,104].  The subchondral bone marrow undergoes significant changes 
during the course of RA, including infiltrating leukocytes [105-108] and 
development of bone resorbing osteoclasts (OC) on the subchondral surface 
[109,110].  Collectively, these studies indicate that the bone marrow 
compartment may be important for the pathogenesis of RA, but this compartment 
has not yet been fully integrated into disease models.  
 
 Bone erosion in RA 
Periarticular bone erosions are highly prevalent in RA and lead to joint 
deformities and impaired function [111].  As the only cell capable of bone 
resorption in the body, osteoclasts have a critical role in inflammatory disorders 
associated with bone erosions and focal bone loss, including RA [112]. In mouse 
models of inflammatory arthritis numerous studies have demonstrated that 
osteoclasts are absolutely required for bone erosions to occur [113-118].  
Osteoclasts form early in disease progression in animal models and initially 
appear at the junction of synovial membrane and periosteal lining and within 
subchondral bone [119].  Even though osteoclasts can be detected on both the 
synovial and subchondral bone marrow sides of the joints, osteoblasts (bone 
synthesizing cells) are only detected on the subchondral side [110,120-122]. 
Therefore the mechanisms of osteoclast differentiation from these two sides may 
be distinct.  
 
Osteoclast differentiation under homeostasis. 
Osteoclasts are hematopoietic cells that differentiate from monocyte 
progenitors through sequential developmental stages.  Although the exact 
identity of osteoclast precursors still remains unclear, studies have found that 
cells with osteoclastogenic potential in the bone marrow do not express lymphoid 
cell surface proteins or the aM integrin (CD11b/MAC1), and instead express the 
macrophage colony stimulating factor-1 receptor (Cfms, CSF1R, CD115) and the 
stem cell factor receptor (cKit).  These cells overlap with the 
macrophage/dendritic cell precursor (MDP) subset [123] and can also 
differentiate into monocytes, macrophages, and dendritic cells [124-127].  More 
recently, a clonogenic, monocyte- and macrophage-restricted progenitor cell 
(named cMoP) derived from the MDP was identified [128], but whether the cMoP 
subset retains osteoclast differentiation potential has not been defined.   
The dominant cytokine that governs osteoclast differentiation in vitro and 
in vivo is RANKL, which signals through its receptor RANK [129-131].  
Osteoblasts are key sources of MCSF (a cytokine required for cell survival and 
osteoclastogenesis) and RANKL [132], and RANKL expressed by osteocytes 
was recently shown to be critical for osteoclast differentiation in vivo [133]. 
RANKL is a type II transmembrane receptor and as such requires cell-cell 
interactions for engaging its receptor RANK expressed on osteoclast precursors. 
This predicts that positional cues are involved in the recruitment of osteoclast 
precursors to interact with RANKL+ cells. For many years it has been appreciated 
that resorbing bone is chemotactic for osteoclast precursors [134].  Recently, 
osteoblasts were reported to express oxysterol-synthesis enzymes, namely 
cholesterol 25 hydroxylase (gene name Ch25h) and 25-hydroxycholesterol 7-
alpha-hydroxylase (gene name Cyp7b1) [135].  They also secrete the oxysterol 
7a, 25 dihydroxycholesterol (7a, 25-OHC), which acts as a potent chemotractant 
for the pertussis toxin sensitive Gai protein coupled receptor EBI2 [135]. 
Furthermore, EBI2 is abundantly expressed in murine osteoclast precursors, and 
its expression increases during osteoclast differentiation [135].  It was reported 
that EBI2 directs the migration of osteoclast precursors to bone endosteal niches 
and promotes osteoclastogenesis in vivo [135]. Besides its role in cell positioning 
at the endosteum, EBI2 signaling also contributes to promote osteoclast 
precursor motility within bone marrow parenchyma [135], possibly in synergy with 
CX3CR1 [136].  Importantly, deficiencies in EBI2 or CH25H resulted in similar 
decreases in osteoclast numbers and increased bone mass in vivo [135], 
indicating that 7a,25OHC is the main EBI2 ligand controlling osteoclastogenesis 
and bone mass homeostasis. In summary, this study provided direct in vivo 
evidence for EBI2 and oxysterols in osteoclast precursor recruitment to endosteal 
surfaces, and consequently in osteoclast differentiation [135].  
The chemokine monocyte chemoattractant protein-1 (MCP-1) is also 
expressed by osteoblasts in vitro when cultured in inflammatory conditions [137-
139] and the MCP-1 receptor, CCR2, is expressed on mouse and human 
osteoclast precursors [140,141]. These findings led to a model where bone 
proximal MCP-1, produced by osteoblasts, attracts osteoclast precursors to sites 
of osteoclast differentiation [142].  In support of this model, CCR2 deficient mice 
display a mild increase in bone mass and stability, likely due to a reduction in 
osteoclast differentiation [143].  In humans, a polymorphism in CCR2 (V64I) was 
associated with increased bone mineral density in middle aged men and 
postmenopausal women [144], but whether this polymorphism alters CCR2 
signaling is unclear [145].  Altogether, the bone mass phenotype reported in 
CCR2 deficient mice is mild and contrasts with the essential role of CCR2 in 
promoting monocyte egress from bone marrow, both in homeostasis and during 
systemic acute inflammation [146-148].   
CCR1 and CCR5 have also been reported as abundantly expressed on 
human, mouse and rat osteoclast precursors, upregulated on osteoclasts, and 
promoting their chemotaxis in response to several of their ligands, as reviewed 
elsewhere [149].  Furthermore, CCR1 and its ligands significantly promote 
osteoclast differentiation in vitro and in vivo (particularly CCL9) and CCR1 
deficient mice are mildly osteopenic [150,149].  Several CCR1 ligands are shared 
by CCR5, but no bone mass phenotypes in CCR5 deficient mice have been 
reported. 
The chemokine receptor pair CX3CR1 and its ligand CX3CL1 are also 
functionally expressed during osteoclast differentiation, as reviewed elsewhere 
[149].  Interestingly, CX3CL1 is produced by mouse osteoblasts [151] and 
CX3CR1 deficient mice have a reduction in osteoclasts that results in a mild 
increase in bone mass [152].  Furthermore, functional inhibition of CX3CR1 
signaling provided protection from bone loss induced by irradiation [153], 
perhaps by disrupting CX3CR1-mediated migration and retention in the bone 
marrow [136]. In summary, while these studies suggest that synergy between 
multiple chemokine receptors controls osteoclastogenesis, only EBI2 was shown 
to be directly required for osteoclast precursor positioning in bone endosteal 
niches (Figure 1).  
In contrast to chemoattractants derived from bone-proximal niches, 
chemoattractants emanating from bone-distal niches can also influence the 
positioning of osteoclast precursors in the bone marrow. Furthermore, the 
balance between bone marrow retention and egress cues is likely an important 
point of control for osteoclast precursor positioning and differentiation.  In favor of 
such a model is the fact that osteoclasts are predominantly in close proximity to 
blood vessels in bone marrow thus making it likely that osteoclast precursors 
encounter bone and blood vessel chemoattractants (Figure 2) [149].   
Emerging evidence has provided insight into leukocyte migration and 
dynamic behavior in steady-state conditions, including the mechanisms 
controlling their egress from bone marrow.  Leukocytes are thought to egress 
from bone marrow through a vast network of blood vessels often referred to as 
bone marrow sinusoids. The majority of bone marrow sinusoids are 
characterized by a single layer of endothelial cells often separated by small gaps 
and without a basement membrane. Several hematopoietic cells exit bone 
marrow parenchyma by moving towards bone marrow sinusoids in a 
chemoattractant-dependent manner. For example, natural killer cells, eosinophils 
and B lymphocytes express S1P receptors and migrate towards high 
concentrations of S1P within sinusoids [154-157]. Other hematopoietic cells, 
such as monocytes and neutrophils depend on chemokine receptors, namely 
CCR2 and CXCR2, for exiting bone marrow parenchyma, and CCR2 ligands are 
abundant around sinusoids [147,62,146].  Osteoclast precursors have also been 
shown to use S1P receptors for exiting bone marrow, and defects in S1PR 
signaling alter osteoclast precursor differentiation [158,159]. CXCR4 is also 
expressed in osteoclast precursors and directs their migration towards CXCL12 
in vitro [160,161].  CXCR4, and its ligand CXCL12, have a well-described role in 
the retention of multiple hematopoietic cell subsets in bone marrow, including 
hematopoietic stem and progenitor cells [162]. Even though CXCR4 is one of the 
most studied chemokine receptors, its role in steady-state osteoclastogenesis in 
vivo remains controversial.  Several studies reported that osteoblasts express 
CXCL12 in vivo [163,164] and it was proposed that CXCR4 promotes osteoclast 
precursor migration towards sites of osteoclast differentiation in vivo [158,165].  
However, studies using CXCR4 deficient and CXCL12 reporter mouse strains 
provided results that are not compatible with this model.  For example, CXCL12 
expression is highest in rare mesenchymal stromal cells capable of multilineage 
differentiation (osteoblasts, chondrocyte, and adipocytes) distributed in 
parenchyma and some adjacent to blood vessels [166-168].  Furthermore, 
CXCL12 expression is reduced by nearly 100-fold in osteoblasts in vivo [169], 
making it unlikely that CXCR4 would direct osteoclast precursors towards 
osteoblasts.  In agreement with this possibility, osteoclast differentiation and 
bone resorption were increased when hematopoietic cells lack CXCR4 
expression, [170], which favors a model where the balance between 
responsiveness to bone chemoattractants and to other chemoattractants 
influences osteoclast development in vivo (Figure 1). 
Cannabinoid receptor-2 (CB2) is abundantly expressed in various 
hematopoietic cells, including monocytes/osteoclast precursors and it promotes 
cell migration to its ligand 2-arachidonoylglycerol (2-AG) [171].  In vivo, 2-AG 
activity is likely high in (or near) bone marrow sinusoids given that CB2 promotes 
immature B lymphocyte positioning in these locations, a process that is also 
dependent on α4β1 adhesion to VCAM-1 [172].  It is, thus, conceivable that 
monocytes and osteoclast precursors are similarly attracted and/or retained 
within bone marrow sinusoids via CB2 chemotactic activity.  In support of this 
hypothesis, CB2 deficient mice exhibit low trabecular bone mass, and CB2 
antagonists inhibit osteoclast differentiation in vitro [173,174].  Furthermore, in 
humans a single nucleotide polymorphism in CNR2 (encoding CB2) was 
significantly associated with osteoporosis [175-177].  
Leukocytes can exit bone marrow through mechanisms that are 
independent of pertussis toxin-sensitive Gαi protein coupled receptors, and 
presumably independent of chemoattractant gradient sensing and cell intrinsic 
motility [178]. B-lineage lymphocytes enforced to express pertussis toxin or 
deficient in CXCR4 expression were found to be largely non-motile within bone 
marrow cavities of live mice, and were rapidly mobilized from bone marrow 
parenchyma into blood [178].  It was also noted that the bone marrow 
parenchyma is under shear stress induced by plasma perfusion and interstitial 
fluid flow [178].  It is plausible that the highly fenestrated nature of the sinusoidal 
network in combination with plasma and interstitial fluid flow back to collecting 
sinusoids allows non-motile cells (e.g. red blood cells) to exit the bone marrow in 
a passive manner, and that such unconventional exit routes are used by 
essentially all leukocytes, including osteoclast precursors.   
Osteoclast differentiation within inflamed synovial space. 
The identity of osteoclast precursors in arthritis may be distinct from 
steady-state osteoclast precursors, but presumably belongs to the myeloid cell 
compartment.  Myeloid cells are accumulated in synovial tissue and synovial fluid 
in RA [48,49]. Some studies have interrogated the phenotype of osteoclast 
precursors in inflammatory arthritis models.  The hTNFα transgenic strain 
develops synovial hyperplasia and lymphocytic infiltrate, pannus formation, 
articular cartilage destruction, and osteoclast driven bone erosion [179].  In this 
model, a cell population expressing the aM integrin CD11b but not Gr-1 displayed 
osteoclastogenic potential, and this population was increased in the bone marrow 
and blood of hTNFα transgenic mice [180].  Another study utilizing the SKG 
model of spontaneous inflammatory arthritis identified a population of cells with 
osteoclastogenic potential that had low to negative expression for CD11b and 
expressed high levels of Ly6C [125], and these cells may overlap with cMoPs 
(Nevius and Pereira unpublished observations). Dendritic cells have also been 
reported to contain osteoclast differentiation potential. Specifically, immature DCs 
were able to form osteoclasts in response to MCSF and RANKL, and unidentified 
soluble factors in human synovial fluid increased the DC differentiation into 
osteoclasts. These findings indicate that DCs may contribute to arthritis not only 
by acting as antigen-presenting cells and promoting T cell activation, but also by 
their potential to differentiate into bone-resorbing osteoclasts [181,182].  
Collectively these studies suggest that multiple myeloid cell populations contain 
osteoclast differentiation potential (Figure 3).  
RANKL is expressed on activated T cells, B cells, DCs, and synovial 
fibroblasts, besides bone-producing cells, RANKL expressed on T cells [133,183] 
and B cells [184] is dispensable for osteoclast differentiation and skeletal 
development and maintenance under homeostatic conditions.  However, in 
mouse models of inflammatory arthritis, and in RA patients, the expression of 
RANKL on T cells and synovial fibroblasts is robust [113,185-187].  In murine 
inflammatory arthritis it has been established that synovial fibroblasts support the 
conversion of FOXP3+ Tregs into pathogenic Th17 cells, which express higher 
RANKL amounts than other CD4+ T cell subsets [188]. Furthermore, Th17-
derived RANKL is able to support osteoclastogenesis in vitro [188,189].  That the 
cytokine IL-17A is an important driver of osteoclastogenesis in arthritis has been 
appreciated for some time now [190], but the mechanisms of its action are still 
being elucidated.  Interestingly, IL-17A has been shown to induce RANK on 
human and murine osteoclast precursors and promotes osteoclastogenesis [191-
193].  In addition, some evidence suggests IL-17A may increase RANKL 
expression on fibroblastic synoviocytes and/or mesenchymal-derived cells [189].   
A recent study has dissected the relative contributions of RANKL derived from T 
cells and synovial fibroblasts and found that synovial fibroblasts provide the 
relevant sources of RANKL in models of inflammatory arthritis [194].  In humans, 
RANKL blockade with denosumab reduces bone erosion possibly through 
inhibition of osteoclast differentiation and function [195].!!In mice, RANKL-
expressing Th17 cells have been reported to interact directly with osteoclasts in 
vivo. By fluorescently labeling osteoclasts and Th17 cells it was observed that 
Th17 cells preferentially located in contact with mature osteoclasts and this 
interaction was partially dependent on RANKL [196].   Finally, by using a pH 
sensitive fluorescent probe and an indicator of local pH decreases associated 
with osteoclast H+ secretion and bone resorption it was observed that Th17 and 
osteoclast interactions occurred in sites of active bone resorption [196]. 
Collectively through these studies a picture emerges in which Th17 derived IL-
17A regulates the expression of RANKL on synovial fibroblasts, enhances the 
differentiation of osteoclasts in the inflamed joint, and exacerbates bone 
resorption in vivo (Figure 3). 
As mentioned previously, MCSF and RANKL are critical cytokines for 
osteoclastogenesis, and while MCSF is a soluble cytokine, RANKL is a type II 
membrane protein.  Therefore osteoclast precursors in the joint presumably 
receive RANK signaling directly from fibroblastic synoviocytes, and possibly from 
T cells, osteoblasts, or from interaction with osteocyte processes at the bone 
surface (Figure 3).  Given that osteoclasts can form bi-directionally in the joint 
(synovium and bone marrow), the specific cell type presenting RANKL (and other 
cytokines) on the synovial or bone marrow side may differ, and may be under the 
influence of distinct cell recruitment mechanisms.   
 
RANKL independent osteoclast differentiation in RA 
It is now appreciated that in inflammatory settings osteoclast differentiation 
can occur independently of RANKL signaling [197].  Inflammatory cytokines such 
as TNFα [198], TNFα with IL-6 [199], and IL-1α [200] can induce osteoclast 
differentiation when in the presence of MCSF, but non-inflammatory cytokines 
like TGFβ have also been shown to trigger osteoclast differentiation [201]. 
Collectively these data identify cytokine-driven alternative pathways of osteoclast 
differentiation not dependent on the RANK/RANKL signaling pathway. Many of 
these pro-osteoclastogenic cytokines can be produced by macrophages, as 
reviewed elsewhere [197], and synovial macrophage numbers correlate with 
severity of inflammatory activity in RA [202].  Although pro-osteoclastogenic 
cytokines are not exclusively produced by synovial macrophages, these 
cytokines are present in the synovial milieu and may contribute to alternative 
pathways of osteoclast differentiation.  Recent work from Harre and colleagues 
found that ACPAs enhanced the differentiation of osteoclasts in vitro [203].  They 
further showed that administration of ACPAs to lymphocyte deficient Rag1-/- mice 
was able to increase osteoclast numbers and reduce bone mass in vivo [203].  
The mechanism by which ACPAs promote osteoclast differentiation is in part 
dependent on the Fc sialylation state of IgG in immune complexes [204].  
Alternative pathways of osteoclast differentiation, driven by the unique 
inflammatory cytokine milieu (e.g. TNFα ) and pathogenic autoantibody 
responses likely synergize with the dominant RANK/RANKL signaling pathway to 
induce bone erosions associated with RA. Indeed, TNFα induces RANKL 
expression on stromal cells via IL-1α signaling and enhance RANKL-dependent 
pathways of osteoclast differentiation [205].  
 
 
 Recruitment of osteoclast precursors in RA 
It is clear in murine inflammatory arthritis and human RA that osteoclast 
precursors populate the synovium and synovial fluid.  Conceptually, osteoclast 
differentiation in RA is likely controlled by multiple guidance cues balancing 
osteoclast precursor retention in bone marrow, migration from the bone marrow 
to egress sites, and migration into tissues, i.e. the synovium (Figure 3).  The 
chemotactic signals guiding cells to these sites are incompletely defined and are 
of great interest.  Some studies indicate that the cytokine TNFα, which is 
abundant in synovial tissue, can expand osteoclast precursors in inflammatory 
arthritis models and can also induce the mobilization of osteoclast precursors 
from the bone marrow into the periphery [206,207,180].  Given that in RA 
patients S1P levels are elevated in the synovium and synovial fluid (even higher 
than serum levels) [89,90], S1P receptor signalling could contribute to monocyte 
recruitment and retention in the joints.  Consistent with this hypothesis, blockade 
of S1P signaling by administration of FTY720 reduces lymphocyte [86-88] and 
monocyte [87] migration to the joints.   
Human and mouse monocytes/osteoclast precursors and osteoclasts also 
express functional CCR1, CCR5, and CCR2.  The CCR2 and MCP-1 chemokine 
receptor pair not only promotes monocyte egress from bone marrow under 
homeostatic and inflammatory conditions [146-148], but MCP-1 expression is 
increased in inflamed synovial fluids [208,209].  Therefore, these collective 
reports suggest that CCR2 attracts monocytes/osteoclast precursors from blood 
circulation to inflamed joints. It remains to be completely dissected the relative 
contribution of CCR2 in the egress of monocytic cells and in the recruitment of 
those cells into tissues like the inflamed synovium.  Potential sources for MCP-1 
include osteoblasts and mesenchymal stromal cells.  
 Early studies in mouse models showed that the severity of inflammatory 
arthritis is mitigated by administration of receptor antagonists to CCR2 and CCR5 
[210,211].  It was subsequently elucidated that the kinetics of CCR2 blockade are 
crucial for a beneficial outcome [212].  However, genetic deletion of these 
receptors had an opposite effect.  Mice genetically deficient in CCR2 and CCR5 
displayed either enhanced severity of inflammatory arthritis (including enhanced 
monocyte recruitment) or had no effect on disease outcome, respectively [77].  
More recently, inflammatory arthritis induced in CCR2 deficient mice were 
described to have increased Th17 cells, which may partially explain the disease 
exacerbation [213].  The blockade of another GPCR, CCR1, in inflammatory 
arthritis mouse models showed both inhibition of chemotaxis and reduction of 
inflammation [214,215,211,216]. 
The promising data from mouse models prompted the development and 
testing of CCR1, CCR2, and CCR5 antagonists as a therapeutic approach for the 
treatment of RA [217-221].  However, the results of the clinical trials were 
variable and did not show an overt efficacy in the treatment of RA patients.  This 
could be in part due to the redundancy of the chemokine receptor and chemokine 
system.  For example, CCR1 has 13 distinct chemokine ligands, some of which 
are shared ligands for CCR2, CCR3, CCR5, and CCR10.  There are additional 
chemokine receptors that have been suggested to regulate the recruitment of 
monocytes/osteoclast precursors in RA.  
Other chemokine receptor pairs that may regulate the recruitment of 
osteoclast precursors to the bone surfaces in homeostasis may also play a role 
in inflammatory conditions, like RA.  For instance, CXCL12 is highly expressed in 
synovial tissues [55,56] and synovial fibroblasts from RA patients [57] and the 
migration of monocytes to supernatants from synovial fibroblasts was 
significantly decreased after neutralization of CXCL12 [222].  In the context of 
RA, CB2 is more abundantly expressed in the synovial tissues of RA patients, 
and administration of a selective CB2 antagonist in a mouse model ameliorated 
inflammatory arthritis and bone destruction [223]. Although the distribution of 2-
AG within bone marrow has not been exactly defined, the fact that CB2 signaling 
occurs in the vicinity of (or within) bone marrow sinusoids under normal 
homeostatic conditions, and that it can be detected in synovial tissues, suggests 
that 2-AG may act as a chemoattractant or a retention signal.  Finally, the 
neutralization of the CX3CR1 ligand, CX3CL1 (fractalkine), in synovial fluid in 
murine inflammatory arthritis reduced overall chemotactic potency [83].  
Blockade of CX3CR1 in a murine model decreased the recruitment of monocytic 
cells to synovial tissues and decreased disease incidence and severity [82].  
CX3CL1 is elevated in RA patients compared to OA patients [81,80] and CX3CL1 
has been shown to be upregulated in mouse bone marrow endothelial cells in 
inflammatory conditions, such as full body irradiation [153].  
CXCR2 and CXCL2 have also been implicated in inflammatory bone 
remodeling [224].  In osteoclast precursors, CXCL2 is induced by RANKL and 
promotes their chemotaxis to CXCL2 [224].  The expression of CXCL2 was 
increased in the synovial fluid of RA patients and CXCL2 significantly enhanced 
bone resorption in vivo [224].  Therapeutic neutralization of this chemokine 
receptor pair had positive results in animal models of arthritis [225,60,226], 
possibly owing to the inhibition of CXCL2-mediated recruitment of osteoclast 
precursors to inflamed joints.  In the K/BxN serum transfer model, the relevant 
chemokine receptor for arthritis progression was shown to be CXCR2, 
specifically for the recruitment of neutrophils [58].  But this study does not 
preclude an important role for CXCR2 in the recruitment of osteoclast precursors 
[58].  
Under homeostasis, EBI2 and CH25H are required for osteoclast 
precursor recruitment and osteoclast differentiation.  But, EBI2 and CH25H are 
also required for the generation of antibody responses, and have also been 
implicated in a variety of inflammatory diseases.  SNPs in Ebi2 or in regulatory 
elements of Ebi2 expression are associated with cardiac inflammation, type I 
diabetes and inflammatory bowel disease [227-229]. Furthermore, Ch25h is one 
of the most induced interferon-stimulated genes [230].  Future studies should 
determine if CH25H activity is increased in the inflamed articular space, and if 
EBI2 ligands play roles in inflammatory cell recruitment and osteoclast 
differentiation in inflamed joints. 
While many studies interrogated functional roles for chemoattractant 
receptors in osteoclast differentiation and bone erosions in RA patients, and 
mouse models of RA, little remains understood about the manner in which they 
contribute to disease.  It is likely that osteoclast precursor differentiation within 
inflamed synovium requires sequential chemotactic signals: at the first stage cells 
must be captured from blood circulation and extravasate into the synovium. 
Subsequently, osteoclast precursors likely follow chemotactic gradients that not 
only promote retention within the articular space but may also direct their 
migration towards sites of osteoclast differentiation.  It is possible that 
redundancy between chemokine and other chemoattractants control such multi-
step process of osteoclast differentiation. 
 
 Inflammation induced changes in bone homeostasis 
Hematopoiesis has been proposed to be regulated locally by cytokines 
[231]. Cytokines are capable of instructing hematopoietic lineage choice by 
acting on 1) HSC, 2) Hematopoietic progenitor cells (HPC), and 3) mesenchymal 
stromal cells that support HSC. Furthermore, inflammatory cytokines, such as 
type I interferons may also function as rheostats of HSC proliferation [232,233]. 
During stress response, HSC enter in cycle and self-renew but when 
homeostasis is reestablished, HSC return to a quiescent state [234].  
The inflammatory cytokine signature of RA includes several cytokines that 
have profound effects in hematopoiesis by biasing cell lineage choices.  Two of 
the most notorious are TNFα and IL-1, and these cytokines can induce 
hematopoietic shifts that favor the production of inflammatory, innate-type cells, 
such as neutrophils and monocyte-lineage cells, at the expense of lymphopoiesis 
[235,236].  Of note, systemic TNFα increases the number of CD11bhigh osteoclast 
precursors in circulation [237], and this effect may in part be due to an increase 
in osteoclast precursor proliferation and differentiation in bone marrow [180].  
Such inflammation-induced shifts in hematopoiesis are most likely dependent on 
local G-CSF production, although it is possible that other inflammatory signals 
contribute to this effect [238]. In experimental mouse models of RA, genetic and 
pharmacologically induced G-CSF deficiency prevented acute and chronic 
arthritis [239], possibly because it reduced myeloid cell differentiation in bone 
marrow.   
 
Concluding remarks 
It is becoming increasingly understood that a variety of processes 
controlled by the adaptive immune system are the major determinants of RA.  
But, adaptive immunity requires instructive signals provided by innate immune 
effector mechanisms, thus leaving open the question of which is/are the triggers 
that inadvertently fire self-reactive lymphocytes.  Furthermore, even though RA 
does not develop without lymphocytes, disease only manifests when innate 
immune effector cells infiltrate articular spaces and cause pathology. Of note, the 
resorptive activity of synovial osteoclasts is a hallmark feature of chronic, 
advanced stage RA and is a major contributor to articular damage.   
Considering the multiple pathways EBI2 signaling is involved in (namely 
osteoclast development and the generation of adaptive immune responses), 
which are central to the development of inflammation in articular spaces, 
antagonists of EBI2 signaling may provide significant protection against RA. 
Understanding the multitude of osteoclast differentiation pathways and 
mechanisms of osteoclast precursor recruitment in homeostasis and during 
inflammation is thus of utmost importance. 
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Figure legends: 
Fig. 1 Trafficking of osteoclast precursors in the bone marrow (BM), blood, and 
peripheral tissues.  Monocytic osteoclast precursor cells (OCP) and inflammatory 
monocytes (Inf Mono) migrate into osteoclastogenic niches where osteoblasts 
(OB) and osteocytes provide important signals for osteoclast differentiation 
(MCSF and RANKL).  EBI2 directs the migration of OCP to the endosteum, 
where the EBI2 ligand 7α, 25-OHC is presumably abundant.  CX3CR1 promotes 
the retention of OCP in BM parenchyma, and possibly directs cells to the 
endosteum in response to CX3CL1 produced by OB.  OB also express CCR1 
ligands (e.g. CCL9) and CCR1 may also direct OCP to sites of osteoclast 
differentiation.  S1PR1 is essential for the egress of monocytic cells in the bone 
marrow as they follow S1P gradients into the circulation and inflammatory 
monocytes egress via CCR2.  CXCR4 is likely to guide OCP away from sites of 
osteoclastogenesis given that its ligand CXCL12 is abundant parenchymal and 
perivacular mesenchymal stromal cells, while it is reduced in OBs.  The CB2 
ligand 2-AG is likely abundant in the BM sinusoids, and may guide OCP away 
from osteoclastogenic niches. Both circulatory OCP and inflammatory monocytes 
re-enter into BM by unknown mechanisms. 
 
Fig. 2 Osteoclasts are located in close proximity to blood vessels in the bone 
marrow.  Image acquired using two-photon microscopy of calvaria bone marrow 
of TRAPRed reporter mouse. Osteoclasts (white); blood vessels (dashed line) 
were visualized with injection of dextran-FITC; and bone (gray). Scale bar= 30µm 
 Fig. 3 Trafficking of monocytic osteoclast precursors (OCP) into inflamed joints. 
Cells with osteoclastogenic potential include CD11b-/loLy6Chi, CD11b+GR-1-, and 
DCs.  In RA, sinusoidal fibroblastic cells provide RANKL, which can be induced 
by IL-17 provided by Th17 cells. The cytokines TNF-α, IL-1, and IL-6, which may 
be locally secreted by macrophages also promote osteoclast differentiation under 
inflammatory conditions.  S1P receptor expression on OCPs possibly directs 
cells into the synovial tissue where S1P is upregulated during inflammation.  
CXCR4 also likely directs cells into the synovial tissue with fibroblasts, and 
possibly other cells, express high levels of CXCL12.  Selective antagonism of 
CB2 inhibits the migration of monocytes into the synovium, indicating that 2-Ag 
levels may be present in synovial fluid. CXCR2, CX3CR1, CCR1, CCR2, and 
CCR5 are also implicated in inflammatory cell recruitment into the inflamed 
articular space.  
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Abstract 
Anemia is an important co-morbidity of chronic infections, as well as other 
inflammatory diseases. Anemia of chronic infections results from defective 
bone marrow erythropoiesis. Although the limitation of iron availability has 
been considered one key factor, the exact mechanisms underlying the 
blockade in erythroid generation during infection are not fully understood. 
Erythropoiesis is a tightly regulated process, which is very sensitive to 
environmental changes. During the last decade, the importance of the bone 
marrow hematopoietic niche has been progressively acknowledged. Several 
bone marrow cell types (such as Macrophages or Mesenchymal stem and 
progenitors cells) and molecular mediators (such as CXCL12) have been 
identified as fundamental for both the maintenance of hematopoietic stem 
cells (HSC) pluripotency and for their most adequate differentiation into each 
hematopoietic cell lineage. Importantly, both niche supporting cells and 
hematopoietic progenitors were found to be able to sense local and systemic 
cues in order to adapt the hematopoietic output to the organism needs. Here, 
we review how hematopoietic progenitors and niche supporting cells sense 
and respond to stress cues, and suggest a potential role for the hematopoietic 
niche in the development of anemia of chronic infections.    
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Hematopoiesis and the Bone Marrow Microenvironment 
 Hematopoiesis is a critical biological process, responsible for the generation 
not only of the different types of leukocytes but also of erythrocytes, which have the 
major task of delivering oxygen to peripheral tissues. All blood cells are generated 
from hematopoietic stem cells (HSC), which are maintained mainly in the bone 
marrow (BM) during adult life. To ensure a continuous and controlled output of 
hematopoietic cells, some HSC lose their quiescence and enter a highly regulated 
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differentiation process. It has been increasingly acknowledged that HSC decision to 
enter a self-renewal or a differentiation process is determined by microenvironmental 
signals1. This BM microenvironment or niche in turn senses and responds to the 
state and needs of different tissues of the organism.  
 In the last decade, the cellular constituents of the hematopoietic niche started 
to be highlighted. Mesenchymal stem and progenitors cells (MSPC), which are 
multipotent cells capable of differentiating into osteoblasts, chondrocytes, adipocytes 
and stromal cells2, produce factors, such as stem cell factor (SCF) and C-X-C motif 
ligand 12 (CXCL12), important for HSC self-renewal, survival and retention in the 
niche3-14. Despite early reports implying osteoblasts in the regulation of HSC 
maintenance niche15-19, it is currently accepted that osteoblasts do not directly 
regulate HSC, but support B lymphopoiesis8,17,20-22. CD169+ macrophages also 
regulate the hematopoietic niche by cross-talking with MSPC, inducing the 
expression of the chemokine CXCL12 and thus promoting the retention of HSC and 
progenitors in the hematopoietic niche23. Other mature hematopoietic cells also play 
a role in forming the hematopoietic niche. Megakaryocytes secrete the chemokine 
CXCL4, which controls HSC cell cycle activity24. Mature hematopoietic cells can also 
stimulate hematopoiesis by acting on MSPC. CD8+ cytotoxic T cells (CTL), a key 
component of the host defense against intracellular pathogens, secret interferon 
gamma (IFNγ), which acts on BM MSPC, promoting their release of cytokines such 
as interleukin (IL)-6. IL-6 produced by MSPC leads to the increase in myelopoiesis, 
through the down-regulation of the transcription factors Runx-1 and Cebp alpha in 
early hematopoietic progenitor cells25. These observations suggest that mature 
hematopoietic cells can influence early multipotent hematopoietic progenitors, 
modulating their differentiation into specific hematopoietic lineages. They also imply 
that MSPC are important constituents of the BM microenvironment/niche, acting as 
regulators of hematopoietic differentiation in response to local and peripheral 
environmental cues. During infections, this response is based most likely on the 
expression of cytokine and chemokine receptors. Apart from these, hormones can 
also impact hematopoiesis. HSC express high amounts of estrogen receptor-alpha, 
whose signaling promotes HSC self-renewal, and erythropoiesis during pregnancy26. 
Additionally, central nervous system (CNS) signals also impact hematopoiesis. 
Sympathetic nerves enwrap MSPC and secret noradrenaline in a circadian-manner, 
which is sensed by MSPC and causes them to reduce the expression of CXCL12, 
thus enhancing the BM egress of HSC and progenitors27,28. 
 Despite all the recent efforts to understand the cellular and molecular 
components of the HSC maintenance niche, there is still a gap in the understanding 
of how the niche instructs and supports specific lineage differentiation, especially 
during stress responses, such as infection.   
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Bone Marrow Erythropoiesis  
 Erythropoiesis occurs mostly in BM during adult life and proceeds through 
highly controlled sequential stages of differentiation from HSC to mature red blod 
cells (RBC) (see figure 1). The transcription factor PU.1 is critical for the different 
hematopoietic lineages fate decisions. In erythropoiesis, PU.1 sustains the self-
renewal of early hematopoietic progenitor cells, preventing their differentiation in the 
erythroid lineage29. 
 HSC as well as megakaryocytic and erythroid progenitors depend on stromal 
cells to be held in place through integrin-mediated adhesion and to receive instructive 
cytokines in order to undergo erythroid differentiation30. HSC and the first erythroid 
lineage committed progenitor, burst-forming unit-erythroid (BFU-E), are dependent 
on SCF (produced most likely by MSPC), whose ligand is cKIT. SCF is needed for 
the survival and proliferation of early erythroid progenitors and precursors up to the 
colony forming unit – erythroid stage (CFU-E).  By preventing further erythroid 
differentiation and maturation, SCF signaling ensures the self-renewal of the 
erythroid progenitor pool.  cKIT is highly expressed in BFU-E and CFU-E, but down-
regulated at later stages of CFU-E differentiation. It is not expressed by 
polychromatic and orthochromatic erythroblasts, suggesting that the later stages of 
erythrocyte differentiation are mostly independent of SCF but critically dependent on 
erythropoietin (Epo). Epo instructs erythropoiesis in vivo by suppressing non-
erythroid lineage potential, inducing an erythroid lineage bias in early hematopoietic 
progenitors, increasing erythropoiesis and decreasing myelopoiesis31. Thus, Epo is 
an example of a systemically-released cytokine which regulates lineage choices in 
multipotent hematopoietic cells present in the bone marrow. Epo is produced by 
cortical interstitial cells adjacent to the proximal tubules in the kidney, and is 
responsible for maintaining the homeostasis of circulating erythrocyte numbers. The 
systemic concentrations of Epo are kept low, and small decreases in the hematocrit 
result in exponential increases in the serum concentrations of the cytokine. Epo and 
SCF act in synergy to induce the proliferation of pro-erythroblasts (Pro-E), which 
differentiate into erythroblasts32. Erythroblasts surround BM macrophages, forming 
the erythroblastic islands dispersed throughout the BM. Within erythroblastic islands, 
erythroblasts proliferate, differentiate and enucleate. CD169+ macrophages are a key 
component of erythroblastic islands in the BM, and promote late erythroid 
maturation33. As mentioned before, CD169+ macrophages also cross-talk with MSPC 
in the BM niche, inducing the expression of the CXCL12, thus promoting the 
retention of HSC and progenitors in the hematopoietic niche23. Depletion of CD169+ 
macrophages (for example through granulocyte colony stimulating factor (G-CSF) 
treatment) leads to mobilization of HSC to the blood and impaired medullary 
erythropoiesis34-36. Within the erythroblastic islands, the macrophages are thought to 
be involved in providing iron to erythroblasts to be used in the synthesis of heme37. 
Erythroblasts, later, expel their nuclei during nuclear extrusion, which leads to the 
formation of anucleated reticulocytes38,39.  
 As part of the erythroblast response to Epo, erythropoietin receptor (EpoR) 
signaling leads to their production of erythroferrone. Circulating erythroferrone acts 
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on hepatocytes, causing a down-regulation of hepcidin translation. The decrease in 
hepcidin (see below) augments the levels of transferrin-bound iron in circulation and 
therefore contributes to the stimulation of erythropoiesis, in a positive feedback loop40.  
 
Iron homeostasis and Anemia of Chronic Infection 
 Iron homeostasis is tightly regulated by several mechanisms, acting either at 
the cellular or at the systemic levels. At a systemic level, tissue iron stores and 
plasma iron levels are mostly regulated by hepcidin, a small peptide hormone 
produced by hepatocytes. Hepcidin impacts iron distribution by binding to ferroportin 
and inducing its degradation. Ferroportin is an iron exporter expressed by 
enterocytes, hepatocytes, macrophages and adipocytes41. Therefore, increases in 
hepcidin levels decrease iron export, causing iron intracellular sequestration (mainly 
inside enterocytes and macrophages) and hypoferremia. Hepcidin expression is 
induced by two main signals: iron overload and inflammation. Increases in plasma 
iron concentration induce hepcidin expression in hepatocytes, by a mechanism which 
involves BMP/SMAD signaling and is important to avoid tissue iron toxicity42. During 
inflammation, IL-6 is mostly produced by macrophages, and induces the production 
of hepcidin in hepatocytes. Macrophages and adipocytes can also express low 
amounts of hepcidin mRNA43-46. Consequently, hypoferremia of inflammation 
develops within a few hours.  
 Anemia of chronic inflammation is a pathologic state characterized by 
impaired erythropoiesis, associated to a low concentration of circulating transferrin-
bound iron as a consequence of a prolonged inflammatory state, such as chronic 
infection47.  Long lasting hepcidin production and consequent hypoferremia have 
been postulated to be responsible for the development of anemia of inflammation. 
Erythropoiesis is known to be very sensitive to the transferrin-bound iron 
concentration48. It is not clear for the moment whether iron scarcity directly impairs 
erythropoiesis (due to unavailability of iron for incorporation in heme) or is sensed by 
erythroid progenitors and/or niche cells and indirectly prevents erythroid 
differentiation.  
 One possible mechanism by which iron scarcity leads to impaired 
erythropoiesis is through the inhibition of aconitase activity in erythroid precursors49,50. 
Aconitases catalyze the isomerization of citrate to isocitrate in the Krebs Cycle. Due 
to its iron-sulfur cluster, aconitase activity is iron-dependent. Aconitase activity is 
necessary for a correct erythropoietic process, by mechanisms involving the 
regulation of PU.1 expression. In situations of anemia caused by iron deprivation or 
by an inflammatory stimulus, the administration of isocitrate, the product of aconitase 
activity, reversed the anemia development49,50.  
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The role of Hematopoietic niche(s) in Anemia of Chronic Infection 
 Although, as stated above, iron deprivation may play an important role in the 
development of anemia of inflammation, several previous studies suggest that 
hepcidin-independent pathways are also important44,45. Chronic mycobacterial 
infection induces anemia independently of the up-regulation of hepcidin51. Anemia is 
triggered by the administration of cytokines such as tumor necrosis factor (TNF) 
alpha, IL-1 and IFNγ in vivo52-54. In vitro studies have highlighted the molecular 
mechanisms by which IFNγ inhibits erythropoiesis.  IFNγ activates IRF1 on erythroid 
precursors, which, in turn, induces the transcription of PU.1 and its target genes. The 
increase in PU.1 antagonizes GATA-1 activity, causing an increase in myelopoiesis 
at the expense of erythropoiesis, which is arrested.  
 IFNγ was also shown to induce the proliferation of HSC55. In response to 
Mycobacterium avium infection, IFNγ directly induces the proliferation of long-term 
repopulating HSC, and consequently the increase of downstream hematopoietic 
progenitors. These results suggest that IFNγ activates HSC proliferation to replenish 
immune effector cells during an ongoing infectious process. IFNα also induces HSC 
proliferation. Interestingly, IFNα receptor-deficient HSC were shown to proliferate in 
response to IFNα treatment in vivo, indicating that an indirect mechanism is involved 
in this effect56. It is possible that MSPC in the hematopoietic niche sense the 
inflammatory stimulus and feedback to the HSC, inducing their proliferation. A 
potential candidate to be modulated by MSPC is CXCL12. CXCL12 and its ligand 
CXCR4 have been implicated in the retention of HSC within the niche7 and in the 
maintenance of HSC quiescence11,57.  
 Several evidences indicate that niche-supporting non-hematopoietic cells, 
namely MSPC, are capable of directly responding to infection and inflammatory 
stimuli. Importantly, murine and human MSPC express functional Toll-like receptors 
(TLR), which recognize molecular patterns expressed by microbial pathogens. The 
activation of TLR on these cells leads to the production of inflammatory cytokines 
and chemokines58-62. Inflammatory monocytes are fundamental for defense against 
pathogens, and are recruited from BM to sites of infection. CCL2, a key chemokine 
necessary for the recruitment of inflammatory monocytes from the BM to the sites of 
infection, is mostly produced by hematopoietic niche-supporting MSPC12,62,63. MSPC 
respond to inflammatory cytokines as it is illustrated by the fact that the local 
concentration of IFNγ in the BM determines whether osteoblastogenesis63 or 
adipogenesis (from MSPC) is predominantly favored, with important consequences 
on bone formation and functionality. In agreement with these observations is the fact 
that advanced osteoporosis is frequently associated with chronic inflammatory 
pathologies64,65. Also of interest, MSPC are capable of stimulating CD4+ and CD8+ T 
cells differentiation towards a regulatory cell phenotype in an IFNγ-mediated 
manner66-68.  
 Interestingly, MSPC also express heme oxygenase 1 (HO1), which is 
fundamental for MSPC immune-modulatory activity69. HO-1 expressed by MSPC 
induces the differentiation of T cells into specific T regulatory subsets as well as IL-10 
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production70, which, in turn, may act on dendritic precursor cells changing their fate 
and inducing the acquisition of regulatory functions71. HO1 is similarly crucial in 
erythroblastic island macrophages for the generation of new erythrocytes, as 
deficiency in HO1 leads to the depletion of blood island macrophages most likely due 
to toxic effects caused by the accumulation of non-catalyzed heme72. Of note, HO-1 
is up-regulated during mycobacteria-induced anemia51 and its expression in 
macrophages is crucial for resistance to mycobacteria chronic infections73. 
 All these observations support the hypothesis that systemic chronic 
inflammation, namely associated with infection, may cause alterations within the 
MSPC microenvironment, which may consequently alter the erythrotopoietic output. 
 
The erythropoiesis regulation triangle  
 BM erythroid progenitors, BM niche cells (e.g. MSPC and macrophages) and 
peripheral signals crosstalk to maintain an optimal but controlled output of RBC 
(Figure 2). During infection, inflammatory signals are sensed by hepatocytes, which 
release hepcidin. Hepcidin in turn acts mostly on enterotocytes and macrophages to 
sequester iron, decreasing the amount of serum iron available for erythropoiesis. 
Erythroid progenitors sense Epo and are instructed to the erythroid fate and feedback 
to the hepatocytes by producing erythroferrone, which will suppress hepcidin hence 
enhancing erythropoiesis. BM MSPC and macrophages are the third corner of this 
triangle. With their capacity to sense inflammatory stimuli and respond to them with 
the release of several mediators, these cells have a strong impact on the fate of 
multipotent hematopoietic progenitors, namely, instructing them towards some 
hematopoietic lineages at the expense of others. The mechanisms by which the 
hematopoietic niche regulates the erythrocyte output are still poorly characterized. 
Inflammatory stimuli decrease the amount of CXCL12 and increase the concentration 
of G-CSF, reducing the numbers of CD169+ macrophages, and increasing the 
proliferation and mobilization of HSPC. The lack of CD169+ macrophages feedbacks 
by mobilizing more HSC and preventing the formation of erythroblastic islands. Of 
note, TNF-α, one of the cytokines overproduced during chronic infections, is a known 
inhibitor of erythropoiesis74. In fact, both MSPC and HSPC can sense the 
inflammatory cytokines and cross talk to adjust their fate. HSPC will differentiate 
mostly into myeloid cells at the expense of lymphopoiesis or erythropoiesis. 
Simultaneously, the inflammatory milieu may favor the differentiation of MSPC into 
adipocytes, which have been described as negative regulators of hematopoietic 
activity75, and expressing low amounts of hepcidin mRNA. An increase in adipocytes 
in the BM may contribute to a local increase in hepcidin levels in the BM. Increased 
hepcidin levels in BM together with systemic hepcidin-induced hypoferremia may 
decrease iron availability for aconitase activity, heme synthesis, and erythropoiesis in 
general.   
 A deeper understanding of the regulation of the BM microenvironment and its 
crosstalk with HSPC to guarantee the best hematopoietic output, either in 
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homeostasis or during stress responses, is clearly needed. Anemia of chronic 
inflammation is an important co-morbidity of several diseases, representing an 
additional challenge in terms of therapeutic options. Filling the gaps in understanding 
the complex networks (cell types and molecular mediators) that enable hematopoietic 
differentiation and lineage choice will enhance the clinical options to deal with anemia 
associated with pathologies such chronic infections or leukemia.  
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Figure 1. Developmental progression of erythroid lineage from HSC to mature 
erythrocytes. The most important factors involved in specific  developmental stages 
are depicted.  
 
Figure 2. The erythropoiesis regulation triangle: crosstalk between MSPC, 
erythroblastic islands macrophages and HSPC during response to systemic 
signals. Changes in systemic signals occur during infection and are sensed by 
HSPC, MSPC and macrophages in BM parenchyma. MSPC and macrophages 
produce constitutive factors that act on HSPC instructing their self-renewal and/or 
lineage differentiation towards specific lineages. Systemic signals such as 
inflammatory cytokines can also modulate the production of these factors and, 
consequently, HSPC are instructed to specific hematopoietic lineages (e.g. myeloid) 
at the expense of others (e.g. lymphoid and erythroid). Chronic exposure to 
inflammatory systemic signals triggers a blockade on erythropoiesis and 
subsequently the development of anemia. 
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